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Preface 
Traditional approaches towards prenatal diagnosis of fetal abnormalities are ultrasonography 
and the invasive techniques of amniocentesis, chorionic villus sampling (CVS) and 
cordoccntesis. Although the invasive methods reach virtually 100 % accuracy, there is a 
small procedure-related risk for the felus. fetal loss rale following all invasive procedure is 
estimated at 0.5 - 1 %, depending on the technique employed. In the Netherlands, invasive 
prenatal testing is offered to women for various reasons: (1) advanced maternal age 
(~36 years); (2) a parental carrier status of a balanced chromosomal anomaly; (3) a previolls 
child wilh a chromosomal abnormality £IndIoI' multiple congenital malformations; 
(4) increased risk of a neural tube detect; (5) increased risk of a monogenic disease 
demonstrated by biochemical or DNA analysis; and (6) tetal congenital defects seen on 
ultrasound examination. 
During the last 15 years, high resolution ultrasound equipment has made possible the 
identification of a host of tetal congenital anomalies as c<uly as the early second trimester of 
pregnancy (\Vladimiroft~ 1994; den Hollander et al., 1998). Late first trimester and early 
second trimester sonographic markers for aneuploidy have been developed of which nuchal 
translucency has been shown to be the most effective onc (Pajkl1 e( a/., 1998: Snijders et al., 
1998). Biochcmical testing for chromosomc anomalies includes first trimester and early 
second trimester maternal serum screening (Wald eJ al., 1997; de Graaf, 1999; van Rijn, 
1999). Both sonographic markers and biochem ical tcsts represent a risk assessment with 
emphasis on Down syndrome. Depending on the nature of these tests, dctection rates of 
70-80 % fOJ' DOWI1 syndrome at a 5 % false positive rate have been claimed. Risk assessmcnt 
by means of maternal serulll screening andlor fetal nuchal transluccncy screening is currently 
subject to debate in the Netherlands (Discussion Oocur,lcnt Dutch Society of Obstetrics and 
Gynecology, 1997), 
An alternative non-invasive approach of potential diagnostic significancc is the isolation of 
fetal cells from maternal blood, whieh is receiving increasing attention during the last two 
decades, This may lead to the elimination of fetal cell sampling by invasive techniqucs sllch 
as CVS or [Hl1nioeentesis. To date, it is not yet clear whether the technique of fetal cell 
isolation from maternal blood will be accurate enough for fetal diagnosis. This thesis will 
give an overview of the current state of the ali offetal cell isolation. 
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Gcneral introduction 
Feto-maternal cell traffic in pathological conditions was tirst recognized in 1893, when 
Schmorl idcntified trophoblast cells in lung capillaries of women dying of eclampsia 
(Schmorl, 1893). In 1969, \Valknowska ef a/. identified male meta phases in cultured 
lymphocytes isolated from blood of healthy pregnant women, who subsequently gave bil1h to 
a boy. They were thc first to demonstrate that fetal cells enter the matel1lal circulation in 
normal pregnancy and they suggested that these cells might be llsed for chromosome 
analysis. Since then, many investigators have focussed on the development of a safe and 
reliable test to perform non-invasive prenatal diagnosis, as an alternative for chorionic villus 
sampling and amniocentesis. Before a non-invasive prenatal diagnostic test using fetal cells 
in maternal blood will be available, a Humber of questions need to be addressed, such as: 
(1) at what period of gestation does feto-matcrnal transfer of cells take place; (2) what is the 
best fetal cell type to isolate; (3) arc fetal cells detectablc in thc ~Iood orall pregnant women; 
(4) do chromosomally abnormal pregnancies result in increased or decreased transfer of fetal 
cells into the maternal circulation; and (5) may fetal cells from prior pregnancies persist in 
the maternal circulation, and hence interfere with a reliable prenatal diagnosis. 
1.1. Biological basis of passage of fetal cells into the maternal circulation 
Passage of fetal cells into the maternal circulation will occur at the feto-maternal interface. 
Knowledge of embl)'onic development and the fonnation of the feto-maternal interface 
(placentation) will gain insight into the process of feto-maternal cell trafficking. Furthcrl11ore~ 
knowledge of fetal hematopoiesis will lead to more information about the fetal cell types that 
circulate in maternal blood during pregnancy. 
1.1.1. Embryonic development and placentation 
After fertilization of an oocyte by a sperm cell, the formed zygote undergoes a series of rapid 
mitotic cell divisions known as cleavage. The zygote is cleaved into a number of blastomeres 
and subsequent cell divisions of these blastomcrcs result in the formation of the morula 
(32-cell stage; day 3). Subsequently~ the morula develops into the blastocyst (64-cell stage: 
day 4-5) which contains an outer cell layer (trophoblast) which gives rise to p1ll1 of the 
placenta, and a group of centrally located cells, the inner cell mass (embryoblast) which gives 
rise to the embl)'o. After the blastocyst has attached to the endometrial epithelium (day 6), 
the trophoblast ditferentiates into two eelJ types: (1) the cytotrophoblast, which is mitotically 
active and forms new cells that migrate into the increasing mass of syncytiotrophoblast; and 
(2) the syncytiotrophoblast. The latter rapidly becomes a large, thick, multinucleated 
13 
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protoplasmic Illass in which no cell boundaries are distinguishable (syncytium). 
Subsequcntly, a lacunar network develops in thc syncytiotrophoblast, and maternal capillaries 
near the syncytiotrophoblast expand to form maternal sinusoids establishing a primitive 
uteroplaccntal circulation, in which the primm)' chorionic villi develop (day 13). In the 
fmiher maturation of the villous tree, fetal blood vessels invadc this villolls connectivc tissue 
and connect the vessels to the cmbl),onic circulation. \Vhcn the fetal hemi begins contracting 
on day 2201' 23, a primitive fetal placcntal circulation establishes (Moore, 1982). 
One of the imp01iant placental structures t hat assures the transfer of nutrients to enhance fetal 
growth is the so-called 'placenta membrane', a thin layer of fetal tissues scparating the 
matelllal and fetal circulation. This membrane consists of syncytiotrophoblast, 
cytotrophoblast, thc connective tissue core of the villus, and the endothelium of the fetal 
capillaries. As pregnancy advances, the placental membrane bccomes progressively thinner 
while simultaneollsly fetal blood tlow and blood pressure increase as the villous tree cnlarges 
(Sullon ('{ (/1., 1990). 
Until now, it is not known at what period during placentation a feto-matcrnaltransfusion may 
OCClll". One can readily imagine that a disruption of the relatively thin placental membrane 
would lead to fetal bleeding into the intervillous space at the timc when this membranc thins 
with advancing pregnancy. Another theoretical possibility may be that feto-maternal cell 
trafficking takes place during the formation of villi, at the time when fetal capillaries are 
formed and the pumping action of the fetal heart begins (Benirschke, 1994). 
1.1.2. Hematopoiesis 
Fetal hematopoiesis is one of the first processes established following implantation of the 
blastocyst, and can be divided into three main overlapping periods: mesoblastic, hepatic, and 
myeloid (tigure 1). It was originally assumed that the mesoblastic hematopoiesis stmis in the 
yolk sac between days 16 and 19 (Huyhn el al., 1995), followed by hepatic hematopoiesis at 
approximately 5 wccks aner fertilization (Migliaccio el al., 1986). The final phase of 
hematopoiesis takes place in the bone marrow, starting at 10 wceks atter fertilization in the 
long bones (Metcalf and Moore, 1971; Kollmann el al., 1994; Charbord ('I (/1 .. 1996). 
Recently, it has been showll that in developing mamnwis stem cells can be derived from an 
intraembryonic site called the amta~gol1ad-lllesonephros (AGM) region Uvledvinsky ef a/., 
1993: Medvinsky and Dzierzak, 1996; Tavian el u/., 1996). Howevcr, the site of origin of 
definitive hematopoietic stem cells in the developing fetus remains controversial. Evidence 
n'om some studies indicates that hematopoietic stem cells from the yolk sac arc responsible 
for transient primitive hematopoiesis, but they appear to lack the ability to reconstitute the 
hematopoietic system in adult animals (Cumano cl al., 1996; Medvinsky and Dzierzak, 
14 
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1996). Instead, stem cells derived from the AGM region have been shown, both in mice and 
man (Tavian et al., 1996), to be responsible tor definitive hematopoiesis (Godin ct al., 1993; 
Medvinskyet al., 1993; Medvinskyand Dzierzak, 1996) by first colonizing the fetal liver and 
latcl' the bone marrow (Delasslls and Cumano, 1996). On the other hand, evidence from other 
studies suggests that hematopoietic stem cells with the capacity to contribute to definitive 
hematopoiesis are present both in the yolk sac and in the AGM region of murine embtyos 
prior to fctallivcr colonization (Yoder et al., 1997n, b). 
Liver 
............ 
'. 
o 2 3 4 5 6 7 8 9 10 
Months 
Figure 1 Hematopoiesis in the fetus (after Kelemen el al., 1979) 
Hematopoiesis in the yolk saC is distinct from that of fetal liver and adult marrow 
hematopoiesis in that it nppears to be restricted to the generation of two lineages: embryonic 
erythrocytes, whit.:h represent the major hematopoietic component of the blood islands in the 
yolk sac, and macrophagcs that are dispersed throughout the yolk sac (Metcalf and rvloore, 
1971; Russell, 1979). These early el)1hroid cells, known as primitive erythrocytes, arc large 
and remain nucleated. These primitive el)1hroid cells predominantly express the c-glohin and 
S-globin genes (the embryonic forms of hemoglobin) and low levels of (1.- and p-globin genes 
(Barker, 1968; Brotherton et al., '1979; Russell, 1979). The transition from yolk sac to fetal 
liver defines the switch from primitive to definitive hematopoiesis and the replacement of the 
primitive el)1hroid cells by multilineagc hematopoiesis including definitive el)1hropoiesis, 
myelopoiesis, and lymphopoiesis (Metcalf and Moore, 1971). Detlnitive el)1hroid cclls 
generated in the fetal liver differ from primitive cl)1hroc)1es in the yolk sac in that they arc 
small and that they enucleate. This coincides with a switch frol11 c- to y-globin gene 
expression and from S- to a-globin gene expression (Peschle el af., 1985). During the fetal 
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period, the site of el)1hropoiesis gradually switches from the liver to the spleen and finaily 
the bone marrow. Gamma-globin gene expression decreases during this period with a 
reciprocal increase in the expression of the adult p-globin gene and the appearance of low 
levels ofadull ii-globin gene expression (tigure 2) (Barker, 1968; BrothClton of a/., 1979). 
o 
Figure 2 
y 
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Expression of globins during fetal development (after Barker, 1968; 
Brotherton <'I al., 1979; Peschle ('I al., J 985) 
\Vith the development of cordocentesis, access to the fetal circulation has provided an 
opportunity to study fetal hematological profiles. However, it is technically difficult to obtain 
Ictal blood before 18-20 weeks of gestation. In the developing fetus, the number of 
erythroc)1es increases linearly, whereas the number of el)1hroblast cells decreases with 
advancing gestation. In contrast, the number of fetal white blood cells increases with 
gestation (table 1) (Millar of a/., 1985; De Waele ef a/., 1988; Nicolaides ef a/., 1989; 
Forestier ef a/., 1991; Thilaganathan of 0/., 1992, 1994). 
For the development of a non-invasive prenatal diagnostic test, fetal el)1hroblast cells appear 
to be the lelal cell type to target, since these cells are the first cells that are formed during 
fctal hematopoiesis in the yolk sac. In addition, erythroblast cells are abundantly present in 
the fetus during the first trimester of pregnancy, when compared with lymphoid and myeloid 
cells. 
16 
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Table 1 rvfenn values for the number of white blood cells, red blood cells !lnd erythroblast 
cells in fClal, neonatal and adult blood 
Gestational age 
16-17 weeks 
18-21 weeks 
22 - 25 weeks 
26 - 29 weeks 
neonate 
adult 
White blood cells 
(xl0'/I) 
2.00 
2.98 
4.51 
5.16 
14.1 
6.00 
Red blood cells EI)1hroblast cells 
(x I 0"/1) (x I 0'/1) 
2.62 2.70 
2.82 1.75 
3.00 0.95 
3.46 0.99 
4.60 0.50 
4.70 <0.01 
Dala arc lIdapkd from t>.lilIar eI al., 1985; Dc Wnelc {'I al., 1988; Foresticr ('/ 01., 1991. 
1.2. Fetal cell types 
The next issue conccrns the types of fetal cells that have been found in the maternal 
circulation. The fetal cell types that have been studied by numerous investigators worldwide 
include fetal leukocytes, i.e. fctal lymphocytes and gr<lnuloc)1es, fetal nucleated red blood 
cells (NRBCs) and trophoblast cells. 
1.2.1. Fetal leukocytes 
L}'f11p/tocyles 
The presence of fetal lymphoc)1es in the maternal circulation was first described in 1969 by 
\Valknowska et a/ .. These investigators demonstrated the presence of a Y chromosome in 
mitogen-stimulated lymphoc)1es obtained from pregnant women c1llTying a male fetlls. These 
results were confirmed by others using similar techniques or by investigating 
quinacrine-stained interphase nuclei for the presence of fluorescent Y chrolllosome signals 
(Schindler and Martin-du-Pan. 1972; Schroder alld de la Chapellc, 1972). 
Another breakthrough was the isolation of fetal lymphocytes by tluorescence-<lctivated cell 
sorting (FACS) lIsing a monoclonal antibody against the human leukocyte antigen HLA-A2, 
which was only expressed on fetal lymphocytes and not on maternal cells (Hcrzenberg ct a/., 
1979; Iverson ct al., 1981). Unfortunately, until now the isolation of fetal lymphocytes is 
considered impractical due to the necessity ofpcrforming HLA typing of both parents and the 
lack of other specific markers ,that distinguish fetal from maternal lymphoc)1es. !'vloreover, 
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the fact that fetal lymphocytes might persist from an earlier pregnancy makes it difficult to 
establish whether isolated lymphoc)1es derive from the current pregnancy (Schroder el al., 
1974). This is especially problematic for the detection or trisomic cells in women with prior 
spontaneolls abortions, given the high likelihood (50%) thal these abortions were associated 
with a chromosomally abnormal fetus (Sargent et (fl., 1994). 
Fetal gruuulocytes 
This fetal cell type has received little .1ttention. In 1975, Zilliaclls el ai, detected fetal 
granulocytes in the circulation of pregnant women. Several years later, \Vessman ef al. (1992) 
isolated granuioc)1es from maternal peripheral blood samples lIsing density gradient 
centrifugation and they corrcctly identified the Y chromosomc in these granulocytes by ill 
situ hybridization. 
1.2.2. Trophoblast cells 
Trophoblast cells are pm1icularly attractive for the development of a non-invasive prenatal 
test because of their unique morphology, which permits microscopic identification. 
Goodtellow and Taylor (1982) were the first to demonstrate trophoblast cells in peripheral 
blood samples fi'olll pregnant women lIsing differential centrifugation and indirect 
immunofluorescence detection. Covone el al. (l984) identified feta I trophoblast cells in the 
peripheral blood from pregnant women using FACS and a monoclonal antibody against a 
syncytiotrophoblast-specific antigen, H315. However, subsequent work showed that thc 
H315-positive cells were of maternal origin (Covone ef al., J988). 1t was suggested that the 
results were due to adsorption of the H315 onto maternal cells and no fetal cells had been 
isolated either in this study or the previous study. These problcms may be overcome by the 
use of new markers, snch as HASH-2, human placental lactogcn hormone (hPL) (Latham ef 
al., 1996) or HLA-G (Moreau el al., 1994; vall Wijk el al., 1996). 
Another difficulty is the fact that trophoblast cells appear to be rarc in the maternal 
circulation, probably because they are able to form large multi-nucleated giant cells which are 
filtered out by the maternal pulmonmy circulation so that they do not reach the peripheral 
circulation (Attwood and Park, 1960). Especially, when the prcgnancy develops normally, 
trophoblast cells do not appear to be present in grcat numbers in maternal peripheral blood 
(Sargent ef al., 1994). However, trophoblast cells arc detectable in increased numbers in 
cascs of preeclampsia, although it is not yet known whether these increased numbers arc a 
calise or an effect of preeclampsia (Chua el al., 1991; Sargent et al., 1994). 
A further concern using trophoblast cells is the fact that they are part of the placenta and 
potential problems may arise when chromosome abnormalities arc prcscnt in the placenta but 
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not in the letus (Henderson el 01., 1996; Goldberg and \Vohlferd, 1997; van Opstal, 1998). 
This confincd placental mosaicism has been documented to occlir in 1 % of all cases of 
chorionic villus sampling. Therefore, genetic analysis of a placental trophoblast cell might 
not be representative of the fetal kmyotypc. 
1.2.3. Fetal nucleated red blood cells 
The last H:w years, most attention has been focussed on the isolation of fetal NRBCs from 
maternal blood. Fetal NRBCs are the prcdomimlllt nucleated cell type in the fetal circulation 
in the first trimester of pregnancy, during the yolk sac and liver phases of hematopoiesis 
(Metcalf and Moore, 1971). In blood of 10- to 20-week fetuses, NRBCs make up 
approximately 10 % oflhe total popUlation, whereas in adults they are quite rare «0.1 %). In 
addition, red cell development in the fetlls is morc advanced than white cell development 
during the tirst trimester (see paragraph 1.1.2., table I). If fetal cell trafficking occurs, they 
are likely to be the major cell type in the maternal circulation. 
NRBCs have been isolated llsing antibodies against membrane-bound markers like the 
transferrin reccptor (CD7I) and glycophorin A (GPA) or intracellular antigens like fetal and 
embl),onie hemoglobin (Lokcn el al., 1987; Bianchi e/ al., 1990; Zheng el 01.,1995; Mesker 
el al., 1998) (see paragraph 1.3.1.). 
Another reason why the isolation of fetal NRBCs is attractive is that fetal NRBCs have a 
limited life span of about 120 days (Pearson, 1967), and are therefore unlikely to persist 
between pregnancies, unlike fetal lymphocytes (Simpson and Elias, 1994). 
1.3. Isolation and identification strategies for fetal cells in maternal blood 
1.3.1. Isolation strategies 
The number of fetal cells in the maternal circulation is limited, and therefore, 1110st efforts 
have been concentrated all the development of a highly efficient enrichment procedure. 
Enrichment call be achieved by either positive selection of target cells using uniquc fetal 
characteristics, or by depletion of contaminating maternal cells. for the isolation of rare cell 
populations two considerations should be taken into account: yield and purity. Yield is very 
impoliant because the number of fetal cells in maternal blood is vcry low and loss of fetal 
cells should be avoided. Purity will be determined by the relative number of fetal and 
maternal cells remaining after enrichment. A relative increase in the absolute number of fetal 
cells after enrichment allows the reduction of the amount of maternal background cells, and 
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thereby, fetal cell idcntificntion by nuorescencc il1 sill1 hybdtii:latioll (FISH) or polymerase 
chain reaction (peR) analysis is facilitated. 
To distinguish ictal cells from the vast majority of their maternal cOlintcll}[lrts a specific 
marker is needed. Until now, no single marker antigen is known that is specific tor fetal cells. 
An overview of isolation approaches that have been designed to recover fctal cells lI'olll the 
maternal circulation is given in tublc 2. 
Table 2 Isolation strategies used for the isolation of fetal cells from the maternal circulation 
-cls~o~la~';~o~n~s~',~a'~,~gLy __________ F~,~ta~I~,c~ILI~')~'p~e ______ ~R~c~~~r~cl~lc~,~s ______________________ . ______ ___ 
Fluorescence activated cell 
sorting (FACS) 
Magnetic activated cell 
sorting (~'IACS) 
Charge now separation 
(CFS) 
Densit)' gradient 
centrifugation 
ImIllunomngnctic bends 
separation 
Illlmunomagnetic colloid 
system 
lymphocytes 
NRBCs 
trophoblast cells 
NRBCs 
trophoblast cells 
NRl3Cs 
lymphocytes 
granulocytes 
trophoblast cells 
NRDCs 
NRI1Cs 
trophoblast cells 
NRBCs 
trophohlast cells 
Avidin-conjugated columns NRBCs 
wilh biotinylated antibodies 
i\licromElnipuiation of NRBCs 
individual cells 
Carbonic anhydrase NRBCs 
inhibition 
Fluorescence actiwtfed cell sorting (FACS,) 
HerLcnbcrg c/ aI., 1979; Iverson e( af., 1981; Bianchi ('I 
al., 1990; Price ('/ a/., 1991; Wachtel el (1/,,1991; Tse 
d al., 1994; Johansen ('( al., 1995; Lewis el 01.,1996; 
Sollda ('I al., 1997 
Ganshil1-Ahlert et al., 1992, 1993; Zheng ellll., 1993; 
Busch e! al., 1994; Durrant ('Ial., 1996; Ganshirt ('I III., 
1998 
Wachtel ('( al., 1996, 1998; Shulman ('( al., 1998 
Bh<lt ct al .. 1993; Ooslt'rwijk Cf a/., 1996; Sitar dill" 
1997; Ganshirt ('( al" 1998; Sekiz(l\\-a ct af., 1999 
WCSSIllOIl ('I af., 1992; Johmls~n ('/ af., 1995; Bianchi c/ 
al., 1996b 
Steele d al., 1996; i\'tartin cl al., 1997; Lim c/ al., 1999 
lIall e/ al., 1994 
Takabayashi ct al., 1995; Sckizawa ('/ al., 1996a, b, 
1998; Watonabe ('I al., 1998 
de Uraafct al., 19990 
FACS or tlowcytometry is used for positive selection of target cells as well as for depletion 
of contaminating maternal cells (Herzenberg el al., 1979; Iverson et al., 1981; Bianchi el al., 
1990; Price el a/., 1991; Woehlel el al., 1991; Tse el al., 1994; .Iolml1sel1 el al., 1995; Lewis 
elal., 1996; Sohda et al., 1997). The sample for s0l1ing is incubated with a tluorescent-
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labeled !lntibody specific for the target cell. The FACSc<ln identifies the cells labeled with the 
tllltibody which arc thell collected into a tube or onto a slide for furthcr analysis, Although it 
is possible to achieve a high purity of target cells making microscopic analysis easier and 
more accurate, this method of fetal cell isolation requires considerable operator expcliisc, is 
time-consuming and the expense of the equipmcnt also limits its application on a wide scale. 
Afagnetic ((ctim/ed cell sorting (XfACS) 
MACS is the most widely uscd method of fetal cell isolation and can be used for positivc 
selection of fetal cells as well as depletion of maternal cells (Ganshirt-Ahlert e/ al., 1992, 
1993; Zhcng ef (II., 1993; Busch ef al., 1994; D'lll'ant ef (II., 1996; Ganshirt ef al., 1998). 
Tmget cells are labeled with an antibody attached to magnetic beads, The cell suspension is 
passed over a separation column with a magnetizable matrix that is placed into a magnetic 
field of extreme strength. Unlabeled cells flow through the matrix, and labeled cells stick to 
the column and can be eluted after being taken away from the magnetic field, MACS 
isolation is less expensive and time-consuming than FACS, and requires less expertise to 
perform, The major disadvantage of MACS is that target cells are contaminated hy maternal 
celis, resulting in low purity, and hence, complicating fetal cell identification. 
Charge .110\1' separation (ep.); 
Charge !low separation, an alternative approach for fetal cell enrichment reqUlnng no 
antibody for cell selection has recently bcen described (\Vachtcl ef aI" 1996, 1998; Shulman 
e/ aI" 1998), The method is based on the migration of cells in an electric field. It permits 
differentiation of cell types according to their characteristic surface charge dcnsities lIsing a 
cross-flow fluid gradient without the need of an antibody. This technology results in a 
signil1cantly higher recovel)' of NRBCs than observed by other groups using conventional 
methods for fetal cell isolation, like FACS and MACS. However, it is presently unclear as to 
whether all NRBCs isolateu by this technique arc offetal origin. 
Antibodies used/or the i.mlation (?!/etal NRBCsji"r)J1111lalernal blood 
A variely of monoclonal antibodies have been used for the isolation of fetal NR13Cs from 
maternal blood samples. The majority of researchers have utilized a 1110noclonal antibody to 
the transferrin receptor (COli) for the isolation of fetal NRBCs (Bianchi et al., 1990; 
Ganshil1-Ahlcli ef al., 1992; Lewis ef al., 1996; Sohda ef al., 1997). CD71 is expressed on all 
cells actively incorporating iron, and 011 nearly all first-trimestcr fetal nucleated blood cells 
(Price ef al., 1991; Wachtel ef a/., 1991; Bianchi ef al., 1992; Ganshili-Ahleli ef al., 1992; 
Durrant e/ al., 1994; Zhcng et aI" 1997). Its expression declines with gestational age but is 
increased in fctuses with an abnormal karyotype (Thilaganathan et aI" 1995; Zheng et aI" 
1999). The disadvantage of C071 is that it is also expressed 011 a sUbpopulation of maternal 
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cells, such as activated lymphocytes, which results in low purity (Bianchi et al., 1994; Zheng 
e!al., 1997). 
Monoclonal antibodies against GPA, present all maturing clythrocyles but not on 
lymphocytes, have been used in combination with anti-CD?I in an altempt to increase the 
specificity of recovery (Price el al., 1991). Unfortunately, anti-GPA causes agglutination of 
the target red cells, preventing efficient sorting (Simpson et al., 1995). 
Other monoclonal antibodies used for fetal NRBCs isolation are those that recognize the 
embryonic (HbE) and lelal (HbF) hcmoglobin (Zheng ef al., 1993, 1995; Reading e! al., 
1995; Cheung el 0/., 1996; Demaria et al., 1996; Lewis el al., 1996; Oosterwijk et al., 1996, 
1998b, c; Mesker ef al., 1998). HbE ("II;-chain), although unique 10 fclal cells, is expressed 
only during a narrow window of time during gestation and ceases during the first trimester of 
pregnancy (Zheng el al., 1999). HbF (y~chaill) is expressed in most fetal cells over a wide 
range of gestational ages. Unf0l1unately, HbF is not fetal-specific since about 1% of adult 
erythroid cells also contain HbF (Turpcincn and Stellman, 1992). Moreover, increased 
cl)'thropoiesis during pregnancy will stimulate the synthesis of fetal hemoglobin in the 
female adult, thereby limiting the usefulness of the HbF antibody (Pembrey et al., 1973; 
Siunga-Tallberg ef al., 1995). 
Additional monoclonal antibodies used for the isolation of fetal NRBCs are presented in 
lable3. 
1.3.2. Identification of fetal celis in maternal blood 
Genetic analysis of fetal cells in maternal blood has relied primarily 011 two techniques: FISH 
using chromosome-specific probes and peR to amplify unique fetal gene sequences enabling 
subsequent DNA analysis of gene mutations. 
Fluorescence in situ hybridization 
The major fetal cell conditions associated with an abnormality in chromosome Ilumber can be 
easily detected by FISH. Since sorted samples arc in interphase, cOllnting the chromosomcs 
by direct visualization is impossible using standard c)1ogcnctic methods. FISH offers this 
possibility by using chromosome-specific labeled probes, which bind to regions of the target 
chromosome. Betore FISH can be applied tor fetal cell identitication, cnrichment of fetal 
cells is necessary to avoid fetal signals being overruled by signals from maternal cells and to 
decrease thc time of microscopic examination to analyse a sufticicnt number of fetal cells. In 
cases of low purity. identification of fetal cells can be improved through bettcr and faster 
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Tabid Cell markers used lor the enrichment of fetal NRBCs and depletion of maternal cells 
Cell marker Expressed 011 
CD7] (transferrin receptor) erythroid cells 
activatcd lymphocytes 
(iPA (glycophorin A) erythroid cells 
HbElHbF erythroid cells 
(embryonic/fetal hemoglobin) 
Blood group antigcns erythroid cells 
Erythropoietin receptor el)1hroid cells 
CD36 (thrombospondin monoeytes 
receptor) platelets 
cl)1hroid cells 
HAE9, FBJ-2, 2-68/6, 113-3 erythroid cells 
(fetlllliver surface antigens) 
CD45 leukoc)1es 
CD32 granu1OC)1CS 
CDI4 monocytes 
Used tor 
enrichmcnt 
cllriehment 
enrichmcnt 
enrichmcnt 
enrichment 
enrichment 
enrichment 
depletion 
depletion 
dcplction 
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recognition of fetal cells through automated scanning (Oosterwijk el al., 1996, 1998a; Tanke 
et al., 1996; de Graaf ct al., 1999a). By combining FISH and immunocytochemical staining 
for HbF, fetal cells can be identified by automated image analysis consisting of computerized 
microscopy, combining bright Held and fluorescence microscopy, and subsequent visual 
evaluation of image memories. Automated image analysis appeared to be more sensitive than 
manual identification of fetal cells (Oosterwijk ct al., 1998a). 
It has now been possible to detect almost all of the significant fetal aneuploidies using fetal 
cells isolated from maternal blood (Price et al., 1991; Bianchi el al., 1992; Cacheux el al., 
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1992; Elias el al., 1992; Ganshil1-Ahlcrt el al., 1993; Simpson and Elias, 1993; Zheng el al., 
1995; Pezzolo el al., 1997; Oostelwijk el al., 1998d; AI-Mufti el a/., 1999; de Graaf el al., 
1999b; Rodriguez de Alba ef al., 1999). These comprise all of the major autosomal trisomies 
including trisomy 13, trisomy 18, trisomy 21, some of the sex chromosome abnormalities like 
47, XXV and 47, XYY, and triploidy. Recent technical advances in FISH analysis of fetal 
cells include the capability to oeteet aneuploidies using multicolor FISH (Bischoff et al., 
1998) and repeated hybridization of cells that permit analysis of all chromosome pairs 
(poly-FISH) (Zhen el al., 1998). Poly-FISH is a technique of sequential FISH analysis that 
involves removal of the previolls hybridized probe and rehybridization with different probes 
to improve FISH efficiency. This technique t:1cilitates the analysis of multiple 
chromosome-specific probes on the Silme nuclei) and thereby) permits analysis of all 
chromosome pairs. 
Interestingly) fetal NRBCs isolated from maternal blood may be more representative of the 
fetal karyotype than chorionic villi obtained through the traditional invasive technique. In a 
case repOli, Bischoff el al. (1995) identified a 46, XY/47, XXV mosaicism in fetal cells 
tlow-sorted from maternal blood. In cultured chorionic villi obtained from the same WOIlUHl) 
only four 47, XXV nuclei were ideillilied out of 500 nuclei analyzed. 
Po~wnerase elwin reaction 
The development of PCR (Saiki et al., 1985, 1988) provides a sensitive method for DNA 
analysis of fetal gene sequences in maternal peripheral blood silmples. peR has been 
successfully applied for the detection of rarc eells such as in cases of minimal residual 
disease in cancer by picking up few malignant eells expressing a genetic markcr susceptible 
of amplification among a large multitude of negative normal cells (Lee el al., 1987, 1989; van 
Dongen et al., 1998). The presence of fetal cells in maternal blood can be investigated by a 
similar approach provided that a suitable genetic marker is available in the fetus and absent in 
the Illothel\ i.e. the Y chromosome and paternally inherited markers. 
Lo et al. (1989) were the first to identify the Y chromosome in the pcripheral blood of 
pregnant women lIsing nested peR for a Y chromosome-specific sequence. They correctly 
identified fetal sex on all 19 cases tested, of which 12 women were calTying a male fetus and 
7 women a female fetus. Thereafter, several groups identil1ed the existence of fetal cells in 
maternal blood by nested PCR analysis (Bianchi el ill., 1990; Lo "I al., 1990, 1993; Kao "I 
al., 1992; Suzumori et al., 1992; Adkison el al.) 1994). However, almost all groups repOlied 
false-positive as well as false-negative results. The main drawback of nested PCR is its 
susceptibility to exogenous contamination necessitating 1110re stringent precautions during the 
tcchnical process to minimize false-positive results. On the other hand, tblse-positive results 
may be ohtained after cross-reactivity with maternal scqllcnces or residual fetal cells from 
previolls conceptuses (see paragraph 1.5.3.). False-negative results can be explained by 
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absence of fetal cells in the maternal circulation or by removal of fetal cells by the matenml 
immune system due to feto-maternal blood group incompatibility. Alternatively, 
false-negative results could simply retleet technical failure because the number of fetal cells 
was below the limit of sensitivity to detect fetal DNA. 
Other uniquely fetal gene sequences that have been detected by peR include variolls 
mutations in bcta globin genes, such as hemoglobin Boston-Lcpore (Camasehella el al., 
1990) or mutations associated with p-thalasscmia (Hawes et al., 1994),lhe HLA-DR and DQ 
alpha genes (Yeoh et (.d., 1991; Geifman-Holtzman et al., 1995), and Rheslls D and Rhesus C 
(Lo e/ al., 1994b; Geilinan-Holtzman e/ al., 1996, 1998; TOtll e/ ,iI., 1998). 
Micromanipulation ([11(/ single cell peR 
Using peR for amplification of fetal sequences that arc contaminated with maternal cells, 
only sex determination and paternally derived disease marker analysis are feasible. In 
approximately 50% of pregnancies, i.e. those with a female fetus, the cell samples can not be 
confirmed to be of tetal origin. Therefore, the development of a ncw method that can 
distinguish between fetal and maternal cells is neeessm)'. By the development of 
micromanipulation of single cells, Ictal cells can be distinguishcd from maternal cells by peR 
amplitication of unique fetal sequences, and thcreby, the identification of other inherited 
diseascs has become available in a laboratol)' setting. Takabayashi et al. (1995) were the first 
to report the lise of micromanipulation to remove single fetal cells isolated from maternal 
blood. They correctly identified fetal sex in ten of clcven cases of which five of six were 
male, with no Hllse positives. The same technique was applied to the diagnosis of Duchenne 
muscular dystrophy, Rhesus D (RhD), HLA-DQ alpha genotype by Sekizawa e/ (/1. (1996a, b, 
1998), diagnosis of spinal muscular atrophy by Chan et al. (1998), and ornithine 
transcarbamylase deficiency by Watanabc el al. (1998). Chcung et al. (1996) lIsed antibodies 
to fetal and/or embryonic hemoglobin to label fetal cells for isolation by miero·dissection 
from slides. They studied 10 pregnancies including one at risk of p-thalassemia and another 
of sickle cell disease. In both cases, they correctly predicted the fetal genotype as confirmed 
by chorionic villus sampling. 
The lise of single cell peR requires a high number of amplification cycles with a risk of 
exogenous DNA contamination resulting in false-positive results. Before single cell PCR can 
be applied for fetal diagnosis, fetal cells have to be identified by e)10iogical/immul1o" 
cytochemical staining requiring cell fixation on slides. This staining procedure and 
subsequcnt manipulation of fetal cells may callse breakage of DNA leading to false-negative 
results. Therefore, amplification of multiple fetal cells should be perfonned in order to obtain 
a reliable diagnosis. So far, micromanipulation and single cell peR of fetal cells has only 
been dcscribed in a laboratory setting. 
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1.4. Feto-maternal cell trafficking 
1.4.1. Timing and proportion 
Another issue involves the timing of feta-maternal transfer. Duc to the vel)' small volume of 
blood in the fetus and placenta, it was originally assumed that too fc\v cells were transferred 
from the fetus to the mother during the first trimester of pregnancy. However, it was 
demonstrated by several investigators that Y chromosomal DNA was present in matenwl 
blood smnples as early as 5 weeks ofgestatioll (La el al., 1990; Hamada el 01.,1993; Uou et 
aI" 1993; Thomas ef a/" 1994), It is most likely that early in gestation trophoblast cells will 
be the first to enter the maternal circulation due to the ongoing process of placentation. 
During this stage of embryonic development the numbers of fetal NRBCs and leukoc)1Cs arc 
expected to be very low. 
In several studies, it has been investigated at what time in pregnancy the number of fetal cells 
in the maternal circulation rcaches its maximum. Rclevant information regarding the 
frequency of rctal NRBCs in maternal blood is contradictOl)" and the frequency of ictal 
NRBCs was reported to Vat)' signiticantly among individuals and throughout the three 
trimcsters of pregnancy ranging from 10.5 to 10-8 (Price et al_, 1991; Hamada et al_, 1993; 
Siunga-Tallberg ef a/., 1995; Smid ef a/., 1997; Ganshh1 ef a/ .• 1998; Kuo, 1998). Using both 
FISH and PCR on llilSOlicd maternal blood, Hamada et al. (1993) reported frequencies of 
fetal NRBCs in the maternal blood ranging from 104 to 10-'. Sohda ef a/. (1997) estimated 
fetal NRBCs frequencies at 8.1 x I 0-5 and 1.6x I 0.5 in the first and secolld trimester. 
respectivcly. Kuo et al. (l998) recently demonstrated all increase in the total number of 
NRBCs in maternal blood as gestation advanced. The frequency increased from 2.4x 10-7 in 
early gestation (6-10 weeks) to 4.2x 10-6 near tenn. Howcvcr, the variations in the frcqueney 
of male DNA equivalents measured by PCR were different, increasing tl-om 2.7:-.:10-7 
(6-10 wecks) to a peak of 1.48x10·6 (15-20 weeks) and then slightly decreased to I.3lx10·6 
(33-39 weeks). This implies that before 24 weeks of gestation a significant proportion of 
NRBCs in matcrnal blood is of tetal origin whilst in late gestation the majority of NRBCs 
llIay be of maternal origin. 
The fetal cell frequency in maternal blood is inlluenced by a number of biological 
parameters_ Factors that may intluence these frequencies include the type of fetal cell 
analyzed, gestational age at the time of sampling and the accuracy of methods to enrich, 
identify and quantify the felal target population_ The occurrence of fetnl cells in matcrnal 
blood has been reported to be increased after chorionic villus smnpling (Jansen ct al., 1997), 
in women with preeclampsia (Chua et a/., 1991; Ganshirt ('I al., 1994; Holzgrcvc el al., 1998; 
La et al., 1999b, Chapter 5), and in pregnancies in which the retal and placental karyotypes 
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were abnormal (Elias et 01., 1992; Ganshirt-Ahlel1 et 01., 1993; Simpson and Elias, 1993; 
Bianchi et al., 1997). For chromosomal abnormal pregnancies, it has previollsly been 
suggested that feto-Illaternai cell trafficking may be the result of altered placental structures 
(Kuhlmann e/ aI" 1990; Simpson and Elias, 1994; Genest el (fl" 1995; Jauniaux and Hustin, 
1998), 
1.4,2, Clearance versus persistence of fetal cells from the maternal circulation 
Disappearance of fetal cells from the maternal circulation atter delivery is an impoliant 
consideration because of the implications for prenatal diagnosis of subsequent pregnancies. 
Clearance of fetal cells from the maternal circulation requires that there arc mechanisms by 
which fetal cells are continuously removed from the circulation. There are virtually no data 
un the fate of fetal cells in maternal blood, at least not in humans. Such data could lead to a 
better understanding of the fetD-maternal immune relationship, and of the purpose of feto-
maternal cell traffic in general. The main mechanisms of fetal cell clearance are removal by 
the maternal immune system, apoptotic cell death due to an inappropriate environment, and 
retention in maternal tissues, 
The fellls is a semi-allograft and it is well established that the paternal antigens elicit a 
response from the maternal immune system (\Vood, 1994). The fetus is protected by an 
unknown mechanism and it is not known whether this protection is also applied to individual 
fetal cells in thc maternal circulation. In mice, a rapid clearance of fetal cells by the maternal 
immune response has been demonstrated and this clearance mechanism would likely affect 
IllOSt types of fetal cells (Bonney and Matzingcr, 1997). Another mechanism may bc 
apoptosis of fetal cells. Proliferating progenitor cells in their variolls stages of differentiation 
nced specific eytokines for survival, otherwise they will apoptosc rapidly (\Villiams et al.) 
1990). These c)10kines are available in the hemopoietic tissues and probably in fetal blood, 
but Inay not be sufficiently supplied in the maternal peripheral blood, leading to fetal ccll 
death. On the other hand, fetal cells can leave the matcrnal circulation to settle in maternal 
tissllcs. These cells are most likely progeny from fetal stem ceUs that have lodged in the 
maternal hemopoietic tissues or trophoblast cells being trapped in the matcrnallungs. 
The possible persistence of fetal cells in maternal blood after delivel), is of concern because 
of the chance that diagnostic error might occur from genctic analysis of circulating cells that 
originated from a previous pregnancy. Long telln persistence of malc fetal cells in maternal 
blood has been described by several investigators (Schroder et aI" 1974; Ciaranti e/ 01., 1977; 
Hsieh et al., 1993; Hamada el 01., 1994; Liou et aI" 1994; Bianchi el al., 1996a). Schroder et 
al. (l974) originally described the persistencc of tetalleukoc)1eS in the maternal circulation 
aner delivel)" In this study, interphase Y body tluorescence was used to determine the 
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frequency of male fetal cells in maternal blood and the kinetics of their subsequent 
disappearance. In a group of 20 primigravidae sampled postpartulll, quinacrine fluorescent 
signals were detected up to I year after delivery. In a related study, Ciaranfi et (II. (1977) 
analyzed samples t1'om wOl11en 5~ 7 years nfter delivcl)' and detected male lymphoc)1Cs 
2 years aftcr bhth in more than half of the 62 samples <lllalyzed, However, these studies were 
performed in the 19705 using techniques that were less sensitive and less accurate than those 
available today. In 1994, Liou et al. investignted the presence of Y chromosome containing 
cells using peR in maternal blood samples from 28 pregnant WOIll.en, These samples were 
obtained lip to 10 months after delivel),. In 11 women, fetal cells were detected lip to four 
months after delivery but in one woman, the Y sequence was still detectable 10 months after 
delivery. Bianchi et al. (1996a) isolated 1110nonucleated cells by F ACS using antibodies to 
CD antigcns 3, 4, 5, 19, 23, 34 and 38, from 32 pregnant women and 8 nonpregnant womell 
who had given birth to malcs 6 months to 27 years earlier. In 4 out of 13 pregnancies with a 
female fetus, male DNA was detected by PCR, whereas in 6 out of 8 nonpregnant women the 
presence of male DNA was demonstrated in isolated CD34+CD38+ cells, even in a woman 
who had her last son 27 years prior to blood sampling. These isolated cells that contained 
male DNA may either have been lymphocytes from that time of pregnancy, or Illay be ,1 
false-positive rcsult since no blood samples were included in this -study that were derived 
from women who never had been pregnant at all. The occurrence of false-positive results is 
not unlikely with the currently used sensitive peR methods used for Y chromosome 
determination (see paragraph 1.3.2.). 
1.5. New research areas 
1.5.1. Fetal DNA in maternal plasma and serum 
Almost all prior studies ill the prist have focused on complete and intact fetal cells in the 
maternal circulation, suitable for either cell culture 01' f-ISH or DNA analysis. Recently, 
however, Lo et 01. (1997, J998a) demonstrated the presence of fetal DNA in maternal plasma 
and serum by llsing a quantitative peR assay tor the sex-determining region Y (SRY) gene 
011 the Y chromosome, as a marker for male fctuses. These Ictal DNA levels gradually 
increased in the course of pregnancy, especially towards the end of pregnancy. They 
demonstrated that significantly more fetal DNA was present in the Sel1l111 and plasma than 
prior studies using intact fetal cells would indicate. A mechanism that could explain these 
t1ndings is continuous leakage of fetal cells across the placcnta which are rapidly destroyed 
by the maternal immune system, leaving DNA remaining in the plasma. This would imply 
that invcstigators who isolated fetal cells fi'ol11 maternal blood only detected a limited fraction 
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of what had entered the maternal circulation. An alternative explanation is that there is active 
remodeling of the placenta at the feto-maternal interi11ce, with continuous ccll lysis and 
release of fetal DNA into the maternal circulation. 
High concentrations of fetal DNA have also been detected in maternal plasma before 
spontaneous pretenn deJivel)l, which may be lIsed as a marker for preterm lahour (Leung ef 
al., 1998). Another clinical application of fetal DNA in maternal plasma/serulll is the 
detection of RhD-speeilic sequences. Knowledge of fetal RhD genotype is imp0l1ant in the 
management of rhesus allo-immunisation during pregnancy. Fetal RhD has been successtlilly 
demonstrated illl11aternal plasma and serum by several investigators (Faas et al., 1998; Lo et 
al., 1998b; Bischoff e/ al., 1999). 
Reccntly, Lo el al. (1999c) analyzed plasma samples of women 1 to 42 days after delivery of 
a male baby and found that circulating fetal DNA was undetectable by day I after delivel)" 
whereas most maternal plasma samples showed undetectable levels of circulating fetal DNA 
by 2 hours postpartulll. Moreover, they demonstrated a rise in plasma fetal DNA 
concentrations shortly after delivel)', i.e. 5 minutes, compared with the predcIivel), fetal DNA 
levels, indicating that a felo-maternal transfusion may OCClll' at time of deli vel)'. The 
observation of rapid clearance of Ictal DNA from maternal plasma suggests that analysis of 
circulating Ictal DNA is morc powerful than analysis of intact fetal cells, because of the 
lower risk to detect Ictal DNA from previous pregnancies. However, technical limitations to 
distinguish fetal DNA from maternal DNA might limit application of this technique. 
The same group (Lo ef al., 1999a) recently demonstrated high concentrations of cell-free fetal 
DNA in plasma samples in a proportion of women carrying a fetus with trisomy 21. 
However, peR amplification of Y chromosomal sequences was lIsed and DNA 
concentrations of normal pregnancies overlapped these of trisomic pregnancies. In order to 
quantitatively analyse the DNA concentration in trisomy 2l pregnancies, additional markers 
on chromosome 21 will be necessary. For a definitive kal)'otypic diagnosis, the isolation of 
circulating nucleated fetal cells still remains the best candidate technology for the 
development of non -invasive prenatal diagnosis of fetal aneuploidies. 
1.5.2. /11 vitro expansion of fetal cells 
If fetal cells could be stimulated to proliferate in culture, the technical limitations of working 
with vel)' small numbers of cells could be overcome. The idea to increase the numbers of 
fetal cells fi'olll maternal blood by amplification of progenitor cells has been discussed for a 
long time. A hemopoietic clonogenic cell can produce hundreds to thousands of progeny, so 
that a culture with even jllst one fetal clonogenic cell could yield a sufficient number of fetal 
cells for the diagnosis of genetic abnormalities. 
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The tirst attempt to culturc fetal cells was reported in 1994. Alter (1994) cultured red cells by 
exploiting the difference in sensitivity of fctal and maternal red cells to cl)1hropoietill in 
culture. The technique was successfully tested in a model system, confinning that there is a 
growth differential in favor of neonatal cells of lip to tenfold. La et aI, (1994a) used a similar 
method in a study on five maternal blood samples where the fetus was known to be male. 
Using peR, they identified the Y chromosome in all five cases after seven days of culture. 
Valerio el al. (1996) utilized a magnetic cell s0I1ing method to separate fetal CI)lthroid 
progenitor cells from maternal blood and slIccessfully cultured them for 10-12 days, followed 
by the detection ofY chromosomal sequences lIsing peR and FISH. 
rvlore recently, Bohmer el al. (I998, 1999) described a novel method to distinguish fetal from 
maternal cells in culture based on differences in fetal hemoglobin production. During the tlrst 
week of culture, fetal el)1hroid cells exclusively expressed HbF, whereas the majority of 
matel1lal cells contained high levels of adult hemoglobin (HbA) alone or a combination of 
HbF and HbA. However, this preferential growth was not observed by others. Two recent 
reports demonstrated that culturing of fetal el)ithroid cells derived from contaminating 
maternal blood mainly produced el)1hroid colonies derived from maternal CI)1hroid 
progenitors (Chen e/ a1., 1998; Han e/ a1., 1999). 
So far, 1110st attcntion has been focussed on thc amplification of fetal cl)1hroid progenitors. In 
1997, Little el al. cultured FACS-s0I1ed CD34+ hemopoietic progenitor cells derived from 
10-13 week maternal blood samples. They showed a slight expansion of fetal CD34+ cells 
after 5 days of culture, but in most cases (10 out of 18 (55 %» 110 male fetal cells could be 
detected. 
These studies suggest that in vitro expansion of fetal cclls is not yet suitable for clinical 
application since the extent of expansion of the different fetal cell types is eontradictOl)' and 
becausc of the small numbers of analyzed cases in the different studies. 
1.5.3. Fetal cell microchimerism 
As described abovc, the possible pcrsistenee of fetal cells in maternal blood after delivel), is a 
concern because of the chance that diagnostic error might occur from genetic analysis of 
circulating cells that originated from a previolls pregnancy. Long term persistence of male 
fetal cells in maternal blood has been describcd by several investigators (Schroder el al., 
1974; Ciaranli el al., 1977; Hsieh et aI" 1993; Hamada el al., 1994; Bianchi el al., 1996a). 
This led to the speculation that normal pregnancy can lead to a physiological state of 
low-grade microchimerislll in a woman. Jt has been suggested that persistence of fetal cells 
atter birth may be related to the etiology of autoimmune disorders that have a higher 
incidence in women and have an onset after the child-bearing years. Evidence for this 
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hypothesis came in 1998, when Nelson demonstrated significantly increased amounts of male 
fetal DNA in peripheral blood of women who suffered from the disease scleroderma, as 
compared to their heahhy sisters and normal controls. In addition, Arlelt et al. (1998) 
demonstrated male lymphoc)1CS in skin biopsies of women with scleroderma. 
At the time of delivel), a feto-maternal transfusion might OCClll" including some fetal cells 
with proliferative potential. These fetal cells can migrate to lymphopoietic organs and 
proliferate. Subsequently, a graft-versus-host response Illay occur, which may result in the 
development of an autoimmune disease. 
1.6. Conclusions and objectives of the thesis 
The last few decades, many investigators have focllssed on the isotation of fetal cells fromlhe 
matel1lal circulation in order to develop a non-invasive prenatal diagnostic test. The optimal 
fetal cell type to target appears to be the fetal NRBCs since they are present most abundantly 
in the fetlls during the first trimester of pregnancy, they have a limited life-span and may not 
persist from prior pregnancies. However, the number of fetal NRBCs in the maternal 
circulation remains velY low and extensive enrichment and purification strategies arc 
necessaty to increase the detectability of these cells. If fetal cells can eventually be isolated, 
possible clinical applications include screening for fetal chromosome abnormalities by FISH 
and for gene abnormalities by PCR. 
Before the isolation of fetal cells can be used for diagnostic purposes! several biological 
questions have to be answered and technical obstaclcs have to be overcome. Froll1 
biological point of view, we need to know more about the number of fetal cells, fctal cell 
types and their propcliies to dit:.tinguish these cells from maternal celis, as well as the 
biological consequences of their presence in the maternal circulation. Data on the frequency 
of fctal cells in maternal blood are contradictOlY as the frequency of fetal NRBCs appears to 
vary among individuals and throughout the three trimesters of pregnancy. Under some 
circumstances, the number of fctal cells in maternal blood is increased, i.e. in cases with a 
chromosomally abnormal fctus, in pregnancies complicated with preeclampsia and anel" 
chorionic villus sampling. From a technical point of view, we need to maximize both yield 
and purity of the isolation procedure to improve the identification of fetal cells. In order to 
optimize isolation strategies, different model systems have been described using m1ifieial 
mixtures of male neonatal cord blood cells 01" male fetal liver ceils, and adult fcmale 
peripheral blood cells. In these model systems, different isolation protocols were evaluated. 
A new research area concerns the ifll'itro expansion of fetal cells. The question as to whether 
fetal cells can he elonally expanded in order to increase their deteetability has partly been 
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resolved by several recent studies. EI)1hroid as well as other hemopoietic progenitor cells 
have been sllccessfully expanded. 
According to these biological and technical questions the following objectives of this thesis 
were detined: 
t. The development of a model system using ill vitro expanded CI)1hroid cells derived from 
umbilical cord blood samples for the evaluation of different isolation strategies for the 
enrichment of fl'lal NRBCs in maternal blood. This part of the study is presented in 
Chapter 2. 
2. Examination of the preferential expansion of hemopoietic progenitor cells derived from 
male umbilical cord blood samples diluted into female progenitor cells, According to this 
expansion protocol, the usefulness of in vitfo expansion of fetal hemopoietic progenitor 
cells isolated from maternal blood for diagnostic purposes was evaluated. Results of this 
part of the study are prcscnted in Chapter 3. 
3. Determination of the effect of chorionic villus sampling on the number of fetal cells 
isolated from maternal blood and 011 maternal serum alpha-fetoprotein levels. Data of this 
study are shown in Chapter 4. 
4. Thc impact of maternal preeclampsia on the incidence of fetal cells in the maternal 
circulation. These results are presented in Chapter 5. 
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The lLMile of iiml vitro expanded erytlmroid 
ICelllis iiml ~ modell systtem fOlf tthe isoli~ttJi.oJtll 
of femli ceHs from m~ttem~li lbliood 
Published in Prenatal Diagnosis (1999), vol. 19, p323-329 
The isolation of fctal cells from maternal blood is hampered by the low frequency of these 
cells in maternal blood requiring extensive enrichment and purification procedures before any 
detection techniques for fetal cells can be applied. A considerable amount of effort has been 
concentrated on the improvement of different isolation techniques. The currently lIsed 
isolation strategies, like MACS and FACS have been optimized usiug model systems in 
which male umbilical cord blood cells or fetal liver cells were diluted into adult female 
peripheral blood mononuclear cells. This chapter describes the use of in vitro expanded 
CI)'throid cells in a model system for the isolation of fetal cells from maternal blood. These 
cells were iml11unophenotypically identical to fetal Ilucleated red blood cells isolated from 
maternal blood expressing high levels o~ CD71 and were lIsed to compare two different 
MACS isolation procedures: isolation of CD7l+ cells after depletion of lymphocytes and 
monoc)1es, and the direct enrichment of CD?I + cells. 
1) John Wiley & Sons Limited; reproduced with permission. 
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ABSTRACT 
The development of a non~invasive prcnatal diagnostic test using fetal nucleated red blood 
cells (NRBCs) isolated from the maternal circulation is hampered by the low frequcncy of 
these cells in maternal blood requiring extcnsive enrichment procedures before any analytical 
procedure can be pertormed. In order to improve and simplify these proccdures, we have 
used in vitro expanded CI),throid cells derived from male umbilical cord blood in a model 
systcm lor thc isolation qf fetal NRBCs from maternal blood. Erythroblnst cells were ill \'ilro 
expanded to high cell numbers and wcre immunophcllotypieally identical to fctal NRBCs 
isolnted from maternal blood. Magnetic activated cell sorting (MACS) isolation procedures 
wcre optimized using in vitro expnllded male NRBCs diluted up to 1 in 400,000 with femnle 
peripheral blood monollueleatcd cells. The number of recovered male cells was determined 
using two-color fluorescence in situ hybridizntion with X and Y chromosomal probes. Using 
this model system, an NRBC isolation technique is described, It is based on a one-step 
MACS enrichment protocol for CD7l+ cells, which showed a signil1cant (\Vilcoxon signed 
ranks test, p<0.05) two~fold higher yidd of male NRRCs than previollsly described ~\'lACS 
methodologies, in which CD7l -+ cells were enriched after depletion of other cell types. 
Application of thl:se isolation strategies to maternnl blood samples resulted in n similar 
improved enrichment of male felnl cells aftcr the direct enrichment ofCD71 + cells. 
INTRODUCTION 
Fetal blood cells that leak through the placenta into the maternal circulation provide a 
potential source of fetnl matcrial tOI' the development of a nOI1~ill\'nsive pret1ntnl dingnostic 
test. Four uifferent fetal cell types have been detected in maternal blood: trophoblast cells 
(Goodfellow and Taylor, 1982), lymphoc)1es (Herzenberg el al., 1979), granuloc)1es 
(Wessman el al., 1992) and nnelcated red blood cells (NRBCs) (Bianchi el al., 1990). Most 
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attention has been focused on the NRBCs which hnve been isolated lIsing antibodies against 
membrane-bound markers (CD7I, glycophorin A) 01' intraccllular antigens (hemoglobin F) 
(Loken el 01., 1987; Bianchi el al., 1990; Zhcng el al., 1995). 
Since the number of fetal NRBCs in maternal blood is very low, isolation of these cells 
requires extensive enrichment and purification procedures. Two nH~ior methods of cell 
separation enable fetal cell isolation from maternal blood: fluorescence activated cell sorting 
(FACS) (Bianchi el al., 1990) and magnetic activated cell s0I1ing (MACS) (Ganshirt-AhlcI1 
el al., 1992). 
In order to obtain an optimal isolation procedure, different modcl systems have been 
described using artificial mixtures of male neonatal cord blood cells or male fctal liver cells, 
and adult female peripheral blood mononuclear cells (Andrews e! al., 1995; Bianchi e! al., 
1996). In these model systems, different isolation protocols were evaluated using density 
gradient centrifugation, MACS, F ACS or illllllullomagnctic beads for the isolation of 
CD7l + NRBCs, after depletion of fcmale peripheral blood mononuclear cells. 
In the present study, we describe a MACS isolation protocol, in which we used in vitro 
expanded NRBCs derivcd from male umbilical cord blood mixed with female peripheral 
blood monollllcleated cells as a model system for the isolntion of fetal NRBCs from maternal 
blood. \Ve were able to expand these NRBCs to high cell numbers and to maintain these cells 
in an erythroblastic cell stage. These in vitro expanded NRBCs also showed a high level of 
CD71 expression, In the described model system, CD7l + cells were isolated lIsing a one-step 
MACS isolation protocol based on the direct enrichment of CD7l + cells. This isolation 
procedure is compared with a previously published and commonly used two-step technique 
based on depletion of lllonoc)1es (CDI4) and lymphocytes (CD45) followed by the 
enrichment ofCD71+ cells (Busch et al., 1994; Jansen e! al., 1997). It is suggested that these 
depletion procedures may cause cell damage and cell loss, leading to lower levels of recovery 
of fetal NRBCs. Isolation efficiencies tor both MACS isolation proccdures were also 
compared tOI' the isolation of male CD71 + fetal cells from maternal blood samples. The 
number of recovered male CD71+ cells was analyzed by two-color FISH for X and Y 
chromosomes. 
MA TERIALS AND METHODS 
/n "itro expansion 0./ elyt hroblas! cells 
Male umbilical cord blood samples (1-5 ml) were collected immediately aner birth into 
vacutainers containing ethylenediaminetetra-acetic acid (EDTA). Blood snlllpies were diluted 
1: I with phosphate buffered saline (PBS) and mononucleated cells wcre isolated by Ficoll~ 
Paque-Plus (1.077 glml; Pharmacia Biotech, Uppsala, Sweden) density gradient 
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centrifugation at 750 G for 20 minutes. Cells were washed once with lscovc's modified 
Dulbecco's medium (Life Technologies B.V., Breda, The Netherlands) containing to % fetal 
calf serum (FCS) and centrifuged at 370 G for 5 minutes. Cord blood cells were cultured as 
recently described by von Lindern et al. (1998). Brietly, cells were cultured at 37 "C and 
5 %C02 at a density of 106 celis/ill I in CFU-E medium as described previously (Hayman et 
al., 1993; Schroeder et al., 1993), with minor modifications: conalbumin was replaced by 
human transferrin-holo (Intergen, Toronto, Canada), chicken serulll was omitted and only 
FCS (12 %) was used. Human stem cell factor (100 ngll11l), human recombinant 
elythropoietin (0.5 U/ml; Boerhinger Mannheim GmbH, GcnllCIIlY), and dexamethasone 
(106 fv1; 0-1756, Sigma-Aldrich Chemie GmbH, Stcinheim, Gennany) were added every 
second day. After two days, remaining erythrocytes were removed by Ficoll-Paquc-Plus 
density gradient centrifugation at 750 G for 20 minutes. After 7-10 days, erythroblast cells 
(NRBCs) were isolated using Percoll (1.072 g/ml; Pharmacia Biotech). The number of cells 
and cell size distribution were"determined in an electronic cell counter (Casy-I.; Schtirfc 
system, Germany), followed by analysis of CD71 and CD45 expression lIsing a FACSscan 
(Becton Dickinson, San Jose, CA, USA). On day l2, ullulilized ill \'itro expanded erythroid 
cells were aliquotcd and stored in liquid nitrogen until further usage. 
To analyze cell morphology, cells were c)10centrifuged onto slides and stained with 
hematological dyes and neutral benzidine for hemoglobin (Beug et 01., 1982). 
AIodel .~ystem 
Two different MACS isolation procedures were compared using a mixture of male in \'itl'o 
expandcd NRBCs and female peripheral blood mononuclear ceils. To this end, 50 or 500 
male CD71+ICD45- cells were diluted in 10-20x106 female cells. The one-step method 
involved the direct enrichment of CD71 + cells, whereas the two-step method included 
depletion ofCD45+ and CDI4+ cells followed by the enrichment ofCD7I+ cells. 
Patient samples 
Peripheral venous blood samples (13-20 Ill!) were obtain cd from pregnant v.,ramen at 
12-14 weeks of gestation immediately before chorionic villus sampling (CVS), and collectcd 
into vaclltainers containing ethylenediaminetetra-acctie acid (EOTA). In 31 cases, the fetal 
kmyotype was 46,XY as was demonstrated by cytogenetic analysis on semi-direct villus 
preparations. The one~step MACS isolation procedure was lIsed in 14 of these maternal blood 
samples, whereas 17 cases were subjected to the two-step method. All blood samples were 
obtained with the patients' informed consent. 
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Allfihm()! labeling, FACS ({na~l'si!:; and MACS' sep(ff'((lio}1 
111 vitro expanded NRBCs derived from male umbilical cord blood were labeled with 
C07l-riTC (5 plll06 cells: 100 pg/llll: LOI.I, IgG2a, Becton Dickinson) and CD45-PE 
(51111106 cells: CLB, Amsterdam, The Netherlands) in 200 III MACS buffer (PBS containing 
1 % BSA, 0.0 I % sodiulll azide (NaN)) and 5 mM EDTA) supplcmented with 5 % human 
serum and the CD71 and CD45 expression was measured lIsing a FACSscan. In evel), 
experiment, only NRBCs with an expression of C07I in 95-99 % of the cells and a CD45 
expression in less than 5 % orthe cells were used. 
Maternal blood samples and peripheral venolis blood samples of non-pregnant fcmale 
volunteers were diluted I: I with PBS and mOllollucleated cells were isolated by Ficoll-Paquc-
Plus density gradient centrifugation at 750 G for 10 minutes. Cells were washed twice in 
MACS buffer and centrifuged at 250 G for 10 minutes. The Humber of viable cells was 
calculated using a BUrkeI' counting chamber. 
Mononuclear cells derived from maternal blood and mixtures of 50 or 500 male C071 + cells 
with 10-20 x 106 female mononuclear cells were processed for the ditlerent MACS isolation 
procedures. For the one-step procedure, cell sllspensions were labeled on ice with 
CD71-FITC (10 1111106 cells) in 200 III MACS buffer with 5 % human serum for 15 Illiuutes. 
Cells were washed in MACS buffer and labeled with IgG2a+b-conjugated microbcads 
(20 pili 07 cells; rvliltenyi Biotcc~ Bergisch Glaubach, Germany) for 15 minutes at 4 \lC. Cells 
were washed ill MACS buffer, resuspended in 1 Illi MACS buffer and applied via a pre-
separation filter (30 pm; CLB) onto a miniMACS column (type MS; Miltenyi). The nOI1-
attached fraction was collected and applied again to the column in order to achieve (111 
optimal depletion. After removing the column from the magnet, C07I+ cells wcre eluted 
with 101111 MACS buffer. For the two-step procedure, cell labeling and MACS separation 
were performed as described previollsly (Jansen et al., 1997). Brieny, cells were labeled for 
15 minutes on icc with CD45-PE (50 11I/20 x 106 cells) in 200 III MACS buffer with 5 % 
human serum, washed once in i'vIACS buffer and labeled with CD1<-1-conjugatcd microbeads 
and rat anti-mollse IgGl-conjugated microbeads (20 ~tl1I07 cells each; j'vtiltenyi Biotec) at 
<-1°C for 15 minutes. Labeled cells were resuspended in I ml i'vIACS buffer and applied to an 
AS-dcpletion column (Miltenyi) using a 26G needle as flow resistor. The negative fraction 
was applied again to the column in order to achieve an optimal depletion. Antibody labeling 
and l\'IACS separation for the negative fraction obtained after depiction was performed as 
described tlJl' the one-step isolation proceJure. The number of viable cells ill each fraction 
was calculated using a BUrkeI' counting chamber. 
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j;1uorescellce ill situ hybridization (VISH) 
Cell fractions were treated with 75 mM KCI, incubated for 18 minutes at 37°C, fixed in 
methanol: acetic acid (3:1) and stored at _20°C until further analysis, Cells were dropped 
onto Vectabond™ (Vector Laboratories, Inc, Burlingame, CA, USA) coated slides and 
air-dried, Slides were heated for 10 minutes at 80°C and pre-treated with pepsin (l00 ~Ig/ml) 
in 0,01 N HCl at 37°C for 15 minutes, followed by postfixation in 3,7 % formaldehyde in 
PI3S for 15 minutes, Subsequently, slides were denatured for 5 minutes in 70 % fOllllamide 
(pH 7.5) in 2X SSC at 75 "c, followed by dehydration in 70 %, 90 % and 100 % ethanol for 
1 minute each, Slides were prewarmed at 45°C until the probe was applied, 
Two-color FISH was performed using a Spectrum Orange labeled alpha-satellite probe 
(DXZl) for centromcre region Xp 11.1-'1 11.1 and a SpectrumGreen labeled satel! ite III probe 
for the Yq12 rcgion (Vysis, Downers Grove, IL, USA), The probes were dcnatured for 
5 minutes at 75°C and hybridization was allowed to eontinlle overnight at 42°C in a 
humidified chamber. 
Slides were post-washed at 70 "c in OAX SSClO.3 % NP-40 (pH 7.2), followed by 
5-60 seconds in 2X SSC/O,I % NP-40 (pH 7,2) at room temperature, Slides were mountcd in 
Vcctashield mounting medium (Vector Laboratories, Inc,) containing DAPI (4', 6-diamidino-
2-phcnylindolc) and analyzed under a Leica Aristoplan fluorescence microscope using a 
triple band-pass filter block, Images were captured using a Xybion CCD 24-bit color camera 
with a Genetiscan Probe Master system and MaeProbc 2,5 image analysis software (PSI, 
Chester, UK). 
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RESULTS 
i\Iodel !lysfem 
Male neonatal NRBCs were in \'itro expanded by exposure to stem cell factor (SCF)~ 
erythropoietin and dexamethasone. After eight days in culture, an increase in cell size 
(figure 1), a decreased expression ofCD45 and an increased expression orCD71 were noted 
(figure 2). The expanded cell population was characterized by all expression of C045 in less 
than 5 % of the cells and a CD7l expression in 95 % to 99 % of the cells. i'vlorphologically, 
these cells predominantly resemble procl')1hroblast cells and basophilic cl),throblast cells 
(tigure 3). 
Cell mixtures of 50 or 500 expanded male NRBCs and 10-20 x 106 female peripheral blood 
mononuclear cells were lIsed for MACS isolation of NRBCs. Two MACS isolation 
procedures were compared: a olle~step protocol based on the enrichment of CD71+ cells 
alone, and a two-step isolation procedure in which CD71 enrichment was combined with an 
initial depletion ofCD45+ and CDI4+ cells. 
Figure 2 
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The number of XY cells in the MACS-cnriched thlctions was dctcnnincd by two-color FISH 
using X and Y chromosome-specific probes (figure 4; table 1). The total number of cells in 
Ihe CD71+ fi'aclionlhal was analyzed by FISH ranged belween 1-25 x 10' (mean 10.8 x 10') 
after the one-step isolation procedlll'e and between I-II x 10"' (mean 5.3 x 10"') after the 
two-step isolation procedure (table 1). Using the one-step isolatiotl procedure, the number of 
XY positive cells recovered after addition of 50 male CD?l+ celis, ranged from 2-25 XY 
cells (4-50 %) with a mean of 8 XY cells (16 %), whereas after addition of 500 male 
CD?! + cells, the number of XY positive cells varied between 32 and 195 XY cells (6-39 %), 
with a mean number of XY cells of 79.8 (16 %). The number of XY positive cells in the 
CD71 + fraction recovered after the two-step isolation procedure ranged fi'om 2-9 XY cells 
(4-19 %) aftcr addition of 50 male CD71+ cclls, with a mcannumbcr ofcclls of 4.2 XY cells 
(8.3 %). After add ilion of 500 male CD71+ cells, between 5 and 130 XY cells (1-26 %) could 
be identified in the CD?l + fraction, with a mean Ilumber of XV cells of39.7 (7.9 %). 
Figure 3 
Combination of a hematological and 
neutral benzidine staining for 
hemoglobin of ill vitro expanded 
erythroid cells derived from male 
umbilical cord blood. More mature 
erythroid cells stained yellow to 
brownish due to the presence of 
hemoglobin. 
Figure ... 
111 sitll hybridization on a MACS· 
enriched fraction of female peripheral 
blood mononuclear cells mixed with a 
known number of ill vitro expanded 
male erythroid cells. One male 
erythroid cell is shown characterized by 
both a Y (green) and an X (red) 
chromosomal signal, and several female 
peripheral blood mononuclear cells are 
shown \vith two X chromosomal 
signals (red). (magnification xlOOO) 
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After addition of 50 as well as 500 male CD7I + cells, the one-step isolation procedure 
showed a mean number ofXY positive cells twice as high as the number orXY positive cells 
recovered after the two-step isolation procedure. This higher level of recovery was significant 
in the condition in which 500 male CD7I + cells were added (\Vilcoxon Signed Ranks Test, 
p<O.05). 
Tnble 1 Number of XY cells recovered after r..'IACS isolation using the one-step and two-step 
procedure 
One-step procedure Two-step procedure 
Number of cells Number xv cells in Number of cells Number XY cells in 
analyzed (x 1 0-1) C07l + fraction analyzed (x 1 O~) CD71+ fraction 
Experiment I 
50XY+ 12x 106 XX 25 (50 %) 9 7 (14 %) 
500 XV + 12 X 106 XX 5 195 (39%) 6 130 (26%) 
Experiment 2 
SOXY+ lOx 106 XX 4 5 (10 %) 3 (6 %) 
500XY+IOxIO(;XX 4 77 (15 %) 11 12 (2.4 %) 
Experiment 3 
50 XY + 20 x 10(; XX 25 4 (8%) 6 9 (\S %) 
500XY+20x 106XX 20 91 (IS %) 3 3t (6%) 
Expcriment 4 
50XY+ 12x 106XX 7 3 (6 %) 3 2 (4%) 
500XY+ 12x 106XX 7 32 (6%) 8 34 (7%) 
Experiment 5 
50XY+15xl06 XX 6 2 (4 %) 2 (4 %) 
500XY+15xlO(;XX 7 45 (9%) 7 26 (5 %) 
Experiment 6 
50XY+15x106 XX 21 9 (IS %) 5 2 (4 %) 
500 XY + 15 X 106 XX 22 39 (8%) 4 5 (I %) 
I\lcan vHlucs 
50 XY 10.7 8.0 (16 %) 4.2 4.2 (S.3 %) 
500 XY 10.8 79,S (16 %) 6,5 39.7 (7.9 %) 
A/aterl/al blood samples 
The two different rvlACS isolation procedures were also used for the isolation of fetal NRBCs 
from maternal blood. Maternal blood samples, from pregnancies from which the 
fetal karyotype was 46,XY, were obtained before chorionic villus sampling (CVS) from 
31 pregnant women at 12-14 weeks of gestation. In 14 cases, cells were isolated using the 
one-step MACS isolation procedure, whereas in 17 cases the two-step isolation procedure 
was used (table 2). The number of mononuclear cells before MACS isolation 
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Table 2 Number of XY cells recovered from mutcrnu[ blood ufter MACS isolution using the 
one-step und two-step procedures 
Karyotype Gestational age Number of cells befixe Number of cells Number ofXY cells 
(weeks) i\lACS isolation (xI06) analyzed (x I 0-1) 
One-step procedllre 
46, XY 12 24.0 5 0 
46, XY 13 32.4 88 IJ 
46,XY 14 24.0 20 0 
46, XV 12 32.4 30 0 
46, XY 12 36.6 48 0 
46, XV 12 30.9 16 0 
46, XY 12 26.3 21 0 
46, XY 13 23.4 15 0 
46, XV 12 33.3 IQ 2 
46, XY 13 24.9 22 2 
46, XY 12 49.8 25 2 
46, XY 12 23.4 23 I 
46, XY 12 16.3 24 0 
46, XY 13 30.9 4Q 2 
iV[ean values 12 29.2 28.9 0.6 
Two-step procedure 
46, XY 12 24.3 II 0 
46, XY 12 28.5 9 0 
46, XY 12 38.7 27 0 
46, XY 12 38.7 18 I 
46, XY 12 31.3 8 I 
46, XY 12 49.0 29 0 
46, XY 12 29.0 25 2 
46, XY 12 35.1 II I 
46, XY IJ 42.0 80 0 
46, XY 12 17.0 6 0 
46, XY 12 55.0 1.5 0 
46, XY 12 41.7 14 0 
46, XY IJ 13.2 8 0 
46, XY 12 31.2 21 0 
46, XY 13 26.4 20 0 
46, XY 12 23.0 14 0 
46, XY 12 30.3 17 0 
1\fean values 12 32.6 18.8 0.3 
ranged from 16.3-49.8 X 106 (mean 29.2 x 106) for the one-step isolation procedure and from 
13.2-55.0 x 106 (mean 32.6 x 106) for the two-step isolation procedure. The Ilumber of cells 
analyzed in the CD71+ fraction ranged between 5-88 x 104 (mean 28.9 x 104) after the 
one-step isolation procedure and between 1.5-80 x 104 (mean 18.8 x 104) after the two-step 
isolation procedure. The number of XY positive cells that was found after the one-step and 
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two-step isolation procedures varied between 0 and 2 Xl' cells! with a mean of 0.6 and 
0.3 XY cells, respectively. In 5 out of 14 cases (35.7 %) and in 4 out of 17 cases (23.5 %) 
XY positive cells could be detected llsing the one-step 01' two-step isolation protocol, 
respectively. This bettcr enrichment of male cells after the direct enrichment of CD71 + cells 
did not reach statistical significance. 
DISCUSSION 
In this paper, we describe a model system for the isolation of fetal cells from mntcrnal blood 
lIsing in "Uro expanded NRBCs derived from male umbilical cord blood. Umbilical cord 
blood was prefered above adult peripheral blood because of the larger amount of immature 
erythroid cells. Although fetal blood samples contain lllallY immature erythroid cells, they arc 
more difficult to obtain and arc frequently contaminated with significant amounts of maternal 
blood. 
Two different MACS isolation procedures were compared by analysis of recovery of known 
numbers of male cells mixed into female cells. In contrast to previously reported model 
systems for fetal cell isolation from maternal blood (Andrews et al., 1995; Bianchi et al., 
1996), in which cord blood cells or fetal liver cells were used, we were able to obtain a 
homogenolls el)1hroid cell population derived from in vitro expanded umbilical cord blood 
cells. These clythroid cclis could be il1vitro expanded to high cell numbers (101_108 el)lthroid 
celis/ill I cord blood, after 10-15 days of culturing) and could be maintained in an 
el)1hroblastic ceIl stage. The expanded el)1hroid celIs were illllllllllophellol),picaIly idenlical 
to fetal NRBCs derived from 10-20 week fetal liver (Bianchi, 1994), expressing high levels 
of CD71, a cell surface Ilwrker frequently used for the isolation of fetal NRBCs from 
maternal blood. This might indicate that the in vitro expanded erythroid cells resemble fetal 
NRBCs circulating in maternal blood. 
Using these CD7l + cells, we were able to quantitatively compare two different MACS 
isolation procedures: a one-step isolation procedure which includes the enrichment of 
CD71 + cells alone, without depiction of other cell types, and a previollsly described (Busch 
el al., 1994; Jansen el al., 1997) and widely employed two-step isolation procedure which 
includes Ihe depletion of monoc)1es (CDI4) and lymphoc)1es (CD45) followed by the 
enrichment of CD71 + cells. Although the results of our experiments demonstrated a marked 
variation in the number of male cells recovered, the MACS isolation based on the enrichment 
ofCD71+ cells alone was found to be two-tbld more efficient and less time consuming than 
the combined depletion/enrichment protocol. 
The two different MACS isolation strategies were also llsed for the isolation of fetal 
CD71 + cells from maternal blood samples. Although the number of male cells that could be 
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isolated from maternal blood was VCI)' low (0-2 cells per sample), it was shown that the one-
step procedure resulted in a tcndency towards a better recovcl), of male cells compared with 
the two-step protocol. 
Thc one-step MACS isolation procedure was also shown to result in a highcr absolute 
numbcr of cells in thc CD71+ fraction, in the model systcm as well as in maternal blood 
samples. This increase was due to the presence ofCD4S+ CD71+ and CD14+CD71+ cells, 
Iikcly representing activated lymphocytes and monocytes of maternal origin, respectively, 
which are depleted atler the two-step MACS isolation procedure. Altelllativciy, the CD71+ 
fraction obtained after the one-step isolation procedurc may comprise cells of the el)1hroid 
lineage that still express CD4S at a low levcl and which werc not depleted using the 
combined depiction/enrichment protocol. This may explain the two-fold higher yield of male 
cells observed after the one-stcp isolation protocol. 
An intcresting question that arises is, whether the ill vitro cxpansion protocol for erythroid 
cclls described in this paper can also be used for the cxpansion of fetal NRBCs derived from 
maternal blood. It has previously been described that fetal committed el)lthroid progenitors 
(CFU-E, M-BFU-E) derived from matcrnal blood were successfully proliferated in vitro after 
their prior enrichment by biotin-labeled human el)1hropoietin ligand and MACS (Valerio el 
al., 1996). Also the expansion of CD34+ hematopoietic progenitor cells isolated from 
maternal blood by FACS has been reported (Little e/ 01.,1997). However, Chen e/ 01. (1998) 
recently showed that culturing of fetal el)1hroblast cells derived from maternal blood mainly 
produced el)1hroid colonies derived from maternal el)1hroid progenitors. In gencral, 
expansion of fetal cells for analytical purposes is highly desirable given the rarity of these 
cells in the maternal circulation. Amplification of the number of fetal NRBCs using 
expansion protocols like the one described in this paper, might facilitate nOll-invasive 
prcnatal detection of genetic abnormalities in the future. Howevcr, fetal eell enrichment 
protocols should be improved tlrst in order to acquire higher rccovery levels of fetal cl)1.hroid 
cells. 
In sllmmm)" a more efficicnt and less time-consllming one-step ivlACS isolation procedure is 
described that improvcs the isolation of NRBCs in both the model system as well as in 
maternal blood samples. In addition, the in vitro cxpanded NRBCs llsed in thc model systcm 
may not only be used to optimize diffcrcnt isolatioll strategies, but may also be of help in the 
developmcnt of new detection and analysis techniques for fetal el)'throiu cells isolated from 
maternal blood. 
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The idea to increase the number of fctal cells from maternal blood by amplification of fetal 
hemopoietic progenitor cells has been discussed for a long time. If fetal cells could be 
stimulated to proliferate in culture, the technical limitations of working with Vel)' small 
Ilumbers of cells could be overcome. This chapter describes the evaluation of the usefulness 
of in Vi/I'D expansion of fetal hemopoietic progenitor cells from maternal blood for diagnostic 
purposes. In order to determine whether limiting numbers of fetal CD34+ cells present in an 
excess of maternal cells are able to overgrow the maternal component, we used a model 
system in which limiting numbers of male CD34+ umbilical cord blood cells were diluted 
into female CD34+ peripheral blood mononuclear cells and in vitro expanded in liquid 
culture. The same culture protocol was applied to CD34+ cells isolated from maternal blood 
samples obtained at 7-16 weeks of gestation and the number of XY positive cells was 
determined lIsing FISH for X and Y chromosomes. 
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ABSTRACT 
Fetal cells present in the maternal circulation are a potential source of fetal DNA that can be 
used for the development of a prenatal diagnostic test. Since their Ilumbers arc vel)' low, 
amplification of fetal cells has been discussed for a long time. So far, most studies have 
focllssed on culturing fetal erythroid cells. In this study, wc evaluated whether limiting 
numbers of fetal hemopoietic progenitor cells present in an excess of maternal cells wcre able 
to overgrow the maternal component. Thercfore, we lIsed a model system in which limited 
numbers of male CD34+ umbilical cord blood cells were diluted in 400,000 female CD34+ 
peripheral blood cells. The number of xv positive cells derived from umbilical cord blood 
was detcrmined lIsing two-color in si(1I hybridization with X and Y chromosomal probes. \Ve 
demonstrated a ISOO-fold relative expansion of malc umbilical cord blood cells ovcr the 
peripheral blood component after 3 weeks of liquid culture, which also corresponded to the 
extent of expansion of CD34+ cclls derived from 20-week fetal blood. However, application 
of the same culture protocol to maternal blood samples obtained at 7-16 weeks of gestation 
showed no preferential growth of tetal hemopoietic progenitor cells. This study, therefore, 
suggests that fetal primitive hemopoietic progenitor cells do eithcr not circulate in maternal 
blood before 16 weeks of gestation, or require different comhinations/concentrations of 
c)10kines for their in vi(ro expansion. 
INTRODUCTION 
Thc development of a non-invasive prenatal diagnostic test using fetal blood cells that leak 
through the placenta into the maternal circulation would eliminate the small but significant 
risk to the fetus associated with more traditional procedures like chorionic villus sampling 
and amniocentesis. Fetal cell types that have been isolated tl"ol11 maternal blood include 
nucleated red blood cells (Bianchi et al., 1990), lymphoc)1es (Herzenberg el al., 1979), 
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granulocytes (Wessman el al., 1992). trophoblast cells (Goodfellow and Taylor, 1982), and 
hemopoietic progenitor cells (Bianchi ef al., 1996b; Little c/ al., 1997). However, frequencies 
of these cell types arc velY low. Factors that may influence these frequencies include the type 
of fctal cell analyzed, gestational age at the time of sampling and the accuracy of methods to 
enrich, identify, and quantify the fetal target population. The incidence of fetal cells in 
maternal blood has been reported to increase after chorionic villus sampling (Jansen ef al., 
1997), in patients with preeclampsia (Holzgrcvc e/ (fl., 1998; La ef af., 1999; Jansen el af., 
submitted), and in pregnllllcies in whkh the tetal and placental kal)'olype were nbnormnl 
(Elias e( ai., 1992; Ganshirt-Ahlel1 e( ai., 1993). 
Despite all efforts to develop enrichment procedures such as tluorescence-activated cell 
s0l1ing (FACS) (Bianchi e( ai., 1990, 1996a) and magnetic cell s0I1illg (MACS) (GanshiI1-
Ahlert el al., 1992; Jansen el al., 1999) that would increase the delectability of fetal cells in a 
maternal blood sample, the number of fetal cells recovered still remains vel)' low. 
Considerable progress has been made in the qualitative assessment of fetal cell populations 
found in maternal peripheral blood. However, more information is needed regarding the 
enumeration and characterization of fetal cell populations that circulate during pregnancy. 
The question as to whether fetal cells present in maternal blood samples ean be in vitro 
expanded has been partially resolved by several investigations. Lo ct al. (1994) were the first 
who were able to eulture fetal el)1hroid cells from maternal peripheral blood by exploiting 
the growth advantage of fetal cells over maternal cells. Also, the successful prolitcralioll of 
fetal committed el)1hroid progenitors (CFU-E, M-BFU-E) derived fi'olll maternal blood has 
been described (Valerio e( ai., 1996, 1997). However, two reccnt repolis (Chcn e( ai., 1998; 
Han et al., 1999) have cast doubt on the proposition that maternal blood reliably contains 
fetal c1onogenic el)1hroid cells. Recently, Little el al. (1997) were able to expand FACS-
s0l1ed CD34+ hemopoietic progenitor cells derived from maternal blood samples. They 
showed a 2-5 fold expansion ofCD34+ fetal cells atter 5 days of culture. 
So far, most attention has been focussed on the amplification of fetal el)1hroid progenitors. In 
the present study, we evaluated the usefulness of the expansion of tctal hemopoietic 
progenitor cells derived from maternal blood samples for the development of a lion-invasive 
prenatal test. Since it is known that after ivlACS separation fetal cells arc otten contaminated 
with an excess of maternal cells, we aimed at selectively expanding tew fetal cells as 
compared to the maternal component. Therefore, limiting numbers of CD34+ cells derived 
from male umbilical cord blood (UCB) were spiked in an excess of CD34+ cells dcrived 
from female peripheral blood (PB). Cells were cultured for lip to three weeks, and the Ilumber 
of XY cells was determined evel), week by fiSH analysis using X and Y chromosome-
specific probes. In order to evaluate whether the expansion capacity of hcmopoietic 
progenitor cells derived from umbilical cord blood was comparable with growth profiles of 
fetal cells in maternal blood, we also examined the culture characteristics of CD34+ cells 
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derived from fetal blood (FB) smnples. FB samples were obtained through cordocentesis at 
20 wceks of gestation. Below that age, the success rate of this technique becomes markedly 
reduced. However, in order to develop a non-invasive prenatal diagnostic test lIsing fetal cells 
in maternal blood, it is important to obtain maternal blood samples as early as possible. Fctal 
hemopoiesis starts in the yolk sac between days 16 and 19 followed by hepatic hemopoiesis 
at approximately 6 weeks, indicating that tetal hemopoietic progenitor cells may be present in 
the maternal circulation 1'1'0111 week 3 of gestation (Metcalf and Moore, 1971). In the present 
study, maternal blood samples were obtained during the first and early second trimester of 
pregnancy, i.e. at 7-16 weeks of gestation, and the samc protocol was used for the expansion 
and detection of fetal hemopoietic progcnitor cells. 
MA TERIALS AND METHODS 
mood samples 
Male umbilical cord blood (UCB) samples (n=5) were obtained from placentas of full-tenn 
normal pregnancics, while peripheral venous blood (PB) samples (n=4) were collected from 
female non-prcgnant volunteers (nulligravidae). For spike experiments, two to three UCB or 
PB samples were pooled in order to obtain enough CD34+ cells after MACS separation. 
Fctal blood (FB) samples (n=2) were obtained from discarded material after medically 
indicated cordocentesis at 20 weeks of gestations. FB samples at the target fetal age of 
between 7 to 16 weeks were unavailable because of the technical impossibility of umbilical 
cord sampling at this fetal age. 
A total of 100 pregnant women who came to the Department of Obstetrics and Gynecology 
for prenatal diagnosis because of advanced matcrnal age (~ 36 years) were enrolled in this 
part of the stully. Thil1y-tive of these 100 pregnant women were carrying a female fetus and 
were used as negative controls for FISH analysis. The other 65 women were canying a male 
fetus. The sex of the fetus was determined by c)1ogenetie analysis on semi-direct villus 
preparations or on amnioeytes. Pregnancy duration varied between 7 and 16 wccks of 
gestation, as calculated from the tirst day or the last mellstrl1a~ period. Maternal blood 
samples were takcn according to a cross-sectional study llesign at: 7-11 weeks of gestation 
(group A; 11=20) at the time of gcnetic counseling; 11-14 weeks of gestation, either before 
(group B; n=I4) 01' after chorionic villus sampling (group C; n=21): or at 15-16 weeks of 
gestation prior to amniocentesis (group D; n=IO). The study protocol was approved by the 
local Ethics Review Board, and all blood samples were obtained with patients' inrol1lled 
consent. 
Blood samples were collected in vaclltainers contallllllg ethylenediamine-tetra-acetic acid 
(EDTA) and were dilnted I: I with phosphatc-bnffered saline (PBS). Mononuclear cells were 
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isolated by ricoll-Paquc-Pllis (1.077 glllll; Pharmacia Biotech, LJppsala, Sweden) density 
'grauient centrifugation at 750 g for 20 minutes. Cells were washed twice in Hanks' balanced 
salts (HBSS; Life Technologies B.V., Breda, The Netherlands). The number of viable cells 
was calculated using a BUrkeI' counting chamber. Cells isolated from umbilical cord blood, 
fetal bloou and maternal blood samples were cl)'opreservcd in Iscove's modified Dulbccco's 
medium (IivIDM; Life Technologies B.V., Breda, The Netherlands) containing 20 % fetal calf 
serum (FeS) and 10 % dimcthylsulphoxidc (DivISO) in liquid nitrogen until further analysis. 
J\Iagnelic Acal'uted Cell Sorting (MACS; 
Isolation of CD34+ cells was performed as described by the manufacturer lIsing a 
CD34 progenitor cell isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany). 
The numbcr of viable cells in the CD34+ fraction was calculated using a BUrkeI' counting 
chamber. Pmi of this ti-action was used for liquid culture as well as for fluorescence in silll 
hybridization (FISH). For the spike experiments, 3, 10, 36 or 71 male CD34+ UCI3 cells were 
diluted in 400,000 female CD34+ PI3 cells. CD34+ derived from FB samples were only in 
vilro expanded and the number of nucleated cells was determined evel), week. 
The perccntage of CD34+ cells in the un separated sample ns well as the purified 
CD34+ fraction was determined by Iluorescence-nctivated cell sOliing (rACS) analysis. The 
percentage ofCD34+ cells in the purified fraction varied between 60-90 %. 
Liquid cult lire (?lCDJ.f 1 cells 
The CD34+ cell tj'actions were seeded in standard six-well plates and cultured as described 
previously, with some modifications (Piacibello el aI., 1997; Rappold e/ al., 1999). Brielly, 
CD34+ cells were cultured at 37°C and 10 % CO2 for 1 to 5 weeks in Stem Cell Growth 
Medium (SCGivl; Boehringer Ingelheim, Heidelberg, Germany) containing 20 % FCS, 
thrombopoietin (tpo; 10 ng/ml; a generous gin from Gencntech, South San Francisco, CA, 
USA), nt3-ligand (50 nglml) and stem cell factor (SCF; 100 nglml; both kindly provided by 
Amgen, Thousand Onks, CA, USA) and IL-6 (l00 ng/ml; a gift from Genetics Institute, 
Cambridge, MA, USA). Both tpo nlld Ilt3-ligand were added twice a week. Every week, the 
number of viable nucleated cells wns determined lIsing a BUrkeI' counting dmmber and part 
orthe cells were treated for FISH analysis, wherens rest of the cells were cultured fllliher. All 
CD34+ cell fmctions were nnalyzed for the presence of X and Y chromosomes without prior 
knowledge of the fetnl km)'otype or donor origin to avoid sampling bias. 
Fluorescence in situ hybridization (FISH) 
Cells were treated with 75 mivl KCI, incubated for 18 minutes at 37 DC, fixed in 
methanol:acetic acid (3: I) and stored at -20 HC until fmiher analysis. Cells were dropped 
onto VectabondThI-coated slides (Vector Laboratories, Inc, Burlingame, CA, USA) nnd 
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air-dried. The number of nucleated cells nnalyzed per sample per slide varied from 
10-20xI0'. Slides were pre-treated with pepsin (l00 flg/ml) in 0.01 N HCI at 37 "c for 
15 minutes, followed by postfixation in 3.7 % formaldehyde in PBS for 15 minutes. 
Subsequently, slides were denatured for 5 minutes in 70 % formam ide (pH 7.5) in 2X SSC at 
75°C, followed by dehydration in 70 %, 90 % and 100 % ethanol for 1 minute each. 
Two-color FISH was performed lIsing a SpcctrumOrangc-labeled alpha-satellite probe 
(DXZl) tor centromere region Xpl1.1-qll.l and a Spectrul11Green-labeled satellite III probe 
for the Yq12 region (Vysis, Downers Grove, IL, USA). Samples were hybridized overnight at 
37°C in a humidified chamber. 
Slides were post-washed at 70 "c in O.4X SSC/0.3 % NP-40 (pH 7.2), followed by 
5-60 seconds in 2X SSC/O.1 % NP-40 (pH 7.2) at room temperature. Slides were mounted in 
Vectashield mounting medium (Vector Laboratories, Inc., Burlingame, CA) containing DAPI 
(4', 6-diamidino-2-phenylindole) and analyzed under a Leica Aristoplan fluorescence 
microscope lIsing a triple band-pass filter block. Images were captured using a Xybion CCD 
24-bit color camera with a Genetiscan ProbeMaster system and MacProbe 2.5 image analysis 
software (PSI, Chester, UK). 
Since only part of the cultured cells was used for FISH analysis, the absolute number of 
XY cells during 1-5 weeks of liquid culture was calculated. 
RESULTS 
In vitro expansion (?f'CDJ.f+ cells deriredJhnn umbilical cord blood, peripheral blood and 
fe/al blood 
CD34+ sOlied cells derived fi'om malc umbilical cord blood (UCB), female peripherol blood 
(PB) and fetal blood (FB) at 20 weeks of gestation were analyzed for their growth in liquid 
culture (figure I). CD34+ cells derived from PB samples did not show any significant growth 
during 3 to 5 weeks of liquid culture. In contrast, CD34+ cells derived from UCB as well as 
PB showed an up to 4-10g fold increase of nucleated cells after 5 weeks of liquid culture, 
indicating that UCB and FB CD34+ cells exhibit similar expansion capacities, and theretore, 
fetal cells derived from maternal blood may show the same growth profiles. 
Spike experimenl.\' (?lmale umbilical cord blood cells infi!11lllle peripheral blood cells 
In ordcr to investigate whether extremely small numbers of fetal cells can be selectively 
expanded in maternal blood, we used a model system in which 3, 10,36 or 71 male CD34+ 
UCB cells were diluted into 400,000 female CD34+ PB cells and culturcd in liquid culturc. 
Evel)' week, the number of nucleated cells and the number of XY cells present in evel), 
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Fold expansion of CD34+ cells from peripheral blood (PO). umbilical 
cord blood (UeB) and fetal blood (FB) during liquid culture, The 
starting concentration of PB, UCB and FB were 40xIO~, 25x104 and 
5xlO~ CD34+ cells per milliliter of culture, respectively. Each line tor 
UCB and PB corresponds with two to three pooled samples. 
mixture was determined using FISH for X and Y chromosomes (figure 2). For each sample, 
the number of nuclei analyzed by FISH betore and after liquid culture ranged between 
IO-20xI04, All four samples showed at least a 250-fold increase ill the absolute number of 
XY cells (UCB) pCI' 10' XX cells (PB), which was most abundant during the first week of 
liquid culture. Even 3 male CD34+ UCB cells (dilution 1) were able to expand up to 
1500-fold after 3 weeks of culture. This suggests that even vel)' low numbers of fetal 
CD34+ cells if present in maternal blood can be selectively expanded over adult female 
CD34+ PB cells, which would filcilitate their detection. This is further supported by the fact 
that we observed comparable levels of expansion of CD34+ cells derived from 20-week FB 
(figure 1). 
/11 vitro culture and detection oJletal hemopoietic progenitor cells in maternal blood 
On the basis of the above described findings, we investigated the possibility to detect male 
fetal hemopoietic progcnitor cells in peripheral blood fi'om pregnant women by expanding 
their relative numbers during liquid culture. Maternal blood samples from pregnancies of 
which the fetal km)'otypc was 46, XY, wcre obtained from 65 pregnant women at 7-16 weeks 
of gestation. CD34+ cells were isolated and cultured in liquid culture during 0 to 5 weeks 
(table 1). For each sample, the number of nuclei analyzed by FISH ranged between 
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Number of XY positive cells per 10--1 XX cells during liquid culture of 
CD34+ cells in cell mixtures of umbilical cord blood (UCR) and 
peripheral blood CPS). Dilution I, 2, 3 and 4 cOITespond to 3, 10, 36 
and 71 mnle CD34+ UCD cells, respectively, diluted into 400,000 
female CD34+ PH cells before liquid culture. 
1O~20xto4. In group A, B, C nnd D, XY positive cells could be detected eithcr before or 
duriug liquid eulture iu 11 out of20 (55 %), 3 out of 14 (21 %), 12 out 01'21 (57 %) aud 2 out 
of 10 (20 %), respectively. In all other samples in the four differeut groups no XY positive 
cells could be detected either before or during liquid culture. The number of XY cells before 
liquid culture varied from 0 to 11.1 and in most of the samples no XY cells could be detected. 
In group A, B, C and D, XY Ijositive cells could be detected before liquid culture in 8 out of 
20 patients (40 %),2 out of 14 (14 %), 2 out 01'20 (10 %) and lout of 10 (10 %) patieuts, 
respectively. After I week of cell culture, the num!:.er of XY cells ranged from 0 to 16.7 XY 
positive cells in the four different groups, whereas in group B no XY positive cells could be 
detected. In group A, C and D, XY positive cells were fOllnd in '-lout of 7 (57 %), 7 out of 8 
(88 %) and lout of4 (25 %) patients, respectively. There W[lS a significant difference for the 
presence of XY cells between group Band Caner 1 week of liquid culture (Fisher's exact 
test, p=0.005). The number of XY positive cells varied from 0 to 22.2 XY positive cells 
aHer2 weeks of culture. XY positive cells were detected ill group A, Band C in lout of 8 
(12.5 %), lout of 5 (20 %) and 3 out of 9 (33 %) patients, respcetively. No XY cells were 
found in the four patients analyzed in group D. After 3 weeks of culture of CD34+ cells, the 
number of male cells varied from 0 to 22.2, with the highest number in a patient from 
group A. In group A and C, 2 out of 3 (66 %) and lout of 4 (25 %) patients showed 
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Tuble 1 FISH analysis ofCD34+ cells before find during liquid culture 
Group.! Number of cultured Number of Xl' cells at week 
patient number (:03<1+ cells (xlO~) 0 2 3 4 5 
Al 14.0 1.0 
A2 4S.0 1.0 
Al 13.0 6.5 3.2 
A4 17.5 5,4 0.0 
AS 6.0 8.0 0.0 
A6 17.0 0.0 5.1 
A7 2.0 2.2 n.u. 0.0 
AS 15.0 2.5 n,d. 0.0 
A9 11.0 0.0 5.6 11.1 0.0 
A10 38.0 0.0 0.0 0.0 IO.t) 0.0 0.0 
All 23.0 5.9 1.0 0.0 22.2 20.0 20.0 
XYneg 23.3 (6-56)* 9 0 1 0 0 0 
III 7.0 6.9 0.0 
H2 7.0 0.0 n.d. 3,4 0.0 
Bl 37.0 11.1 0.0 0.0 0.0 0.0 0.0 
XYncg · 19.7 (9-55)* 11 3 3 0 0 
e1 28.9 4.3 
C2 31.0 1.0 
Cl 3.0 0.0 6.0 
C4 19.0 0.0 4.8 
C5 15.0 0.0 5.7 
C6 3.3 0.0 6.6 
C7 17.0 0.0 n,d, 7.0 
CS 9.0 0.0 n.tI. 7.1 
C9 60.0 0.0 \6.7 22.2 0.0 
C10 14.0 0.0 5.6 0.0 0.0 
ell 37.0 n.d, n.u. 0.0 2.6 0.0 
el2 32.0 0.0 2.4 0.11 0.0 0.11 0.0 
XYneg · 16.1 (4-24)' 9 3 0 0 0 
D1 lU,O 1.3 n.d. 0.0 
D2 37.0 0.0 2.4 0.0 0.0 0.0 0.0 
XYneg · 12.8 (2-20)* 8 1 2 0 0 
C034+ cells wcre isolated from 7-2'2 Illl rnatemal blood and cultured for I to 5 wccJ\s, Weekly, part urlhe cells 
were collected and tlw absolute number of XY positive cells was determined. For each sample, the number of 
nuclei analyzed by FISH ranged between IO-20xlO~. Only samples with detectable Xl' cells either before or 
during liquid culture are presented. Group A maternal blood samples were collected <It 7-11 \\'1.'1.'1\" of gest<ltion; 
group B amI C s<lmples <It 11-14 weeks of gestation, betore or aner chorionic villus sampling, respectively; and 
group 0 samples at 15-16 weeks of gestation. All mntcmal blood sampll's were deri\'ed from wOlllen cllITying a 
male fetlls . 
. lHulIber ofsnmpics without dctcctnble XY positi\'e c",'II~; * mean number of cultured CD34+ cells (range); n.d. 
not determined. 
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XY positive cells, respectively, whercas no male cells were found in group Band D. After 
4 and 5 weeks of liquid culture, only in group A, in one out of two patients 20.0 XY positive 
cells were found. These results illllicate that fetal hemopoietic progenitor cells, if present at 
all, may not preferentially expand over the maternal CD34+ component, which is in contrast 
with the observations in the spike experiments. 
As negative controls to determine the background level for FISH analysis, a total of 
39 peripheral blood samples from 35 control patients eanying a female fetus and 4 female 
non-pregnant volunteers (nulligravidae) were analyzed for the presence of male cells. From 
all 39 blood samples CD34+ cells were isolated. CD34+ cell fractions from 20 pregnant and 
4 non-pregnant women were cultured during 0 to 3 weeks, whereas from the other 15 samples 
only FISH analysis was performed after MACS isolation. In none of the non-pregnant 
samples male cells could be detected, whereas in 2 out of 35 pregnant wOlllen (5.7 %) 
XV positive cells were found; 3.3 XY cells were detected all week 0 in one patient and 
5.2 XY cells werc detected after 2 weeks of liquid culture in an other patient. In both cases a 
prior male pregnancy was ascel1ained. These data suggest that the presence of male cells in 
female pregnancies may be caused by aspecitic binding of the Y chromosomal probe or 
might be the result of persisting fetal cells from earlier pregnancies. 
DISCUSSION 
The development of a non-invasive prenatal diagnostic test lIsing fetal cells present in the 
maternal circulation is hampered by the low ti'cquency of these cells in maternal blood. The 
idea to increase the number of fetal cells by amplification of progenitor cells has been 
discllssed for a long time. In most recent studies, the expansion of fetal el,)1hroid cells is 
described (Lo c/ (//., 1994; Valerio e/ (//., 1996, 1997; Chell e/ (//.,1998; Hall c/ (//.,1999), 
whereas less is known about the amplification of fetal CD34+ progenitors (Little el al., 
1997). In the present study, we evaluated the lIsefulness of ill vitto expansion of CD34+ fetal 
cells isolated IhHll maternal bloou samples for diagnostic purposes. Two major methods of 
cell separation enable fetal cell isolation lI'om maternal blood: tluorescence activated cell 
sorting (F ACS) (Bianchi el al., 1990) and magnetic activated cell sorting (ivIACS) (Ganshirt-
Ahlert ct 01.,1992), Both isolation techniques have the disadvantage that the purified lI'action 
still contains many maternal cells. In order to evaluate whether limited numbers of fetal 
CD34+ cells present in an excess of maternal cells are able to overgrow the maternal 
component, we lIscd a Illodel system in which CD34+ cells derived frolllillale umbilical cord 
blood (UeB) were diluted up to 3 in 400,000 with CD34+ cells derived t1'om non-pregnant 
female volullteers (nulligravidae) and in vitro expanded in liquid culture. We showed that 
even vel)' low numbers of CD34+ cells derived from UCB (3 XY positive cells) diluted into 
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an excess of PB cells were able to expand to high cellilumbers, corresponding to the il1l'il}'o 
expansion ofCD34+ nucleated cells derived from undiluted UCB samples. As the magnitude 
of in \'itro expansion of CD34+ cells derived from 20-week FB samples corrcspondcu to the 
growth of hemopoietic progenitor cells derived from UCB, it is suggested that the grO\\1h 
capacities of fetal hemopoietic progenitor cells of between 7 and 16 weeks of gestationnl age 
may show similar expansion patterns, Consequently, the limHcd numbers of fetal 
hemopoietic progenitor cells present in maternal blood samples may show the same growth 
profiles. In cuntrast to the tlndings in the model system, we were not able to show abundant 
growth of fetal male CD34+ cells isolated from maternal blood samples. In only a few 
samples in group A and C, cell grO\\1h of male fetal cells could be detected. These results are 
in concordance with the observations described by Little et al. (1997). Using an other 
e)10kine combination, they also showed a limited expansiun of C034+ fetal cells derived 
from 10-l3 week maternal blood samples after 5 days of cuhure, but in most cases (10 out 
of IS (55 %)) no XY cells could be detected. 
In many studies it has been investigated at what time in pregnancy the number of fetal cells 
has reached its maximum. Relevant information regarding the frequency of fetal nucleated 
red blood cells (NRBCs) in maternal blood is contradictOlY, and the frequency of fetal 
NRBCs Was rep0l1ed to villy significantly among individuals and throughout the three 
trimcstcrs of pregnancy (Hamada et (fl., 1993; Siunga-Tallberg eI al., 1995; Smid et al., 1997; 
Kuo, 1998). Fetal cell frequency in maternal blood is influenced hy a number of biological 
parameters that are mainly unknown. Gestational age seems to be one of the factors involved. 
The optimal period during pregnancy for detecting circulating fetal cells remains unclear. 
Therefore, we have analyzed maternal blood samplcs of different gestational ages, val)'ing 
between 7 and 16 weeks of gestation (group A, B and D). In most cases no male fetal cells 
could be detected, whereas in 28 out of65 maternal blood samplcs of women can)'ing a male 
fetus XY positive cells could be observed. However, there was no statistically significant 
increase in the number of patients with one or more XY positive cells between 7 and 11 
weeks of gestation (group A) compared to patients of later gestational ages (group B and D). 
This suggests that the number of fetal hcmopoietic progenitor cells present in blood 11'0111 tirst 
trimester pregnant women might 110t be high enough or that these cells are even absent in 
1110st pregnant women. 
Another question concerns the stability of fetal cell properties. Are fetal progenitor cells 
present in the maternal circulation cionnl and possess unchangeable characteristics or are they 
transient and respond to a changing environment? Until now, it is nol known whether fetal 
cells continue to express the same marker antigens in the new maternal environment after 
crossing the placenta, and respond to similar c)1okines. The cytokine combination used in 
this study has previously been shown to be capable of extensive amplification and 
self-renewal of human primitive hemopoietic progenitor cells derived ti'om umbilical cord 
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blood (Piacibello e/ al., 1997; Rappold e/ al., 1999). However, other, perhaps yet unidentified 
(combinations or concentrations ot) grO\\1h fnctors Illay induce n more vigorous proliferative 
response, promoting the in \'itI'O expnnsioll of fetal cells isolated from maternal blood 
samples. 
Another 1~lctor that intluences the incidence of fetal cells in maternal blood is chorionic villus 
sampling (CVS), which has previously becn rcported to cause a fcto-maternal transfusion of 
fetal NRBCs (Jansen el al., 1997). The qucstion arises as to whether it may also havc an 
etfect on the number of fetal hcmopoietic progcnitor cells in the maternal circulation. 
Although there was a significant incrcnse of male cells aftcr one wcek of liquid culturc in 
samples obtained after chorionic villus sampling (CVS)(group C) compared to before CVS 
(group B), in most of the post-CVS samples the Ilumber of male fetal hemopoietic 
progcnitors docs not markedly exceed the number of male cells in blood samples obtaincd 
before any invasive procedure (group A, B and D). 
Male cells were found in 2 out of 35 pregnant women eallying a female fetlls. In both cases a 
prior male pregnancy was confirmed. Therefore, these cells may either represent 
H1lsc-positivcs dlle to non-specitic binding of the Y chromosomal probe to non-target 
sequcnces, or rcpresent residual fetal cells persisting from prior male pregnancies, since fctal 
progcnitor cells have been rep0l1ed to circulate in nwternal blood as long as 27 years after 
birth (Bianchi el al., 1996b). FlII1hermore, a fcto-maternal transfusion may OCClll' at the time 
of bh1h. This may establish fetal microchimerism in the mother, which has been reported to 
be implicated in the subsequent development of diseases, such as scleroderma that are 
common in womcn (Art lett et (fl., 1998; Nelson, 1998; Evans el al., 1999). Therefore, it is 
important to know whether fetal cells might persist from prior pregnancies, not only for the 
development of n non-invasive prenatal diagnostic test, but also to evaluate the 
immunological consequences of feto~maternal transfusion. 
Until now, most attention has been focllsed all fetal NRBCs which have been isolated lIsing 
antibodies against membrane-bound markers (CD7l, glycophorin A) or intracellular antigens 
(hemoglobin F) (l.oken e/ al., 1987; Bianchi e/ al., 1990; Zheng e/ al., 1995). The number of 
fetal NRBCs in maternal blood is vel)' low, and expansion of these cells might enhance the 
detectability of this cell type. A previously reportcd cell culture protocol for erythroid cells 
(Janscn el al., 1999; von Lindern el al., 1999) was used for CD71+ cells in a spike 
cxpcriment similar to that used for hemopoietic progenitor cells described in this paper (data 
not shown). CD71+ cells dcrived from male UCB wcre dilutcd lip to 1 in 400,000 in 
CD71+ cells derived from female PB samplcs. This ccll mixture was culturcd according to 
the previously described el)1hroid cell culture protocol (Jansen el al., 1999; von Lindern ef 
01., 1999) and the number of XY positive cells was determined weekly. However, preferential 
expansion of CD71 + UCB cells as shown for CD34+ UCB cells could not be observed, 
suggesting that the expnllsion potential of fetal NRBCs in maternal blood samples is not 
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comparable with the expansion potential of hemopoietic progenitor cells, and therctbrc~ fetal 
NRBCs may not be able to overgrow the excess of maternal cells. These results were similar 
to those reported by others (Chell ef a/., 1998; Hall ef a/., 1999), who rccently showed that 
culturing of fetal cl)1hroblasts derived from contaminating maternal blood mainly produced 
erythroid colonies derived from maternal erythroid progenitors, 
In summary, expansion of retal cells isolated n'om maternal blood samples for analytical 
purposes is highly desirable given the rarity of these cells in the maternal circulation. 
Amplii1cation of the number or fetal cells llsing cell culture protocols might facilitate 
non~in\'asivc prenatal detection of genetic anomalies. In the current study, the described 
protocol for the expansion of hemopoietic progenitor cells resulted ill a dramatic expansion of 
even vel)' few CD34+ UCB cells spiked into PB samples, which also corresponded to a 
similar marked increase in the numbcr of CD34+ cells from 20-wcck fetal blood. However, 
the expansion of fetal CD34+ cells dcriveu from 7-16 week matcrnal blood samples did not 
result in signifil:ant growth of these rare cells and therdorc is not yet suitable for uiagnoslic 
purposes. 
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The presence of fetal cells in maternal blood is supposed to be the result of a feta-maternal 
transfusion at the placental interface. It has previollsly been rcpol1cd that the introduction of a 
biopsy needle into placental tissue to aspirate chorionic villi via the transabdominal route 
might induce a feta-maternal transfusion. Such a transfusion has been demonstrated by 
elevated levels of maternal serum alpha-fetoprotein after chorionic villus sampling. In this 
chapter, the effect of an invasive procedure like chorionic villus sampling was investigated by 
analyzing the number of fetal nucleated red blood cells in the maternal circulation before and 
aftcr transabdominal chorionic villus sampling. 
f) John Wiley & Sons Limited: reproduced with pemlission. 
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ABSTRACT 
Fetal cells are present in the circulation of pregnant women and can be isolated lIsing density 
gradient centrifugation and magnetic cell sorting, In the present study~ maternal cell 
preparations were depleted for CD4S- and CD14-positivc -cells and enriched for 
CD71-positive celis, The number of fetal nucleated cells was determined using fluorescence 
in situ hybridization for X and Y chromosomes, Analysis of maternal blood samples taken 
before and atter transabdominal chorionic villus sampling (TA-CVS) showed an increase in 
the number of fetal cells in 10 out of 19 male pregnancies after the invasive procedure. This 
cellular transfllsioll was found to correlate with elevated maternal serum alpha-fetoprotcin 
levels, TA-CVS-induced cellular transfusion Illay form a good in vivo system to optimize 
fetHI cell isolation procedures and to study fetal cell dynamics and characteristics. 
INTRODUCTION 
Cells of fetal origin have been isolated from blood of pregnant womcn and can be used tor 
non-invasive prenatal detection of genetic abnormalities. Cell types isolatcd from maternal 
blood include nuclcated rcd blood cells (NRBCs) (Bianchi e/ al., 1990), lymphoc)1es 
(I-Ierzcnbcrg et aI" 1979)~ granuloc)1es (Wessman et (fl.~ 1992)~ and trophoblast cells 
(Goodfellow anti Taylor, 1982), Attention has been focused primarily on NRBCs as they 
express both mel1lbrane~bollnd markers (CD71, glycophorin A) and intracellular antigens 
(hemoglobin f) which aliow their isolation and identification (Loken et ai" 1987; Bianchi et 
al., 1990; Zheng e/ al., 1995). 
The occurrence of fetal NRBCs in maternal blood is a rare event, and extensive enrichment 
and purification procedures are necessary to detect these cells. Isolation tcchniqucs currcntly 
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available have succeeded in the isolation of only a vel)' small number or fetal cells in SOI11;': of 
the pregnancies investigated (Reading et (1/., 1995; Lewis et aI" 1996), Improvements in 
isolation technology that will result in a larger number of fetal cells me necessaI)' to allow the 
lise of these cells for diagnostic purposes. 
The presence of fetal cells in the maternal circulation is supposed to be the resull of a 
feto-maternnltransfusion (FMT) at the placental interface (Price el a/., 1991; Bianchi ef a/., 
1992), This FMT has also been postulated to occur as a consequence of transabdominal 
chorionic villus sampling (TA-CVS), which was shown to induce an increase in maternal 
serum alpha-fetoprotein (MSAFP) levels (Los el al., 1989, 1993; Smidt-Jensen el al., 1993; 
Brezinka el al., 1995), In the present study, we investigated whether the transfer of fctal 
plasma components after TA-CVS is accompanied by a concurrent tllcrcase in the number of 
fctal nucleated cells in the matclllal circulation. 
MA TERIALS AND METHODS 
Patient samples 
Peripheral venous blood samples (13-18 1ll1) were obtained 1'1'0111 32 pregnant women 
(11-14 weeks of gestation) ref cITed for prenatal diagnosis because of advanced maternal age 
(11=29), familial Down syndrome (n=2), or a previous child with congenital abnormalities 
(11=1). Mean maternal age was 37 years. Two blood samples were taken fi'om each patient, 
the first one immediately before TA-CVS, the second 5-20 minutes after the invasive 
procedure. Blooti samples were collected into vacutaincrs containing cthylenediaminetclra-
acetic acid (EDTA). TA-CYS was performed according to Jahoda el al. (1990). In all patients 
a single needle puncture was needed to obtain 5-30 mg of chorionic villi. Fetal kaJ)'ot)'ping 
was performed on semi-direct villus preparations, All samples were obtained with the 
patient's intollned consent. 
Cell prepm'afiOll 
Venous blood samples were diluted to 30 ml with phosphate-buffered saline (PBS) and 
l11onol1uelcated cells were isolated by Ficoll-Paque-Plus (1.077 glllll; Phannaeia Biotech, 
Uppsala, Sweden) density gradient centrifugation at 750 G for 15 minutes. Cells were washed 
twice with PBS and centrifuged at 250 G for 10 minutes. For each sample, human serum was 
collected and stored at - 80 {IC until further analysis. 
A /plra-feloproteil1 meas IItemen/ 
["Iaternal serulll AFP UvISAFP) was measured with Amerlex ~\'I second-trimester radio-
illll11ullo-assay (RIA) kits for AFP (Kodak) and was expressed in kJU/1. 
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l\Iaglletic (fctiwlfed cell sorting (J\IACSj 
Fetal cells were isolated according to a procedure described by BUsch et al. (l994) with 
modifications. Briefly, cells were labeled for 15 minutes on ice with CD45-PE 
(50 rdl20x106eells; KC 56, T-200 (lgG1), Coulter, Kretcld, Germany) in 200 rd PBNHS 
(PBS containing I % bovine serum albumin (BSA), 0.01 % sodium azide (NaN3), and 10 % 
autologous serum), washed once in PBNHS, and labeled with 30 ~d of CDl4-eonjugated 
mierobcads and 30 ~tI of rat anti-Illollse IgGI-conjugated microbeads (Miltenyi Biotec, 
Bergisch Gladbach, Germany) in 200 pi of PBNHS at 4 "c for 15 minutes. Labeled cells 
were washed once ~n PBNHS, resuspended in 500 ~tI wash butTer (PBS containing I % BSA, 
0.01 % NaN,. aud 5 mM EDTA), and applied to a pre-separation filter (30 fun; CLB, 
Amsterdam, The Netherlands) in order to obtain a single cell sLlspension. The labeled cell 
~uspension was applied to an AS-depletion column (Miltenyi) using a 26G needle as flow 
resistor. The negative fraction was applied again to the column in order to achieve an optimal 
depiction, followed by elution with 3 1111 wash buffer. After an additional wash using a 24G 
needle, the column was removed from the magnetic device and CD45- and CDl4-positive 
cells were collected, 
The negative fraction was labeled tor 15 minutes on ice with CD71-FITC (10 ~d/l06 cells; 
100 pg/ml; LOl.l, IgG2a, Becton Dickinson, San Jose, CA, USA) in 200 ftl of PBNHS. 
Cells were washed once in PBNHS and labeled tor 15 minutes at 4 °c with 30 pi of rat 
anti-mouse IgG2a+b-conjugated microbeads (Miltenyi) in 200 ~tI of PBNHS, and washed 
again in PBNHS. Labeled cells wcre rcsllspended in 500 ~ll wash butTer and applied to a 
pre-separation tilter (30 pm; CLB). The cell suspension was added to a mini MACS column 
(type MS; Miltcnyi) and the non-magnetic cell fraction was collected, After removing the 
column 11'0111 the magnet, the CD71+ cell fraction was eluted. 
The number of viable cells in each fraction was calculated before and after loading the 
MACS column using a BUrkeI' counting chamber. 
Fluorescence in sUu hybridization (FISH) 
Cell fractions were treated with 75 mM KCI, incubated tor 18 minutes at 37°C, fixed in 
methanol: acetic acid (3:1), and stored at _20°C until further analysis. Cells Were dropped 
onto 3-aminopropyltriethoxysilane (2 % in acetone) -coated slides and air-dried, Slides were 
treatcd with 70 % tonnamide (pH 7.0) in 2X SSC, washed in PBS, and dehydrated in 70 %, 
90 % and 100 % ethanol tor 5 minutes each. Atter heating the slides tbr 10 minutes at 80°C, 
cells were pretreated with pepsin (lOO ~lg/ml) in 0.01 N HCI at 37 llC tor 15 minutes, 
followed by post-fixation in 3.7 % formaldehyde in PBS for l5 minutes. Subsequently, slioes 
were denatured for 5 minutes in 70 % f0I111amide (pH 7.5) in 2X SSC at 75°C, followed by 
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dehydration in 70 %, 90 % and 100 % ethanol for 1 minute each. Slides were prewanned at 
45 t1C until probe was applied. 
Two~color FISH was performed using a SpcctrumOrange labeled alpha-satellite probe 
(DXZI) for centromere region Xpll.l-qll.l and a SpeetrumGreen labeled satellite III probe 
for the Ygl2 region (Vysis, Downers Grove, fL, USA). The probes were denatured for 
5 minutes at 75°C and hybridization was allowed to continue overnight at 42 (lC in a 
humidified chamber. 
Slides were posHvashcd three times at 46 nC in 50 % formam ide in 2X sse (pH 7.5) for 
10 minutes each, followed by one wash in 2X sse (pH 7.0) for 10 minutes and one wash in 
2X SSC/O.I % NP-40 (pH 7.0) for 5 minnles, both al 46 "C. Slides were mounled in 
Vcctashield mounting medium (Veclor Laboratories, Inc" Burlingame. CA, USA) containing 
DAPI (4', 6-diamidino-2-phenylindolc) and analyzed under a Leica Aristoplan tluorescence 
microscope using a triple band-pass filtcr block. Images were captured with a Genetisean 
ProbeMaster system (PSI, Chester, UK) using a Xybion CCD 24-bit color camera. 
RESULTS 
Blood samples were obtained from 32 pregnant women at 11-14 weeks of gestation (table 1). 
Cytogenetic analysis of the villus sample showed a female karyotype in 13 cases and a male 
km)'otypc in 19 cases. Two chromosomal abnormalities (47,XXY; 47,XY, +13) were 
encollntered in two pregnancies refen'ed for advanced maternal age. 
C07l-positive cells were isolaled ti'Om maternal blood laken before and after TA -CVS using 
MACS separation. First, mOlloeytes (CD14) and lymphoc)1es (CD45) were depleted, 
followed by enrichment of CD7l-positive cells. The number of XY cells in the 
C07I-positive fractions was dctennined by FISH using X and Y chromosome-specific 
probes. The number of cells analyzed in the CD7I-positive fracttons ranged from 0.3 to 
80 x 10' (table I). 
In 3 out of the 13 female cases (23 %), olle XY positive cell pel' sample could be detected, 
either before or after TA-CVS. in two alit of these three cases, a prior male pregnancy was 
either ascertained or could not be excluded due to a previolls spontaneous abortion. In the 
third case, only prior female prC!~,'llancies were reported. The number of XY -positive cells 
before TA-CVS in the male cases ranged from 0 to 4 XY cells, with the highest amount of 
X- and Y-positive cells in the 47,XXY case (table 1 and figure lA). The number of 
XV-positive cells after TA-CVS in the male cases ranged fi'om 0 to 187, with the highest 
alllount of cells in the ease with trisomy 13 (table I and figure 18). A total of ten out of 
19 male eases (53 %) displayed an increase in the number of XY positive cells after 
TA-CVS compared with the number ofXY cells before TA-CVS. 
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Table 1 Number of XY cells and a[pha~fetoprotein values before and after TA~CVS 
Case Fetal Ge~latiollal Number of cells Number of XY cells AFP villucs (kIUlI) 
no. kal)'otype age analyzed* (x 1 O~) 
(weeks) Befor~ cvs Allcr CVS Before CVS After CVS Before CVS After CVS 
I ;6. xx 12 17 22 0 0 7.9 14.6 
2 ;6. xx 12 15 15 0 I 3.0 8.8 
3 ;6. XX 11 13 15 II 0 1.0 1.0 
; 46. XX 12 13 I; 0 0 1.6 3.3 
5 46. XX 12 11 12 0 0 1.0 32.2 
6 ;6. XX 12 10 17 0 0 14.3 1J.8 
7 46. XX 12 21 24 0 II 2.5 3.4 
8 46. XX 12 13 12 I 0 8.0 10.3 
9 46. XX 12 28 41 0 II 8.7 8.4 
10 46. XX 12 29 25 0 0 7.4 12.0 
11 46. XX 12 7 II 0 0 2.0 9.9 
12 46. XX 12 8 20 0 1 1.4 3.3 
13 46. XX 12 28 17 0 0 14.7 19.3 
14 46. XY 12 II 12 II 0 3.0 2.3 
15 46. XY 12 9 II 0 0 4.4 7.8 
16 46. XY 12 27 8 0 0 1.0 9.0 
17 46. XY 12 18 18 I I 7.2 17.9 
18 46. XY 12 S 14 I 175 1.4 332.6 
19 46. XY 12 29 32 0 185 3.8 720.0 
20 46. XY 12 25 24 2 15 29.9 63.9 
21 46. XY 12 11 9 I 0 2.9 16.8 
22 46. XY 13 80 40 0 I 5.8 11.5 
23 46. XY 12 6 0.8 0 0 10.8 11.1 
24 46. XY 12 1.5 0.3 0 7 10.8 18.1 
25 46. XY 12 14 25 0 0 4.6 6.3 
26 46.XY 13 8 8 0 2 6.5 164.3 
27 46.XY 12 21 11 0 I 1.4 2.5 
28 46.XY 13 20 10 0 4 1J.8 3;.0 
29 46. XY 12 14 10 0 II 4.5 28.8 
)0 46. XY 12 17 22 0 0 6.4 10.9 
3 I 47. XXY 12 19 25 4' 23' 4.4 26.4 
32 47.XY.+13 IJ 28 21 2 187 4.2 72.2 
* All cells obtained aner C07l enrichment were analyzed by FISH lIsing X and Y chromosome 
specific probes; t number of XXY cells 
MSAFP levels before and after TA~CVS were determined and compared with the number of 
XY cells before and after TA-CVS (lab Ie I). The mean level ofMSAFP before TA-CVS was 
6.3 klU/l (combination of all male and female pregnancies) and 53.0 klU/1 after TA-CVS. 
indicating a significant 8.4~fold increase in i\'ISAFP Icvels due to the TA~CVS procedure 
(two~sal11ple Wilcoxon test: p < 0,01). For the male cases, ~vISAFP levels were found to be 
positively correlated with the number of XY cells after TA~CVS (Speannan rank correlation 
coetlicient r = 0.78; n = 19; P < 0.001). No significant difference could be observed in 
MSAFP Icvels after TA-CVS between male and female eascs (Mann-Whitney U-tcst, 
p=OA7). There was no correlation between the amollnt of villi taken (range 5-30 mg) and 
increases in fetal cell counts or MSAf-P levels. 
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Figun;'1 
DISCUSSION 
[11 silll hybridization on nucleated cells isolated from maternal blood 
showing X (red) <lnd Y (green) chromosomal signals. ivlatcrnal cells 
present with Iwo X signals per cell, while fetal cells present with two X 
and nne Y signal in the case ofa fetal 47, XXY karyotype (A) and with 
one X and one Y signal in the case ofa fetal 47,XY, +13 karyotype (8). 
(magnification IOOOx) 
In this paper, we have shown that TA-CVS not only leads to a FMT of fetal plasma 
components, but also results in the transfer of fetal nucleated cells into the maternal 
circulation. The extent of plasma FiVlT was fOllnd to be positively correlated with the amount 
offetal nucleated cells that could be isolated from maternal blood. 
Previously, it has been reported that the introduction of a biopsy needle into placental tissue 
to aspirate chorionic villi via a transabdominal route might induce a FrviT. This was 
demonstrated by elevated levels of i\'ISAFP measured after TA-CVS. Estimates of the extent 
of the FMT have indicated cases in which lip to 40 % of the fetal plasma volume has leaked 
into the maternal circulation (Los ef a/., 1989; Rodeck et a/., 1993; Smidt-Jensen ef a/., 1994; 
Brezinka et al., 1995). In spite of this extensive trauma, fetal demise as a result ofTA-CVS is 
rare and has been documented only in sporadic cases (Los et a/., 1993). In the present study, 
we have shown that the transfer of plasma components after TA-CVS is accompanied by a 
transfllsion of fetal nucleated cells. However, the extensive plasma FMT estimated on the 
basis of MSAFP may nut rellect a transfusion of a comparable volume of whole blood, 
because the number of fetal nucleated cells detected after TA-CVS is relatively low. If the 
size of the FMT is estimated on the basis of the assumption that a rise in i\'lSAFP corresponds 
to an equivalent transfusion of whole blood, it can be calculated that a rise of 650 kIU/I 
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corrcsponds to a FMT of I 1111 (Los et al., 1989). A transfusion of this size will lead to a 
leakage of at least 4 x 106 fetal nucleated cells into the maternal circulation (Millar et al., 
1985). This estimated level does not correspond to the observed number of fetal nucleated 
cells in the present study, which is at least an order of magnitude lower. This lower level of 
fetal nucleated cells might be explained by removal of these fetal cells by the maternal 
immune system, by retention of fetal cells in maternal tissucs, or by an inefficient isolation 
procedure. Alternatively, it is possible that an extensive plasma FMT as indicated by a large 
rise in MSAf-P is not accompanied by a prop0l1ionai cellular transfusion. In the prcscnt 
study, the extent of plasma FMT after TA-CVS significantly correlates with the extent of 
cellular FMT, although in individual cases an increase in plasma FMT was found that was not 
accompanied by a demonstrable cellular FMT. Retention of the fetal blood cellular 
component compared with the plasma FMT after TA-CVS might explain why relatively few 
cases with extreme plasma Fi''vIT are accompanied by fetal death. 
The number of fetal cells that could be isolated fi'om maternal blood before TA-CVS was 
found to be very low in the male cases (0-4 cells per sample). This is in agreement with other 
recent repolis in which similar levels of fetal cells were found (Reading el al., 1995; Lewis ct 
al., 1996). In the two cases with a chromosome abnormality (47,XXY; 47,XY, +l3), a 
relatively high number of fetal nucleated cells were isolated. It has previously been suggested 
that a higher level of fetal cells can be found in maternal blood in cases with chromosome 
abnormalities, possibly as a result of an altered placental structure (Simpson and Elias, 1994). 
More studies are needed to investigate whether higher levels of cellular FMT occur in 
abnormal pregnancies, as this will facilitate prenatal diagnostic procedures. 
Some XY -positive cells were found in female pregnancies; these cells Illay either represent 
false positives due to non-specific background staining of the V-chromosome probe, or 
represent cells persisting from prior male pregnancies, since t(~tal lymphoc)1es were fOllnd to 
circulate ill maternal blood as long as 27 years after birth (Bianchi el al., 1996). 
Elevated ivlSAFP levels induced by TA-CVS were found in both male and female 
pregnancies; although the three cases with the largest FMT were all male pregnancies, no 
signiticant difference between the two groups could be observed. 
The increase in fetal cell Humber after TA-CVS, resulting in the detection of XY cells in ten 
out of 19 male pregnancies, represents an interesting experimental in vh'o system. 111 vilro 
mooel systems bascd on artificial mixtures of neonatal conJ blood NRBCs and adult female 
peripheral blood cells have been described (Andrews et al., 1995), but they have the 
disadvantage that cell characteristics of el;1hroblasts at the 20 to 40-week stage may differ 
from those at 12 weeks of gestation, The present in vivo modcl of TA-CVS-inouced cellular 
Fi'vIT has the imp0l1ant advantage that fetal cells are derivcd from the correct gestational 
stage and may be used to improve isolation procedures and to study fetal ccll dynamics and 
characteristics. 
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Submitted 
Preeclampsia is a common, pregnancy-specific disease defined by clinical findings of 
elevated blood pressure combined with proteinuria and edema. Although the etiology of 
preeclampsia is not knowll, there are indications that abnormal placentation and endothelial 
dysfunction are involved in the pathogenesis of preeclampsia, In this chapter, we investigated 
whether this nbnormai placentation results in a transfusion of increased numbers of fetal 
nucleated red blood cells in the maternal circulation. 

feto-Illuternal cell trafficking in preeclampsia 
Significantly higher number of fetal nucleated red blood cells in the 
maternal circulation in women with preeclampsia 
Mieke W.J.C. Jansen'·2, Karin Korver-Hakkennes', Dik van Leenen', Willy Visser', 
Peter A. in 't Veld2, Christianne J.M. de Groot', Juriy W. Wladimiroff' 
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ABSTRACT 
Although the pathophysiology of preeclampsia is unknowll) several studies have described 
that abnormal placentation early in pregnancy might play a key role, Therefore~ we 
investigated whether this abnormal placentation results in a feto-maternal transfusion of fetal 
nucleated red blood cells in wOlllen with preeclampsia. Male fetal nucleated red blood cells 
were isolated using magnetic activated cell sorting from 20 women with preeclampsia and 
20 controls, matched for gest. tl iOllal age and parity. The number of XY cells was determined 
lIsing two-color fluorescence in situ hybridization for X and Y chromosomes. Significantly 
more XY cells could be detected in women with preeclampsia (0.61 ± 1.2 XY cells/ml blood) 
compared to women with ullcomplicated pregnancies (0.02 ± 0.04 XY eclls/ml blood) 
(Manll-\Vhitney U test, p<O,OOI), These results suggest that fetal cell trafficking is enhanced 
in women with preeclampsia and may contribute to the understanding of the disease, 
INTRODUCTION 
Preeclampsia is a pregnancy~specific syndrome particularly manifested in late pregnancy. 
Preeclampsia is clinically characterized by hypertension and proteinuria, Although the 
etiology of preeclampsia is unknown, in the last decade it has been proven that preeclampsia 
is related to abnormal placentation early in pregnancy. Abnormal placentation might be due 
to incomplete trophoblast invasion, The cause of failure of trophoblastic invasion is 
unknown, but therc appears to be a combination of different tactors, including genetic and 
environmental h1etors (Roberts and Rcdman, 1993). 
Abnormal placentation has been suggested to play an important role in feto-maternal cell 
traffic) which was first recognized in 1893, when Schmor! identified trophoblast cells in the 
lung capillaries of women dying of eclampsia. For the last 20 years, investigators have lIsed 
the presence of fetal cells in maternal blood in all attempt to develop a non-invasive prcnatal 
diagnostic test (Simpson and Elias, 1994; Bianchi, 1998), Trafticking of fetal cells into the 
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maternal circulation have raised several questions, pal1icularly regarding the types of cells 
that arc able to pass the placental barrier, the number of fetal cells, and the consequences of 
semi-allogeneic cells in the new hosl. 
In several reccnt studies, the exchange of fetal and maternal blood cells in women with 
preeclampsia has been investigated (Chua et al., 1991; Holzgrcvc et al., 1998; Knight et (fl., 
1998: La ef al., 1999), Recently, Holzgrcve et at, (1998) showed that <1 substantial propOI"tion 
of erythroblast cells present in the blood of women with preeclampsia (n=8) were of fetal 
origin, and that a significant increase in cross-placental tnllTic of fetal cells occurred in 
wOlllen with preeclampsia compared to controls. In addition, Lo et al. (1999) recently 
demonstrated a similar feto-maternal transfusion on the basis of abundance of fetal DNA in 
maternal serum ofpaticnts suffering from preeclampsia (11=20). 
To investigate whether abnormal placentation associated with preeclampsia results in a fcto-
maternal transfusion, we isolated fetal nucleated red blood cells (NRBCs) from women with 
preeclampsia compared to controls, both carrying a malc fetus, using a very efficient 
magnetic activated cell sorting (MACS) protocol and two-color fluorescence in silu 
hybridization (FISH) for X rmd Y chromosomes. 
MATERIALS AND METHODS 
Patfu/Us 
The study protocol was approved by the local Ethics Review Board. After patients had given 
infonned consent, matcl'Ilal blood samples (8-24 ml) were collected in vacutainers containing 
ethylenedinlllinetetra-acetic acid (EDTA). Blood samples were obtained from 20 singleton 
pregnancies associated with preeclampsia and 20 women with uncomplicated pregnancies, 
both carrying [\ male fetus. Samples were matched for gestational age (± I week) and parity. 
The gender of the Ictus was confirmed after delivel),. Preeclnmpsia was defined as an 
absolute diastolic bloodpressllI'e 290 mmHg, combined with proteinuria, which was defined 
as ;0:0.3 gil in 24 hours urine (Davey and MacGillivray, 1988). HELLP (hemolysis, elevated 
liver enzymes, and low platelets) was defined as thromboc)1es <lOOx109/1, ASAT and ALAT 
both >30 U/I. and haptoglobin < 0.28 gil. 
Eighteen healthy pregnant controls carrying a female fetus werc recruited as negative 
controls. These controls were included in order to determine the background level for fiSH 
analysis. 
,\laglletic activated cell sorting (AfAeS) 
Maternal blood samples were diluted 1:1 with phosphate-buffered saline (PBS) and 
Illononllcleated cells were isolated by Ficoll-Paque-Plus density gradient centrifugation at 
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750 G for 10 minutes. Cells were washed twice in MACS buffer (PBS) containing 1 % 
bovine serum albumin (BSA), 0.01 % sotliurn azide (NaN3). and 5 mM EDTA) and 
centrifuged at 250 G for 10 minutes. The numbcr of viable cells was calculated using a 
BUrker counting chamber. 
Monollllclear cells derived fi'om maternal blood were labeled on ice with C071 
(10 ftillO' cells) in 200 ftl MACS buffer for 15 minutes. Cells were washed in MACS burrel' 
and labeled with IgG2a+b-conjugated microbeads (20 ~t1/107 cells: iVliltcnyi Biotec, Bergisch 
Gladbach, Germany) for 15 minutes at 4 Pc. Cells were washed in MACS butfer, 
resuspended in 1 III I ivlACS buffer and applied via a pre-separation filter (30 pill; CLB; 
Amsterdam, The Netherlands) onto a miniMACS column (type ~vIS; Miltenyi). Atter 
removing the colullln from the magnet, CD71 + cells were eluted with 15 III I MACS buffer. 
The number of viable cells in each fraction was calculated using a Blirker counting cha;nber. 
Fluorescence in situ hybridization (FISH) 
Cell fractions were treated with 75 111M KCI, incubated for 18 minutes at 37°C, fixed in 
methanol: acetic acid (3:1) and stored at _20°C until further analysis. Cells were dropped 
onto Veetabond™ (Vector Laboratories, Inc, Burlingame, CA, USA) coated slides and 
air-dried. Slides were pre-treated with pepsin (100 fIg/ill!) in 0.01 N HCI at 37 "c for 
IS minutes, followcd by postfixation in 3.7 % formaldehydc in PBS for 15 minutes. 
Subsequently, slides were denatured for 5 minutes in 70 % formam ide (pH 7,5) in 2X SSC at 
75°C, followed by dehydration in 70 %, 90 % and 100 % ethanol for 1 minute each. 
Two-coloI' FISH was performed llsing a SpcctrumOrange labekd alpha-satellite probe 
(OXZ 1) for centromere region Xp 11, l-q 11.1 and a SpeetrumGreen labcled satell ite III probe 
for the Yql2 region (Vysis, Downers Grovc, IL, USA). Samples were hybridized overnight at 
37°C in a humidified chamber. 
Slides were post-washed at 70 "c in O.4X SSe/0.3 % NP-40 (pH 7.2), followed by 
5-60 seconds in 2X sse/o.1 % NP-40 (pH 7.2) at room temperature. Slides were mountcd in 
Vectashicld mounting medium (Vector Laboratories, Inc.) containing OAPI (4', 6-Jiamidino-
2-phcnylindolc) and analyzed under a Leica Aristoplan tluoreseence microscope using a 
triple band-pass filter block. Images were captured using: a Xybion CCO 24-bit color camera 
with a Genetiscan ProbeMaster system and MacProbc 2.5 image analysis sot1ware (PSI, 
Chester, UK). 
All slidcs were nnalyzed without prior knowledge of the gender orthe teills . 
.)'tatistic ({na(l'sis 
Clinical data ofwol11cl1 with preeclampsia and their controls are presented in table 1 as mean 
vailles ± SD. The unpaired Student t-test was used for a normal distribution, tested by 
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Kolmogorov-Smirnov and Shapiro- Wilk tests. For nOll-normal distributions the 
I'Vlann-\Vhitncy U lest was applied. Intra-uterine growth restriction is defined as a bit1h 
weight below the fifth-percentile according to Kloosterman (l970). The exact Pearson chi-
square test was lIsed to lest the fifth-percentile, Two-tailed tests with p<O.05 were accepted as 
significant differences. 
RESULTS 
Patients characteristics 
As expected, women with preeclampsia displayed a significantly higher mean systolic and 
diastolic blood pressure and a lower gestational age at delivCI)l and fetal birth weight thun 
women with ullcomplicated pregnancies (table 1). Preeclampsia was also associated with a 
higher incidence of intra-uterine growth restriction. Unexpectedly, women with preeclampsia 
had lower levels of hematocrit. 
Table I Clinical characteristics 
l'vtaternal age (years) 
Nullipumc (N) 
Systolic blood pressure (mmHg) 
Diastolic blood pressure (mmllg) 
Proteinuria (gil) 
Gestational age at blood sampling (days) 
Gestational age at delivery (days) 
Bil'thwcight (gram) 
Intra-uterine gro\\1h restriction (N) 
Hematocrit at blood sampling (vo1/vol %) 
n.d. not determined 
Pregnancies witll a male/etus 
Women with preeclampsia 
N=20 
29.6 ± 5,4 
14(70%) 
169.2 ± 28.8 
107.0± 13.3 
5.07 ± 4.5 
207.9± 21.3 
213.3±21.8 
1244 ± 530.2 
6 
32.7 ± 1.3 
Control !,'TOUp 
N=20 
29.7±4.7 
15 (75 %) 
117± 8.0 
75 ± 9.0 
n.d. 
207.7±20.5 
276.5 ± 14.6 
3206 ± 670.9 
0 
J5.I±J.6 
p- vall!<: 
0.95 
n.d. 
<0.001 
<0.001 
n.d. 
0.88 
<0.001 
<0.001 
0.02 
0.014 
XV positive cells were found in 70 % of women with preeclampsia (11=20, 0.61±1.2 XY 
cells/ml blood), whereas this was in 10% of controls (IF20, 0.02 ± 0.04 XY eells/ml blood) 
(figure 1). This difference in the number of XY cells is statistically significant (i'vIallll-
Whitney lJ test, p<O.OOl). The total number of cells analyzed ill the CD71+ fraclion ranged 
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bctween 23-2000x I 0' (216.5x 10' ± 440.4x 10') in wOlllen wilh preeclampsia and 14-375x10' 
(mean 145.1x104±440Ax104) in controls. This difference was not statistically significant 
(Mann-Whitney U tesl; p~0.95). 
In women with preeclampsia, no correlation was observed between the number of 
XY~positivc cells and the severity of the disease, i.e. HELLP (n=12), proteinuria (n=20) and 
hypertension (diastolic blood pressure :2:90 Il1mHg; systolic blood pressure :2:.140; n=19) 
(Spearman's rank correlation coefficient, p>0.22). 
Figul'e 1 
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preeclampsia control 
Number of XY positive cells per milliliter maternal blood in 20 women 
with preeclampsia Ce) and 20 women ""ith uncomplicated 
pregnancies (0). Each symbol corresponds to an individual woman, 
whereas the horizontal line represents the mean number of XY cells per 
1111 blood. 
Pregnancies with a/ema/e/ctus 
As negative controls to determine the background level for FISH analysis of XY cells, 18 
control patients can),illg a female fetus (mean gestational agc 209 days) were analyzed tor 
the presence of male cells alier MACS isolation of CD7l + cells. In 3 out of 18 (16.7 %) 
control patients 0.07 XY cells pel' ml maternal blood wcrc found. 
101 
Chapter 5 
COMMENT 
\Ve demonstrated an increased transfusion of fetal IlUclC<'llcd red blood cells in women with 
preeclampsia compared with women with ullcomplicated pregnancies. The number of male 
fetal cells found in the maternal circulation of women with preeclampsia was lip to 30-fold 
higher than in controls, indicating a six times higher level of fetal cells compared to 
previously repOited results (Holzgreve ef al., 1998; Lo ef al., 1999). Holzgrevc ef al. (1998) 
isolated fetal nucleated red blood cells using the same MACS protocol as described in this 
study, although they used directly labeled CD?I beads. This might explain our promising 
higher rccovcl), of male cells since we have previollsly demonstrated in a model system lIsing 
in vitro expanded erythroid cells (Jansen et al., 1999) that the isolation ofuucloated red blood 
cells was more efi1cient using indirect beads labeling (unpublished results). In the study of Lo 
el al. (1999), fetal DNA concentrations appear to be fivefold higher in maternal serum 
samples derived from women with preeclampsia compared to controls, indicating that the 
aillount of DNA in matcrnal blood samples Illay not correspond with the number of cells that 
enter the maternal circulation in women with preeclampsia. 
Some XY~I)()sitive cells were found in pregnancies can)'ing a female fetus. In 2 out of 3 of 
these pregnancies a previolls pregnancy carrying a male fetus could not be excluded due to a 
previolls spontaneous abol1ion, whereas in one case a previous male pregnancy was 
ascel1ained. No XV-positive cells were found in primigravidae efln:Ang a female fetus. These 
male cells in female pregnancies may either represent false positives due to nOll-specific 
background staining of the Y chromosome probe, or represent fetal cells persisting from 
previous pregnancies call)ling a male fetus, since fetal cells have been found in the maternal 
circulation as long as 27 years allel' birth (Bianchi el al., 1996). 
The increased feto-matcrnal transfusion observed in women with preeclampsia might be 
explained by a decreased intravascular volume due to vasoconstriction and leading to an 
increased absolute cell concentration and consequently. a higher number of fctal cells. 
However, unexpectedly hematocrit valucs were significantly lower in women with 
preeclampsia compared to conlrols. These lower le"els can be explained by Ireatmenl or 
women with preeclampsia with plasma volume expansion medication before the timc of 
blood sampling. 
Thc mechanism of fetal cell escape into the maternal circulation is unknown. Preeclampsia is 
related to poor placental transfusion probably due to abnormal placentation early in 
pregnancy. This might result in the release of unknown factors, which in turn will lead to 
destruction of the maternal vascular endothelium. Thc abnormal placentation may explain the 
increased transfusion of fetal products in preeclampsia. Furthermore, feto-maternal 
transfusion has been observed in patients with chromosomal anomalies and aller chorionic 
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villus sampling, possibly as a result of disrupted or altered placental morphology (Simpson 
and Elias, 1994; Jansen e/ (/1., 1997). 
The clinical findings of preeclampsia become manifested late in pregnancy, lIslially aner the 
20th week of gestation and can develop in a life~thrcatcning disease. Precclampsia is a major 
cause of fetal and maternal morbidity and 1ll0l1ality. Therefore, it is important to develop a 
predictive screening test early in pregnancy. Relevant information regarding the frequency of 
fetal nucleated red blood cells in maternal blood is contradictOl)I, and the frequency of fetal 
nucleated red blood cells varies signitlcantly among individuals and throughout the three 
trimesters of pregnancy (Hamada e/ at"~ 1993; Shmga~ Tall berg e/ a/" 1995; Smid et at"~ 1997; 
Kuo, 1998), The question arises as to whether fetal cells are present in maternal blood of 
women with preeclampsia early in pregnancy and whether they can be used for the 
development of a prognostic test. Longitudinal studies are needed to invcstigate the 
frequency of fetal cells in maternal blood throughout gestation and in particular in those 
patients at risk for preeclampsia, 
The presence of fetal cells in blood of women with preeclampsia may contribute to the 
disease process. Although we did not demonstrate a significant correlation between the 
number of male cclls in the circulation of women with prceclampsia and the severity of their 
clinical symptoms, fetal cells are foreign to the maternal host and may have immunological 
consequcnccs for mother and fetus. Furthermore, a feto~matcrnal transfusion may occur at the 
time of labor and delivel)', This may establish fetal cell microchimerism in the mother, which 
may be implicated in the subsequent developmcnt of diseases sllch as scleroderma that are 
more common in fcmales (Artlett et a/., 1998; Nelson, 1998; Evans et aI" 1999). 
In summa/Y, we dcmonstrated an increased number of male fetal nucleated red blood cells in 
pregnancies complicated with preeclampsia, which could not be observcd in their matched 
controls, This suggests that fetal cell trafficking is enhanced in women with preeclampsia and 
may contribute to our unuerstanding orthe disease, 
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Gcncral discllssion and conclusions 
The isolation of fetal cells from the matclllal circulation may have implications in prenatal 
dingnosis since it would eliminate the sillall but significant risk to the fetus associated with 
morc traditional procedures like chorionic villus sampling and amniocentesis. If true fetal 
cells are conclusively isolated, clinical applications could includc screening for fetal 
chromosome abnormalities by FISH and gene abnormalities by PCR. Most attention has been 
focllssed on the isolation of fetal NRBCs. A small number ofNR13Cs occur in the peripheral 
venolls blood of women during normal pregnancy, but they are less common in the blood of 
healthy non-pregnant W0111el1 (Bianchi e/ al., 1991; Ganshil1-Ahlert el al., 1992; Siunga-
Tallberg el al., 1994). It was, therefore, believed that these cells were of fetal origin and 
could be a promising source of fetal material tor non-invasive prenatal diagnosis, especially 
since the short lifespan of erythroid cells eliminatcs thc possibility of such cells to persist 
fi'om previolls pregnallcies. However, most of these N RBCs in pregnant women appearcd to 
be of maternal origin (Bianchi el al., 1994a; Busch el al., 1994; Siunga-Tallberg el al., 1995, 
1996), leaving a vel)' small number of fetal NRBCs which may not be sufficient for a reliable 
prenatal diagnostic test on a large scale. To cstnblish high purity and yield of these rare fetal 
cells, morc specific and/or more efficient enrichment techniques arc needed, which have been 
developed using different model systems (Andrews et al., 1995; Bianchi et al., 1996a; 
Troeger el a/., 1999). 
6.1. Model systems used for the isolation offetal cells from maternal blood 
Attempts to isolate fetal cells from malel'llol blood has been frustrated due to very low yields 
ofNRBCs or even no detectable fetal cells in many matcrnal blood samples. Absence of fetal 
cells has been rcpolicd in numerous pttpers and might be caused by inefficicnt isolation 
stmtegies or low sensitivity of the uscd identification methods. In ordcr to improve the 
efficiencies of isolation techniques, dinerent model systcms have been described. In most of 
these studies, m1iticialmixtures of maJe umbilical cord blood cells, fetal blood cells or male 
fetal liver cells and adult female peripheral blood mononuclear cells were lIsed (Andrews e/ 
al., 1995; Bianchi el al., 1996a: Troeger el al., \999). In these model systems, different 
isolation protocols were evaluated using density gradient centrifugation, i\llACS, F ACS or 
illllllullomagnetic beads for the isolation of CD71 + NRBCs, after partial depletion of 
contaminating maternal cells. In addition, Troeger e/ al. (1999) also compared the retrieval of 
NRBCs lIsing antibodies against GPA, CD36 and the fetal Jivcr sLlrHlce antigen HAE9. 
In the study described in Chapter 2, we have llsed in vitro expanded CI)rthroid cells derived 
from male umbilical cord blood mixed with female peripheral blood mononuclear cells as a 
model system Jor the isolation of fetal cells from maternal blood. In contrast to the previously 
reported model systems (Andrews el al., 1995; Bianchi el 01., 1996a; Troeger t!I al., 1999), 
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we were able to obtain a homogenolls erythroid cell population, that could be expanded in 
vitro to high cell numbers, i.e. 107_108 el)1hroid cellsll111 cord blood after 10-15 days of 
culture, and these cells could be maintained in an el)1hroblastic cell stage. Morc importantly, 
the expanded CI)1hroiJ cells were imllllll1ophcnotypically identical to fetal NRBCs derived 
Ii-om 10-20 week tetal liver (Bianchi, 1994b), expressing high levels of CD71. This might 
indicate that the in vitro expanded CI)lthroid cells resemble fetal NRBCs circulating in 
maternal blood. Nevertheless, it should be mentioned that the most ideal source of fetal 
material lIsed in any model system tor the isolation of fetal cells n'ol11 matcl1lul blood would 
be fetal blood of 8-15 weeks of gestation. However, it is technically difficult to obtain fetal 
blood via cordocentesis before the gestational age of 20 weeks. To overcome this problem, a 
1110re physiological model system, which is the isolation of fetal cells after chorionic vilius 
sampling, can be used to optimize fetal cell isolation procedures. \Ve demonstrated, as 
described in Chapter 4, a significant increase in the 11l1l11ber of detectable fetal NRBCs in the 
maternal circulation directly after chorionic villus sampling. This indicates that maternal 
blood samples obtained shortly after chorionic villus sampling arc 1110re likely to reveal fetal 
NRBCs, and that these fctal cells are derived from the correct gestational age, i.e. at 12 weeks 
of gestation, which may be an optimal time in pregnancy for the development of a 
non-invasive prenatal diagnostic test. This ill vivo 1110del system has been used by several 
investigators (Oosterwijk el al., 1996, 1998a, b; de Graaf el al., 1999). 
For the isolation of fetal NRBCs, many investigators have lIsed antibodies against C071, the 
transferrin receptor (Bianchi et al., 1990; Ganshirt-Ahlel1 el al., 1992; Lewis el al., 1996; 
Sohda et al., 1997). C07l is IlOt only expressed on the entire el)1hroid lineage (Loken et al., 
1987), but also on activated lymphoc)1es, monoeytes, trophoblast cells and any cells 
incorporating iron (Krantz, 1991). To improve overall efficiency for fetal cell isolation using 
the CD7l antigcn, a strategy based on prior depletion of total white blood cells has recently 
been devised using monoclonal antibodies against CD45 and CD14 for depletion of 
lymphoc)1es and monocytcs, respectively (Bianchi el al., 1991; Busch el al., 1994; Reading 
el ai" 1995; Lewis et al., 1996). In this thesis (Chaptcr 2), we show a signilicant two-fold 
highcr yield of male NRBCs derived from il1 vitro expanded erythroid cells using a direct 
enrichmcnt protocol for CD71 + cells compared to the combined depletion/cnrichment 
protocol. This suggests that dcplction of lymphoc)1es and/or l11onoc)1es may also lead to loss 
of fetal cells, which may comprise cells of the el)1hroid lincage that express CD45 at a low 
level. Consequently, this will result in a lowcr yield of fetal NRBCs. A disadvantage of the 
direct enrichment ofC071+ fetal cells is that the isolated fraction has a low purity due to the 
prcscnce ofa high number of maternal cells. This might hamper the subsequent identification 
of fetal cells by FISH or PCR analysis_ 
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6.2. In vitro expansion of fetal cells 
For selective amplification of the target cell population for prenatal genctic tliagnosis, a 
simple conceptual approach may be the in vitro cultivation of fetal cells. So far, the number 
of fetal cells that have been isolated hom maternal blood samples is velY low, and theretore, 
it is generally desirable that fetal cells can be selectively expanded in vitro. In order to 
develop a non-invasive prenatal diagnostic test, it is impol1ant to obtain maternal blood as 
early as possible. Fetal hemopoiesis stm1s in the yolk sac between days 16 and 19 tollowed 
by hepatic hemopoiesis at approximately 6 weeks, indicating that fetal hemopoietic 
progenitor cells may be present in the maternal circulation from week 3 of gestation (Metcalf 
"nd Moore, 1971). 
Several studies have suggested that fetal progenitor cells differ from those of adults (Forestier 
et al., 1991; Weinberg ('I a/., 1992). This urges tor nn approach to exploit these differences 
tbr the selective expansion of fetal progenitor cells. It may be possible to lise cultures of 
mononuclear cells obtained from matel1lal blood to improve the proportion of fetal to adult 
progeny by manipulation of the culture conditions, and thereby exploiting the grO\\1h 
advantages of fetal cells over maternal ones. This may result in an enhancemcnt of both the 
relative and absolute number of fetal cells. 
The most suitable candidates among the variolls types of fetal cells that cross the placenta are 
the hemopoietic progenitor cells. These cells are characterized by the expression of the 
CD34 cell surface antigcn. Previolls studies lIsing in vitl'o colony-forming nssays as a 
mcasure of felal hemopoietic progenitors have demonstrated that both early (l2-24 weeks of 
gestation) and pre~term (25-32 weeks of gcstation) fetal blood samples have a highcr 
frequency of hemopoietic progenitors compared with term umbilical cord blood, adult 
peripheral blood, and bone marrow, and this frequency declines with advancing gestation 
(Linch et al., 1982; Clapp et al., 1989; Andreu, et al., 1991; De Bruyn et al., 1995). 
Moreover, Shields and Andrews (l998) recently demonstrated that early second trimester 
tctal blood produced a significantly greater number of el;,1hroid burst-tbrming units (BFU-E) 
compared with umbilical cord blood from term gestations. This higher number of BFU-E 
may be related to a large Illimber of hemopoietic progenitors committed to red blood cell 
differentiation bccause the fetal red blood cell mass is expanding rapidly enrly in gestation. 
These early gcstation el)lthroid progenitors also appear to have a greater proliterative 
response to a given growth factor stimulus relative to those in term umbilical cord blood. 
Recently, Campagnoli et a/. (2000) investigated the number and cell characteristics of 
circulating progenitor cells in first trimester fetal blood and demonstrated a higher number of 
CD34+ cells compared to term cord blood. This suggests that circulating CD34+ cells are 
likely to contribute significantly to hematopoiesis in early fetal life. Moreoyer, shurt-lenn 
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liquid culture of first trimester fetal blood cells rcvealed extcnsive ill vitro proliferation in 
response to various c)10kines. 
In our study, described in Chapter 3, we evaluated whether fetal hemopoietic progenitor cells 
derived t1'om maternal blood samples call be selectively expanded ill vitro in order to develop 
a non-invasive prenatal diagnostic tcst. Although to date some success has been reported 
(Valcrio el al., 1996), most groups havc found the degree of expansion insufficient against 
the higher numbcr of background maternal cells (Little et al., 1997; Chen et al., 1998; Han el 
al., 1999). To mimic this situation, i.e. low number of fetal cells in all excess of matemal 
cells, we first lIscd a model system in which limiting numbers of CD34+ umbilical cord 
blood (UCS) cells were diluted in up to I in 400,000 with CD34+ adult peripheral blood cells 
to detennine whether these limited numbers can be selcctively expanded. \Ve demonstrated 
that even very low numbers of CD34+ UCB cells could be expanded 1500-fold, which also 
corresponded to the expansion of CD34+ cells derived from 20-week tetal blood. 
Unfortunately, application of the same culturc protocol to maternal blood samplcs obtained at 
7-16 weeks of gcstation did not show preferential growth of fetal cclls. This suggest that 
primitive fetal cells might either not circulate in maternal blood or may require ditTerent 
combinations and/or concentrations of c)10kines for their in \'iII'O expansion. 
Another question concerns the stability of tetal cell propel1ies. If fetal hemopoietic progenitor 
cells arc present in the maternal circulation, the question arises whether they are clonal and 
possess unchangeablc characteristics or whether thcse cells arc transient and respond to a 
changing cnvironment. \Vhen fetal cell propertics arc determined, for example surface 
antigens, this is performed 011 cells recruited directly from fetal blood or umbilical cord blood 
samples. However, it is not known whether these cells keep the same marker antigens 
expressed in the new environmcnt, i.e. the IlHlternal circulation, after crossing the placenta. 
Therefore, the question arises, especially for cclls ill culture, as to whether fetal cells after a 
few rounds of proliferation and differentiation maintain or acquire properties thnt make them 
distinguishnble from the abundant maternal counterparts. 
FUl1her development of in vitro expansion approaches will involve detection of differcnccs in 
optimal growth factor rcquirements bctween matcrnal and fetal hemopoietic progenitor cells 
in order to exploit them for selective Ictal ccll expansion. F1II1hennorc, properties of fetal 
cells circulating in maternal blood and after ex vil'O cultivation should be investigated. 
6,3, Clinical implications offetal cells in the maternal circulation 
A major point of interest about fetal cells in the maternal circulation is whcther their 
existence may have an effect on the maternal immune system, especially in cascs with high 
numbers of tetal cells. The incidence of fetal cells in mnternal blood has been reported to 
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increase in pregnancies in which the fetal and placental karyotype was abnormal (Elias et at.. 
1992: Ganshirt-Ahlcl1 et al., 1993: Simpson and Elias, 1993: Bianchi el al., 1997), aner 
chorionic villus sampling (Chapter 4), and in women with preeclampsia (Chapter 5: Chua et 
01., 1991: Gallshil1 el ill., 1994: Holzgreve el 01., 1998: Lo e/ al., 1999). 
6.3.1. Aneuploidy 
Almost all numerical chromosomal disorders have been detected in fetal cells isolated from 
maternal blood. including trisomy 13, trisomy 18, trisomy 21, some of the sex chromosome 
abnormalities and triploidy. In most aneuploid pregnancies, it has been shown that the 
number of fetal cells in the maternal circulation is increased compared to normal pregnancies 
(Elias e( al., 1992: Ganshit1-Ahlert et a/., 1993: Simpson and Elias, 1993: Bianchi e{ al., 
1997). This increased feto-maternal cell trafficking could be the result of altered placental 
structures, i.e. destruction of the placental feto-maternal barrier (placenta membrane: see 
Chapter 1. paragraph 1.1.1.), reduced vnscularization or disturbed ucvelopment or fUllction of 
plncental villi (Kuhlmnnl1 el a/., 1990: Simpson nnd Elins, 1994; Genest el al., 1995; 
Jmmiaux nnd Hustin, 1998). This elevated number of fetal cells in chromosomally abnormal 
pregnnncies cnn also be explnined by nn incrensed isolntioll efficiency of fetal NRBCs, since 
it hns previollsly been rep0l1ed that both CD71 expression as well ns the number ofNRBCs is 
increased in fetal bloou snillpies of nnellploid fetllses (Thiiaganathull e( al .. 1995: Zheng el 
al., 1999). Therefore, it might be expected that the isolation ofenoLlgh fetal cells is fncilitnted 
in most nneuploid pregnancies, nlld hence, may be npplicnble tor prenatal dingnosis in the 
near future. 
6.3.2. The effect of chorionic villus sampling 
It has previollsly been reported thnt the introduction ora biopsy needle into placentnl tissue to 
aspirate chorionic villi via the trnnsabdominnl route might induce a feto-maternal transfusion. 
This wns demonstrnted by elevated levels of mnlernal serum alpha-fetoprotein levels 
measured before and nner trnnsabdominal chorionic villus sampling (Los ('( al., 1989: 
Rodeck el (// .. 1993: Smidt-Jenscn e/ al .. 1994: Brezinka ('( a/., 1995). Although estimates of 
the extent of the feto-maternal transttlsion indicnted thnt lip to 40 % of the fetal plasmn 
volume may have leaked into the mnternal circulation, Ictal demise is a rare occurrence nnd 
Iws been doellmcnteu only in sporadic cnses (Los e( aI., 1993). \Ve were interested in the 
question whether this tmnsfer of fetal pin sma was accompanied by n concurrent incrense in 
the number of fetnlnuclented cells in the maternnl circulntion (Chapter 4). We isolnted fetal 
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NRBCs from maternal blood before and after chorionic villus sampling and were able to 
demonstrate an increase in the number of fetal cells in 10 out of 19 male pregnancies 
following the invasive procedure. This fcto·maternal transfusion not only leads to the transfer 
of fetal nucleated cells but also results in the leakage of alpha·fetoprotein. However, 
feto-maternal plasma trafJsfusion estimated on the basis of alpha-fetoprotcin concentrations 
docs not reflect a transfusion of a comparable volume of whole blood! because the number of 
fetal NRBCs detected after chorionic villus sampling is relatively low. This lower level of 
fctal NRBCs might be explained by removal of these fetal cells by the maternal immune 
system, by retention of fetal cells in maternal tisslles, or by an inefficient isolation procedure. 
The question remains what the consequence is of these semi-allogeneic cells in the new host. 
6.3.3. Feto-maternal cell trafficking in preeclampsia 
In Chapter 5, we demonstrated a 30-fold higher number of fetal NRBCs in patients with 
preeclampsia compared to women with uncomplicated pregnancies. The mechanism of this 
fetal cell escnpe is not known. Preeclampsia is related to a poor placental transfusion 
probably due to an abnormal placentation early in pregnancy. This might result in the release 
of unknown factors, which in turn will lead to destruction of the maternal vascular 
endothelium. The abnormal placentation may explain the increased transfusion of fetal 
products in preeclampsia. 
Although we did not demonstrate a significant correlation between the number of fetal cells 
in the circulation of patients with preeclampsia nnd the severity of their clinical symptoms, 
fetnl cells are foreign to their maternal host and may have immunological consequences for 
mother and fetlls. Together with a feto-l11nternal transfusion occurring at the time of labor and 
delivclY, these retal cells may establish microchimerism in the mother, which may be 
implicated in the subscquent development of diseases sllch as scleroderma thnt nre more 
C0l111110n in women (Artlett et al.! 1998; Nelson, 1998a; Evnns et a/., 1999). It would, 
therefore! be of interest to investigate whether nutoilllll1UI1C diseases will occur more often in 
patients with a previolls histOl)1 of preeclampsia. 
6.4. Fetal-maternal immunology: tolerance versus autoimmune disease 
The application of molecular biological tcchniques to the study of human pregnancy has 
resulted in the recognition of two-directional cell trafficking of nucleated cells between the 
fetus nnd the mother (Lo ct al., 1996). It has, therefore, been suggested that pregnancy may 
estnblish as a long-term, low-grade chimeric state in the human Icmnle. Chimera is 
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mythologically described as having the head of a lion, the body of a goat, and the tail of a 
serpent. In medicine, the term "chimera" is lIsed to indicate a body that contains cell 
populations derived from (a) different individual(s). 
Fetal cells have been detected in the maternal circulation as early as 4 weeks and 5 days 
postconccption (Thomas (II al., 1994). The origins of these cells are presently unknown. It has 
been suggested that active cellular traffic across the placcnta early in gestation is important 
and perhaps necessary for inducing tolerancc to the human fetus. Recently, Bianchi el al. 
(J996b) demonstrated fetal progenitor cells in matcrnal blood as long as 27 years after bh1h 
of a male infant. The establishment of fctal progcnitor cells in maternal lymphoid organs or 
bone marrow may help to maintain tolerance of the fetal gran in a manner analogous to 
allogeneic organ transplantation. Starzl el al. (I 993a, b) have demonstrated chimcrism 
resulting t1'om widespread secding of donor dendritic and hemopoietic cells that were derived 
from whole organs being transplanted, such as kidney, liver, or intestine. They have 
postulated that bi-directional ceJlmigration and repopulation is the first step in the acquisition 
of dOllor-specific tolerance, and, ultimately, successful graft acceptance. The human 
pregnancy may thereforc benefit from similar one-way or even two-way traffic of fetal andlor 
matcrnal cells. 
On the other hand, it has previously been hypothesized that microchimerislll may contribute 
to the pathogenesis of some autoimmune diseases, such as scleroderma, systemic IUPlls 
el)1hematoslls (SLE), Sjogren's syndrome, Hashimoto's thyrioditis, and primm)' bilim)' 
cirrhosis (rursz)1er ef al., 1970; Hochberg, 1985; Danielsson ef al., 1990; Kelly ef al., 1991; 
Silman, 1991). Autoimmune diseases are thought of as disorders in whieh a body's cells 
inexplicably attack its own tisslles. The exposure to fetal cells during pregnancy represents an 
imlllullological event because these cells express gene products that are inherited from the 
father, and are thus foreign to the pregnant woman. 
An example of an autoimmunc diseasc in which microchimerislll Illay be involved in the 
pathogenesis is scleroderma. Scleroderma has a strong predisposition to women with a 
female-to-male ratio ranging from 3:1 to 8:1, and the highest incidence of scleroderma in 
women occurs between the age of 35 and 54, generally alter the childbearing ycars (Silman el 
al., 1988). Scleroderma also has clinical similarities to a known condition of human 
chimerism: chronic gran-versus-host disease that occurs after allogeneic transplantation of 
hematopoietic tissue (Furst el 01.,1979). 
Recently, microchimerislll has been studied in women with scleroderma who had previously 
given birth to at least one son prior to the diseasc onset. This patient group was compared 
with healthy controls with at least one son (Nelson el al., 1998a). Male DNA was found more 
frequently and in greater amounts in women with scleroderma than in healthy controls. This 
observation was extended in a study by Artlett el al. (1998) addressing the important issue as 
to whether microchimerism could be detected in the primal)' target organ of scleroderma, 
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which is the skin, In their study, a Y-chromosome-specitic scqucnce was found more ottcn in 
DNA extracted from skin biopsy specimens and pcripheral blood samples in women with 
scleroderma than in controls. The majority of women with positive results had previously 
given birth to a male child, although for some women with positive results the pregnancy 
histOl)' Was unknown or included miscarriage but 110t the birth of a SOIL 
Pregnancy presents an immullological challenge to a woman since half of the genes of the 
fetus arc derivet! from the father, HLA genes are of particular intercst since they encode for 
molecules that arc known to tlmction as classical transplantation lIntigens and also govern 
immunc responses. Il has been suggested that HLA compatibility of a previously born child 
might constitute a risk factor for thc subsequent development of scleroderma in the mother 
(Nelson, 1996), Accordingly, a strong association between HLA-DRB 1 compatibility and 
scleroderma has recently been demonstrated (Art lett et aI., 1997; Nelson et al., 1998b). No 
association was observed for HLA class I antigens. 
The finding of persistent microchimerism of fetal cells, however, docs not explain the 
occlirrence of scJerodenna in men or in women who have never been pregnant. Alternative 
sources of microchimerism in those patients include the engraftment of donor cells atter a 
blood transfusion, or from a twin (Nelson, 1996). Another possibility is that microehimerism 
is deri\'ed from maternal cells, since these cells have been detected in cord blood samples, 
indicating that the traffic of cells during pregnancy is bi-direetional (l-Iall et al., 1995; La et 
a/., 1996). 
A mechanism by which microchimerislll might contribute to the pathogenesis of scleroderma 
is unknown, but insight can be gained through knowledge acquired from studies of 
microchimerislll in transplantation biology. It is also not known how a small degree of 
microchimerism might result in either tolerance, breaking of tolerance or gratt-verslls-host 
disease. Although fetal cells could be primarily sequestered in the affected tissues, the low 
concentration of fetal cells argue against a role for these cells as direct effectors of damage to 
host tissues. Another possibility is that a small popUlation of non-host cells (or peptides) 
could start a process in which subsequent damage is caused by these host cells. Alternatively, 
a small popUlation of nOll-host cells could down regulate host immunoregulatory cells, which 
would allow damage by flutoreactive host cells (Fink et at"~ 1988). 
In conclusioll, it seems that microchimerisl1l may account for a balance between a 
host-verslls-graft reaction and a gran-versus-host reaction, leading to acceptance of the 
allogeneic fetlls. Under some circumstances this halance has becn disturbed and an 
autoimmulle disease might develop, The rcason for disturbance of this balance has not yet 
been discovered, 
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6.5. Conclusions and future research 
The isolation of fetal cells from the maternal circulation has the potential to allow early nOIl-
invasive genetic analysis without endangering the fetus, Targeting these cells has proved to 
be technically challenging because of their low frequency and the absence of suitable unique 
fetal cell markers and corresponding monoclonal antibodies. To be useful in prenatal 
diagnosis, fetal cells must be distinguished from the vast majority oflllatcrnal cells, they must 
be enriched to an acceptable level of purity, and mllst then be identified as cells of fetal 
origin. A major cOllcern is the identification of female fetal cells necessitating unique fetal 
markers in combination with FISH or PCR. 
Fetal cell detection and genetic analysis by PCR or FISH is hampered by the presence of 
matemal sequences excluding the detection of maternally inherited and X-linked disorders. 
Thereby, detection of aneuploidy and paternally inherited disorders is most accessible for 
prenatal diagnosis lIsing tetal cells isolated t)'01ll maternal blood. In order to diflerentiate 
between maternal and tetal sequences single fetal cells should be retrieved by 
111 icrod issection, 
Despite some promising results from investigations in this field, many of the basic questions 
regarding the circulation of fetal cells in the maternal blood remain unanswered. Specifically, 
numerous questions have to be addressed concerning the frequency and the type of fetal cells 
that circulate in the maternal blood during pregnancy. Espccially in nornlal pregnancies, the 
possibility of clonal expansion of fetal cells needs to be further explored, Furthermore, 
techniques that facilitate the identification and isolation of fetal cells needs to be optimized 
before this technique can be lIsed for prenatal diagnosis, 
It has prcviollsly been reported by variolls groups that ancuploid pregnancies arc associated 
with an increased feto-matcrnal transfusion as a result of altered placental structures, 
Therefore, it may be expected that a non-invasive prenatal dingnostic test using N~lal cells in 
maternal blood may only be applicable in cases of tetal chromosomal abnormalities, In our 
opinion, it will not fully replace currently used invasive procedures like chorionic villus 
sampling and mnniocentesis. Instead, the isolation of fctal cells may provide an additional 
screening test adjunct to the current nOIl-invnsive tests, like ultrasound screening and 
Illatelllul serqm screening. 
Another question concerns the imlllunological consequences of the presence of fetal cells in 
the circulatiOil of pregnant women and after pregnancy. Fetal cells may establish 
microchimerism in the mother after the occurrence of a teto-maternal transfusion, e.g. after 
chorionic villus sampling, in patients with preeclampsia, or in pregnancies with a 
chromosomally abnonnni fetus, and even in normal pregnancies, These fetal cells could be 
engraftcd in maternal lymphoid organs or bone marrow. Alternatively, fetal progenitor cells 
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could remain in the circulation and continue to divide for years. It is also conceivable that in 
subsequent pregnancies, in the presence of appropriate stimuli, these cells might begin active 
cell cycling and feed cells of other hemopoietic lineages, sLlch as gnllluloc)1es, cl")1hrocytes, 
macrophagcs and I11cgakaryocytes. The next question is whether these (persistent) fetal cells 
might be implicated in the pathogenesis of preeclampsia andlor in the development of 
autoimmune disorders. 
In conclusion, the lise of fetal cells isolated from maternal blood remains a promising 
approach for the development of a non-invasive test. Nevcl1heless, after more than two 
decades of research numerous questions remain unsolved. i\'lost of these questions can be 
answered once technical problems have been overcome, and sensitivity of detection methods 
has increased, Only then, tetal cell detection in maternal blood may be applied as a screening 
lest for prenatal diagnosis. 
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Summary 
Summary 
Current methods for prenatal diagnosis of genetic abnormalities include chorionic villus 
sampling and amniocentesis. Although these invasive methods arc accurate, there is a small 
procedure-related risk for the fetus. The development of an equally reliable non-invasive 
prenatal diagnostic test using fetal blood cells that leak through the placenta into the maternal 
circulation would eliminate this small but significant risk. 
Chapter 1 comprises a literature appraisal about the current knowledge of fetal cells in 
maternal blood. The fetal cell types present in maternal blood that have been studicd by 
numerous investigators include fetal lymphoc)1es, granuloC)1es, trophoblast cells and 
nucleated red blood cells (NRBCs). Most altention has been focussed on the isolation of fetal 
NRBCs, since they arc abundantly present in the fetlls during the first trimester of pregnancy, 
they have a limited life span and Illay not persist from previolls pregnancies. Fetal NRBCs 
have been isolated using antibodies against both membrane-bound markers, including the 
transterrin receptor (CD?1) and glycophorin A (GPA) and intracellular antigens, like 
embl)'onic (HbE) and fetal (HbF) hemoglobin. Despite all effOlis to develop enrichment and 
purification strategies that would increase the detectability of tetal cells in a maternal blood 
sample, the number of fetal cells recovered still remains vel)' low. Two l1l'lior methods of cell 
separation enable fetal cell isolation from maternal blood: fluorescence-activated cell sorting 
(FACS) and magnetic-activated cell sorting (MACS). If tetal cells are conclusively isolated, 
genetic analysis of these cells include fluorescence il1 situ hybridization (FISH) using 
cIlrol1losome~specific probes for the detection of chromosomal abnormalities, and polymerase 
chain reaction (peR) to ampm).' unique fetal gene sequences for the detection of gene 
abnormalities. 
QUI' research has primarily been focussed on the technical and biological aspects of fetal cell 
isolation. Since the number of fetal cells in maternal blood is very low, their isolation is 
technically challenging and requires extensive cnrichment procedures before any analytical 
procedure can bc performed. In Chapter 2, we describe the use of in vitro cxpanded erythroid 
cells ill a model system for the isolation of fetal cells from maternal blood. ElY throb last cells 
derived from male umbilical cord blood cells were in vitro expanded to high cell numbers. 
These cells could be maintained in an erythroblastic stage and expressed high levels ofCD?l, 
a marker frcquently lIsed for the isolation of fctal cells from maternal blood. Two approaches 
of MACS isolation were evaluated using a mixture of in vitro expanded male NRBCs diluted 
in up to 1 in 400,000 female peripheral blood monollucleated cells. The first strategy was 
based Oil the direct enrichment of CD?1 + cells using a one-step MACS isolation protocol. 
This isolation procedure was compared with a previously published and commonly used 
two-step technique based on depletion of monoc)1es (CD14) and lymphocytes (CD45) 
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tollowed by the enrichment of CD71+ cells. The number of recovered male cells was 
determined using two-color FISH with X and Y chromosomal probcs. We demonstrated a 
significant two-fold higher yield of male NRBCs using the one-step enrichment protocol. 
Application of these isolation stl'ategies to matcrnal blood samples resulted in a similarly 
improved enrichment of male fetal cells after the direct enrichment of CD71+ cells. An 
interesting question remains as to whether the described expansion protocol for erythroid 
cells can also be used for expansion of fetal NR Bes derived from maternal blood samples. 
The idea to increase the number of fetnl cells from maternal blood by amplificntion or fetal 
hemopoietic progenitor cells has been discussed for a long time. If fetal cells could be 
stimulatcd to proliferate in culture, thc technical limitations of working with vcry small 
number of cells could be overcome. In Chapter 3, we evaluated the usefulness of the in vUro 
expansion of fetal hemopoietic progenitor cells (CD34+) from maternal blood samples tor 
diagnostic purposes. After ivlACS isolation, fetal cells are often contaminated with an exccss 
of maternal cells and the question was whether fetal cells are able to ovcrgrow the maternal 
component. Therefore, a model system was used in which limiting numbers of male 
CD34+ umbilical cord blood (UCB) cells werc diluted in lip to 400,000 fen,"lc 
CD34+ peripheral blood cells. \Ve demonstrated a 1500~fold increase of male UCB cells over 
the female peripheral blood component after 3 weeks of liquid culture, which also 
corresponded to the extent of expansion of CD34+ cells derivcd from 20-week fetal blood. 
Unf0l1unately, we were not able to confirm these results lIsing fetal CD34+ cells isolated 
from maternal blood samples obtained at 7-16 weeks of gcstation, indicating that hemopoietic 
progenitor cells do either not circulate in maternal blood before 16 weeks of gestation) or 
require different combinations and/or concentrations Ofc)10kines tor their in vitro expansion. 
The presence of fetal cells in maternal blood is supposed to be the result of a feto-maternal 
transfusion at the placental interface. The incidence of fetal cells in matcrnal blood has been 
reported to increase in chromosomally abnormal pregnancies, after chorionic villus sampling 
(Chapter 4), and in women with preeclampsia (Chapter 5). It has previously been rep0l1ed 
that the introduction of a biopsy ncedle into placental tissue to aspirate chorionic villi via the 
transabdominal route might induce a feto-maternnl transtlJsion. Such a transfusion has been 
demonstrated by elevated levels of maternal serum alpha-fetoprotein Icvels nfter chorionic 
villus sampling (CVS). In Chapter 4, we investigated whether this transfusion of alpha-
fetoprotein was accompanied by a concurrent transfusion of fetal NRBCs in the maternal 
circulntion. We isolated fetal CD71+ cells from maternal blood samples obtained betore and 
after chorionic villus sampling, aner depletion of maternal lymphoc)1es (CD45+ cells) and 
monoc)1cs (CD14+ cells). Analysis of these CD71+ t}actions revealcd an increase in the 
number of tetal cells in 10 out of 19 male pregnancies after the invasive procedure, which 
also correlated with elcvated maternal serum alpha~fetoprotein levels. Moreover, this 
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CVS-induced cellular transfusion may form an interesting in vivo model system, which call 
be used to improve isolation procedures and to study fetal cell dynamics and characteristics. 
Several recent reports suggest that fetal cell trafficking into the maternal circulation is 
disturbed in preeclampsia. Preeclampsia is a common, pregnancy specific disease defined by 
clinical findings of elevated blood pressure combined with proteinuria and edema. Although 
the etiology of preeclampsia is not known, there are indications that abnormal placentation 
and endothelial dysfunction are involved ill the pathogenesis of preeclampsia. In Chapter 5, 
we investigated whether this abnormal placentation results in a transfusion of fetal NRBCs in 
the maternal circulation of women with preeclampsia. We demonstrated a 30-fold higher 
number of fetal NRBCs ill women with preeclampsia compared to WOlllen with 
uncomplicated pregnancies, suggesting that fetal cell trafficking is enhanced in women with 
preeclampsia. Furthermore, this feto-maternal transfusion may provide insight into the 
pathophysiology of the disease. 
In conclusion, the isolation of fetal cells from maternal blood has proved to be technically 
challenging because of the low frequency of these cells in the maternal circulation requiring 
extensive enrichment procedures for their subsequent isolation. To be useful in prenatal 
diagnosis, fetal cells must be distinguished from the vast majority of maternal cells, they must 
be enriched to an acceptable level of purity~ and must then be identified as cells of fetal 
origin. One promising technique may be the il1 vitro expansion of fetal cells in order to 
overcome the technical limitations of working with vel)' small numbers of celis. Erythroid as 
well as other hemopoietic progenitor cells have been sllceessfully expanded, but the 
technique has to be fllliher improved. 
A major point of concern remains the possibility that fetal cells from previous pregnancies 
persist in the maternal circulation, not only in view of the development of a non-invasive 
prenatal diagnostic test, but also because of their immunological consequences. Especially in 
cases with an increased teto-matel11al transfllsion, fetal cell microchimerism may have 
immunological consequences and may subsequently result in the development of an 
(auto)iml11l1lle disease in these women. 
In conclusion, the use of tetal cells isolated from maternal blood remains a promising 
approach for the development of a non-invasive prenatal diagnostic test. Nevertheless, after 
more than two decades of research numerous questions remain unsolved. Most of these 
questions can be answered once technical problems have been overcol11c~ and the sensitivity 
of the detection methods has been improved. Only then, fetal cell detection in maternal hlood 
may be applied as a screening test for prenatal diagnosis. 
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De huidige methoden voor prenataie diagnostiek voor de detectie van genetische afwijkingen 
omvatten met name de vlokkentest en vruchtwaterpunctie. Hocwel deze invasieve melhoden 
zeer nauwkeurig zijn, is er loch een klein risico voor de foetus gerclatcerd aan de procedure. 
De ontwikkeling van een geIijkwaardig betrouwbare niet-invasieve prenatale diagnostische 
test zal dit kleine, maar significante risico elimineren. Bij deze test wordt gcbruik gemaakt 
van foetale cellen die via de placenta het perifere bloed van de moeder bereiken. 
Hoofdstuk 1 omvat een literatuurstudie over de huidige kennis van de isolatie van foetale 
cellen uit mocderlijk bloed. VerschiHende foetale celtypen circuleren in het moederlijke 
bloed, zoals foetale lymfocyten, granulocyten, trofoblastcellen en kernhouclende rode 
bloedcellen (KRBCs). De mceste aandacht wordt besteed aan de [oetale KRBCs, omdat zij in 
grote aantallen voorkomen in het llloederlijke bloed, met name in het eerste trimester. 
Bovendien hebben zij een korte levensduUf waardoor de aanwezigheid van KRBCs van een 
cerdere zwangerschap vrijwel uitgesloten is. Foetale KRBCs worden ge'isoleerd door gebruik 
te maken van antilichamen gerichl tegen lOwel membraan-gebonden merkers, zoals de 
transferrine receptor (CD71) en glycoforine A (GPA), als tegen intracellulaire antigenen, 
zoals embryonaal (HbE) en foetaal (HbF) hemoglobine. Ondanks aile inspanningen om 
verrijkings- en zuiveringsstrategieen te ontwikkelcn die het aanlal [oetale cellen in moederlijk 
bloed zouden vergroten, blijft het <Hmlal ge'isoleerJe 1'oelale cellen erg klein. 1\vce technieken 
die veel gebruikl worden voor de isolatie van foetale cellen uit moederlijk hi oed zijn: 
Fluorescent-Activated Cell Sorting (FACS) en Magnetic-Activated Cell Sorting (MACS). 
Indien foelale cellen daadwerkeJijk gdsoleerd zijn, worden deze cellen op gene tisch niveau 
gCi'dentificeerd. Chromosomale abnol'Inaliteiten worden gedetecteel'd middels fluorescentie ill 
shu hybridisatie (FISH) door gebruik Ie maken van chromosoom-spedfieke probes. De 
detectie vnn afwijkingen op genniveau geschiedt door middcl van amplitkatie van unieke 
1'oetale gensequenties met bchulp van de polymerase ketting reactie (PCR). 
Het onderzock beschreven in dit proefschrift richt zich met name op de technische en 
biologische aspecten van de isolatie vall foetale cellen uit mocderlijk bloed. Aangezicn het 
aanlal foetale cellen in l110edcrlijk bloed bijzonder klein is, wordt de isolatie van deze cellen 
bel11oeilijkt, en zijn geavanceerde verrijkingsmethoden noodzakelijk voordat foe tale cellen 
genetisch ge'identificcerd kunnen worden. In Hoofdstuk 2 wordt het gebruik van ill vitro 
geexpandeerde erythroide cellen in een 1110delsysteem voor de isolatie van foetale cellen uit 
moedcrlijk bloed beschreven, Erythroblast cellen ge'isoleerd uit mannelijk navelstrengbloed 
\verden in \'itro geexpandeerd lot grote aantallen, Deze cellen konden behouden worden in 
een erythroblast stadium en ze expresseren een hoog niveau van CD7l, een merkel' die vaak 
gcbruikt wordt voor de isolatie van fnetale cellen nit l110ederlijk bloed. Twee MACS 
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isolatiestrategiecn werden gecvalueerd door gebruik to maken vall een mCllgsei van ill vitro 
geexpandeerdc mallllelijkc KRBCs die 400,000 keel' verdund werden in kerndragcnde cellen 
atkomstig van perifeer biDed van vrouwelijkc, niet-zwangcre vrijwilligers, De eerste 
isolatiestmtegie was gebascerd 01' dc directe verrijking vall C071 + cellen door gebruik te 
maken van een eell-staps MACS isolatieprotoeol. Oeze isolatieprocedure werd vergeleken 
met een cerder besehrcven en een vank gebruikte methode, namelijk een twee-staps tcchniek 
waarbij cerst de monoeyten (COI4+) ell Iymfocyten (C045+) verwijderd worden, gevolgd 
door de verrijking Vall C071+ cellcn, Het aantal verkrcgen mannclijke CD71+ eellen lla 
MACS isolatie werd bepaald mel behllip van een lwee-klcurcn f-ISH met X- en 
Y-chromosomale probes, Het een-staps MACS pl'oloeol blcck een twce keel' zo grote 
opbrengsl vall mannelUke KRBCs 01' te levcrell dan de twee-staps strategic, Toepassing van 
beide isoiaticprotocollen 01' Illoederlijke bloedmonsters rcsulteerde in een vcrgelijkbaar 
verbeterde vcrrijking van Illannelijkc foetalc cellen na de direete verrijking van 
C071+ foctale cellen (een-staps protocol). Een interessante vmag is of het beschrevcn 
expansieprolocol voor el)1hroide cellen ook geblllikt kan woruen voor de expansie van 
foctale KRBCs gci'soleerd uit moederlijkc bloedmonsters, 
Het idee om hct beperkte aantal foetale ccllen uit moederlijk bloed te verlllenigvuldigen door 
toetale hemopoietische stamcellen (CD34+ cellen) te kwcken, wordt al een lange tijd 
besproken, Als toetale cellen gekwcckt kunnen worden, dan zouden de lechnische 
beperkillgcn door tc werken met hele kleillc aantallcn cellen omzeild kUllnen worden. In 
Hoofdstuk 3 wordt gcevalueerd of de in \'itro expansie van foetalc hemopoietische stamcellen 
uit Illoederlijkc bloedmonstcrs toegepast kan worden voor de ontwikkeling vall een 
niet~invasieve prenatole diagnostische tcst. Aangezien na i'vlACS isolatie vall foctale cellen 
uit 1110edcrlijk biDed vrijwel altijd cen ovennaat aan l110ederlijke ecllen aanwczig is, was de 
eerste vmag of de gC'isoleerde foetalc cellen in staat zijn om boven de Illoedcrlijke componcnt 
lIit te groeien. Om dit aall te {on en hebben we gcbruik gemaakt van een modelsystcem 
waarbU hele kleine aantallcn CD34+ stamecllen uit mallnelijk navelstrcng bloed 
400.000 maal verdulld zijn in CD34+ stmncellen afkomslig uit peri leer bloed vall een 
vrouwelijkc, !liet zwangere, volwassen vrijwilliger. Na drie wcken kwcken bleken de 
mannelijkc CD34+ stamcellen lIit navelstrcngbloed 1500 maal vcrmenigvuldigd tc Zijll in 
vergelijking tot de vrouwelijkc volwassen C034+ stamcellen. Deze expallsic van mannelijke 
C034+ nuvelstrcngbloed ccllen correspondeerde met de mate van expansie van 
C034+ cellcn afkomstig uit toetaal bloed van 20 weken, Expansie van toetale 
hell1opoietisehc stamcellcn (C034+) vcrkregen uit moederlijke bloedmonsters afgenomen 
tussen 7 en 16 we ken van de zwangerschap was echter niet sllccesvol. Dit betckent enerzijds 
uat toetalc hemopoietische stameellen niet aanwezig zijn ill het bloed van zwangcrcn VOOI' 
16 weken van de zWllngcrschap, of anderzijds dat andcl'c combinaties of concentralies van 
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groeifactoren noodzakclijk zijn voor de ill vitro expansie van foetalc stamcellen aanwezig in 
moederlijk bloed. 
De aanwezigheid van foctalc cellen in moedcrlijk bloed is Illogelijk het gcvolg van een 
ccllulairc tmnsfusic tussell moeder Cil kind (feto-matcrnale tmnsfusie) op het niveau van de 
placenta. Het is eerder beschrevcn dnt de frequcl1tic vall foetnle cellen in de mocdcrlijke 
circulatie vcrhoogd is wnnneel' het cen zwangerschap bctrcft met een chrolllosomaal 
afwijkcnd kind. Ook nn vlokkentcst (Hoofdstuk 4) en bij vrouwen mel pre-eclmnpsie 
(Hoofdstllk 5) wordt cen verhoogd aanlal foetale cellen gcvonden in het moederlijk bloed. 
Reccntelijk is gcblcken dnt de introductie van een biopticnaald in placenlaweefsel, 0111 
choriollvlokken 01' te zuigell vin een transabdomillale route, mogclijk cell feto-maternale 
transfusie veroOl'zaakt. Dit is aangetoond door de annwezigheid van vcrhoogde concentralies 
van het alfa-foetoprote'ine in moederlijk serum na het uitvoeren van een vlokkcntest. In 
Hoofdstuk 4 onderzoeken we of deze transfusie van foctale eiwitten samen gnat mct een 
tmnsfusie van foetalc KRBCs in de 1110ederlijke perifel'e circulatie. Foetale CD7I + cellen zijn 
gei'soleerd lIit moedcrJijke bloedmonstcrs die afgenolllen zijn zowcl VOOl' als na de 
vlokkentest. Aliereersl zijn de moederlijke lymfoc)1en (CD45+ cellen) en monocyten 
(CDI4+ cell en) gedepleteerd, gevolgd door de verrijking van CD71+ cellen middels 
MACS-isolntie. Analyse vtln de CD7I+ cclfracties toonde aan dat na de invasicvc ingrccp 
een verhoogd aantal foetale cellen aanwezig was in 10 vall de 19 zwangerschaPP'!Il. Deze 
vcrhoogde tnillsfusic van foetale cellen correleerde met l'en verhoogde concentratie van 
alfa-foetoproteInc in het moederlijke serum. Bovendien vormdc dcze door de vlokkentest 
ge't'nduceerde cellulaire transfusic een goed in vivo modelsysteem, dat gebruikt knn worden 
voor verbetering en optimalisatie van isolatieprocedurcs, cn VOOI' he! bestudercn vall de 
dynamiek cn karaktcristiekcn van toctale cellen in helmoederlijk bloed. 
In vCl'schiliende rcccnte studies is onderzocht of de uilwisseiing van foetale en Illoederlijke 
cellen verstoord is bij patienten met pre-eclampsie (zwangerschapsvcrgiftiging). 
Pre-eclampsie is een ernsligc, veelvoorkomendc aandoening in de zwangerschap, die 
gekcnmerkt wordl door vcrhoogde bloeddruk en eiwitverlies in de urine. Dc ontstaanswijzc 
van pre-eclampsic is onbekend, maar er zijn aanwijzingen dat abnormalc olltwikkeling van de 
placenta en vaatwl.1ndbeschadiging (cndotheel) bij de mocder cen belangrijke rol spelen. In 
Hoofdstuk 5 wordl ollderzocht of deze abnol'malc ontwikkeling van dc placenta rcsultecl1 in 
een transfusie van foetalc cellen ill de pcrifcre circulntie. In hel bloed van vrOllwell met 
prc-cclmnpsie blekcn 30 maal zovccl toetale KRBCs aanwezig te zijn in vergelijking met 
bloed van vrouwen met een ongecompliceerde zwallgcrschap. Oil sllggerecrl dat cr bij 
vrouwen met pre-eclampsie een verhoogde transfusie plaatsvindt van toetalc cellen. Mogelijk 
zou deze verhoogde feto-matelllale transfusie meer illzicht kunnen geven in de 
ontstaanswijze vall prc-eclmnpsie. 
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Concluderend kan gesteld worden dat de isolatie van foctale cellen uit Illoederlijk bloed 
crnstig bcmoeilijkt wordt door de zcer lage freqllcntie van deze cellen, am deze zecr 
zeldzame foctale cellen te isolcren zijn effeclieve verrijkingsmethodcn Iloodzakclijk, Voor de 
ontwikkclillg van eell nict~invasievc prenatale diagnostischc test Illoetcn foelalc cellen 
onderschcidcn worden van moederlijke cell en, vcrvolgens nlClcten ze ge'isoicerd wordell lot 
een accept abel zuivcrhcidniveau voor analyse, en tens lotte moclen ze gc'idcntiticeenJ worden 
als zijnde toetaal. Een veelbelovende technick is de ill vitro expansic van foetalc eellen 
waarmee de teehnische beperkingcn van het wcrkcn met zcer klcine aantllllen toetale cellen 
omzcild kUBnen wordell. Zowel foetale el)1hro'idc cellen als hel11opoietischc slmllcellen zijn 
rccentelijk sliecesvol geexpandccrd, Het blijft cehler noodzakelijk am dcze klonale expansie 
verdeI' te evalueren en te verbctcrcn, 
Een groat problcem bij dc isolatie vall foetale cellell uit mocdcrlijk bloed blijfl eehler de 
mogelijkhcid dat toetale hemopoietische eellell van eell cerdere zwangcrsehap blijven 
circuleren in de mocderlijke circulatie, Dit is niet aileen belangrijk met het oog op de 
ontwikkeling vall cen betrouwbare niet~invasieve prenntale diagnostische test, maar zekcr 
001\ met bctrekking tot de immul1ologische reaetie die de aanwczigheid van I'oetale cellen 
lllogeJijk vcroOl~Laakt. Met name in gevallen van een verhoogde fcto-maternalc transfusie kan 
microehimcrisllle van foetalc cellen il11l1lullologischc eonsequenties hebbcll, en l110gelijk 
resultercn in de ontwikkeling van een (auto)immuunziekte bij deze vrouwen, 
Dc ontwikkeling van een niet~invasieve prenatale test door gebruik te maken van toetalc 
cellen uit Illoederlijk bloed blijt1 cen veelbclovende techniek, Desalnieltemin zijn na Illcer 
dan 20 jaar onderzoek nag steeds een aantal belangrijke vragen onbeantwoord, De meeste 
vragen zullcn bcantwoord worden wallneer de technische problem en van foctale cclisolatie 
opgclost zijn, en de sensitiviteit van de detectiemethoden vcrbeterd is, HopelUk zal dam"door 
in de toekomst toctnlc celdetectic gebruikt kUl1nen gaan worden als screeningstest voor 
prenatale diagnostiek, 
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AGM 
BFU-E 
CD71 
CFS 
CFU-E 
CVS 
FACS 
FB 
FISH 
FMT 
OPA 
HbA 
HbE 
HbF 
HELLP 
HLA 
KRBCs 
MACS 
MSAFP 
NRBCs 
PB 
PCR 
RhD 
SRY 
TA-CVS 
liCB 
Aorta-gonad-mcsoncphros 
Erythroid burst-forming unit 
Transferrin receptor 
Charge flow separation 
Erythroid colony-forming unit 
Chorionic villus sampling 
Fluorescence activated cell sorting 
Fetal blood 
Fluorescence ;,/ shu hybridization 
Felo-maternal transfusion 
Glycophorin A 
Adult hemoglobin 
Embryonic hemoglobin 
Fetal hemoglobin 
Hemolysis, elevated liver enzymes, and low platelets 
Human leukocyte antigen 
Kernhoudcnde rode bloedcellen 
Magnetic activated cell sorting 
Maternal serum alpha-fetoprotein 
Nucleated red blood cells 
Peripheral blood 
Polymerase chain reaction 
Rhesus D 
Sex-determining region Y 
Transabdominal chorionic villus sampling 
Umbilical cord blood 
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en van hitiek te voorzicn. 
Ik ben 01' vee I labs "Ie gasl" gewccst, was overal een vrccmdc cend in de bijt, Illaar ik heb dat 
zeker nooit zo ervaren!!! De meesle lijd heb ik op het ciwit-lab van de Klinische Genetica 
doorgebracht en dat was een gewcldigc lijd, danKzij mijn fijne eollega's. Ueve Manou, jij 
was mijn eerste kamergenootje. Van jou heb ik aile fijne kneepjes van het "compulervak" 
gclcerd (en Ill! nog steeds!!!), en ik ben blij dat ik die weer op anderen kan overdragen. Oak 
naas! het werk dcden we vcle dingcn samen: we squash(d)en en zongen erop los. Ik ben zcer 
blij dat jc dit bockje doorgeworslcld hebt op zock naal' "folltjes" alvorells het naar de drukkcr 
ging en dat jij mijll paranimfwilt zijn!!! Lieve Leontine, alias CorIcone (hoc ik er aan kOI11 
weet ik niel meer, volgens mij heeft het iets met een soap Ie makcn?), bedankt VOOI' 
al die ontspanncn "ten-thirty cappuccino times", de gezelligheid op het lab, tijdens 
balletvoorstellingen, BBQs, etc, Ik ben blij dat oak jij mijn paranimf wilt zijn. Ciao Filippo 
(papa pippa, tlipjc), jammer dat je weg bent, het is wei erg stil in OilS hokje. Ik beloofje dat 
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ik nu weer meer tijd zal hebben om gezellig te gaan lunchen, Karin, hartelijk dank voor je 
hulp tijdens mijn onderzoek, Toen je weg was kwam ik er achter hoevccl werk je verzet hebt, 
oak al was het maar voor 2 dagen in de week!! Dik, bedankt dat jij daarna samen met mij de 
eindsprint hebt willen inzetten, Oak aile overige (ex-)collega':-i van het eiwitlab wil ik 
bedanken: Marian en Elly (bedankl dat jullie de receptic willen coordineren), Cecile ('t is zo 
stil zonder jOll), Frans, Gracia, Andre, Arnold, Jocp (bedankt voor je nuchtere kijk op liel 
leven en de vele pep-talks (het lijkt weI of iedereen van "ons kantoor" wegvlllcht)), 
MarK (heb ik het goed geschreven?), Miriam, Paul, Joris, Fcnna, Debby, Agnes (de kleine 
zal er IlU wei zijn!l), Coleta (zuurkoo! met vette jus,.,), Adrie, Daniela (ciao, comme staja, 
bienne, spannend he). 
De collegu's van het prenatale lab wil ik harlelijk danken voor het transporteren van de vele 
huisjes bloed en de behulpzaamhcid aIs ik weer eens wilde weten of het een jongetje of een 
meisje was, Beste Armando, jij was onmisbaar bij de lotstandkoming van dit proefschrift, 
Mede dankzij jou ziet elit boekje er zo mooi uit, waren de dia's, piaatjcs en figuren (zelfs met 
een log-schaal!!) altijd perfect en ga zo maar door, Ik sta nog heel wat kilo's drop bij jon in 
het krijt!!! Cardi en Diane, bedankt voor het bijbrengen van de grondbeginselen van de FISH. 
Cardi, bedankl voor je helpende hand ais ik weer eens gegevens nodig had, en vee I succes 
met schrijven (misschien moet je toch cens overstappen op 'Word?), Beste Diane, bedankt 
voor de gezellige, maar vooral leerzame uurtjes, Ik hoop dat we in de toekomst nog veel van 
elkaar kunnen leren. Frans, bedankt voor de leerzame discussies en de gastvrijheid op het 
prenatale lab, Annet en Bert (postnallllll), bedankt voor jullie nultige "FISH" en "mie" 
adviezen, 
Ecn aanlal medewerkers bij de afdeling Hcmalologie wil ik bedankcn voor de gezelligc lijd 
die ik daar heb gehad, Marieke (von Lindem), bedankt voor je hnlp bij de erythroblastkweken 
en je aanstekelijke enthousiasme voor het onderzoek. Paula en Nuray, bcdankt voor jullie 
"stamcelkweektrainingen", en veel Sllcces bij de afronding vaIl jullie onderzoek. Irene, 
\Vendy, Robin, Alexandra, Angeliyue en Elwin: bedankt voor de gezeIligheid op het lab, 
Het onderzoek zoaIs beschreven in dit proefschrift had niet uitgevoerd kunnen worden zonder 
de bereidwilligheid van de vele patiCnlen die bloed hebben afgestaan, Ik wil hen daarvoor 
hartelijk danken, De medewerkers van de afdeling Verloskunde en Vrouwenziekten (sector 
Prcnatale Diagnosliek) wiI ik bedanken voor hun bereidheid am patienlcn Ie motiveren bloed 
at' te staan voor mijn onderzoek. Helen Brandenburg, Hajo \Vildschut, Annemarie 
Westenreld, Roger Heydanus, Titia Cohen-Overbeck, Nicolette den Hollander, \VilIy Visser 
en Christi<II1I1e de Groot: bedankt voor jullie bijdnlge nan het onderzoek. 
Tijdens een proTl1otie-onderzoek zijn er vele mensen die een belangrijke rol or de 
achtergrond speIen, Sylvia (bedankt dat je de afspraken mel de professor zo perfect regelde), 
Jacqueline, Jeanette, Cilesta, Joyce en Hanneke: bcdankt voor aHe hulp bij secretarieel werk 
en voor het beantwoorden van de vele vragen die ik op jullie afvuurde (moet de uitgaande 
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post IlU ill ofuit de zak?). Zonder schoon glaswerk en andere steriele benodigdheden bereikje 
niets in het onderzoek. \Vilma, Jopie, Joke, Prema en Rob, hm1cIijk bcdankt voor aI het 
"keukeuwerk". Rein, l'vlelle en Mieke, bedankt voor dc vclc bcstcliingen. Tom cn Ruuu, 
bedankt voor dc fotografische ondcrstcuning. 
Het laatste woord richt ik tot de bclangrijkste mensen in mijll leven. Licve mciden (de 
Saskiaatjes Henzel, Knoop en Passchier, Debby, Chava, Stephanie en Helen). Dc vrielldschap 
die wij hebbcl1 is uniek!!! \Ve kennen elkaar al bijna 20 jaar, hebben lief en Iced met elkaar 
gcdecld CII ik hoop dOlt we dit nog lang zullen doell. 13edankt voor de broodnodige 
ontspanning tus~cn de versehilicnde drukke beurijvcn door!!! 
Lievc Jolandt, ondanks dat wc elkaar niet meer zo vaak zicn (Brazilie is weI heel vel' weg), is 
onzc vriendschap altijd geblevell. Ik ben blij dat ik je hcb leren kennen en ik hoop dat jc cr dc 
13c bij kan zijn. 
Lieve mam en pap, bcdankt dat juliic mij de 1110gelijkheid hebben gegcven 0111 te studercn. 
Ell pap, jc mag het nog een keel' zeggen, maar dam"na weet ik wei dat je trots op mij bent. Ik 
bell oak trots op jullie en zekcr als ik naar de ol1lslag van dit proefschrift kijk. De combinatic 
van mam's miistieke kUllsten en papa's computerkul1sten hebben de kroan op mijn 
levenswerk gezet. 
Lieve Ingmar, ik weet niet wat ik zonder jotl ZOU moeten. Dit boekje draag ik op aan jOll, 
omdat zonder jou onvoorwaardelijke stelln dit boekje er nooi! gekomen zou zijn . .Ie hebt het 
zwaar te verduren gehad met mij, als ik me opsloot in het studeerhok, de computer d,lg en 
naeht bezetle en me onuitstaanbaar gedroeg. De laatste tijd Was het de promotie waal' alles 
011 draaide, maar het klusje is IlU geklaard, we kunnen nu van andere dingen gaan gcnieten. 
Ik hoop dat we samen hcel aud 1110gCI1 woruen. 
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